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ABSTRACT 
 
PAMELA ROSE HESKER:  Defining the function of Pyrin, the Familial 
Mediterranean Fever-associated protein, in inflammation. 
(Under the direction of Dr. Beverly H. Koller, Ph.D.) 
 
 Every day, the immune system makes decisions to differentiate harmful and inert 
stimuli, which allows protection against pathogens and prevents unnecessary or 
uncontrolled inflammation.  Perturbations to the innate immune system can lead to 
autoinflammatory disorders such as Familial Mediterranean Fever (FMF), which is an 
inherited disorder characterized by unprovoked episodes of inflammation and fever.  The 
genetic abnormality underlying FMF disorder is mutations in the gene MEFV 
(Mediterranean Fever), which encodes the protein Pyrin.  Previous research indicates 
that Pyrin alters function of the inflammasome multiprotein complex that mediates post-
translational IL-1 family cytokine processing.  This work has led to disparate conclusions 
about the function of Pyrin.  Interpretation of these results is ambiguous, in part, because 
mutations within the Pyrin protein are not defined as gain or loss of function.  Previous 
research also indicates that the expression of MEFV is abundant in neutrophils, and that 
neutrophils from FMF patients display altered immune function and survival in 
comparison to neutrophils from healthy donors.  However, there is no direct evidence 
that mutations in Pyrin affect neutrophil cell processes.  We postulated that mice lacking 
Pyrin (Mefv-/-) would allow us to clarify the function of Pyrin in the regulation of the 
immune response and FMF pathophysiology.  Characterization of naïve Mefv-/- mice 
revealed no deficits in immune cell development or distribution and no indication of 
unprovoked inflammation.  In response to immune challenge in vitro, IL-1β cytokine 
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levels were increased by the absence of Pyrin.  However, neutrophil recruitment and 
survival  were not affected by the loss of Pyrin.  In vivo models of peritonitis 
demonstrated that Mefv-/- mice generate a normal hypothermic response and recruit and 
retain inflammatory cells normally.  No difference in the physiological outcome of 
immune challenge was detected.  These studies indicate that Pyrin negatively regulates 
the immune response by altering IL-1β secretion.  Since IL-1β is at least in part 
responsible for FMF-associated inflammation, our findings support a model in which 
loss-of-function mutations in Pyrin can cause FMF. 
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CHAPTER 1 
Introduction 
 
Familial Mediterranean Fever (FMF) is a disorder of the innate immune system 
 Familial Mediterranean Fever (FMF) is an inherited autoinflammatory disease characterized 
by sudden episodes of fever and inflammation that typically last 1 – 3 days.  Fever and acute 
abdominal pain are the most common symptoms, but symptoms can also include pain in the 
joints or lungs or lesions in the skin.  The location and the severity of pain and inflammation 
differ between patients and between attack episodes within each patient.  Acute attack periods 
are interspersed with remission periods of either low-grade or undetectable inflammation.  FMF 
has long-term consequences that include tissue scarring, which is secondary to inflammation, 
and amyloid deposition within organs, especially the kidneys.  Severe cases result in kidney 
failure and subsequent death.  Disease onset and diagnosis usually occurs in children before 
age eight (1, 2).   
 The innate, but not the adaptive, arm of the immune system mediates FMF pathologies.  
Local tissue inflammation is due, in part, to considerable deposition of neutrophils.  Neither T 
lymphocyte infiltration, nor auto-reactive antibodies have been detected, indicating that T and B 
lymphocytes are unlikely to be involved in mediating inflammation.  Patients have an increase in 
the acute phase reactants:  erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), 
serum amyloid A (SAA), β-2 microglobulin, and fibrinogen.  They also have increased levels of 
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the Interleukin (IL) cytokines 6 and 10 (3), and the cytokine SA100A12 (4) in comparison to 
healthy controls.  IL-1β cytokine levels are also elevated in some patients (3).  IL-1β is of 
particular interest because it is elevated in patients with several different overactive immune 
system disorders, and blocking the signaling of IL-1β can decrease inflammation.  IL-1β is 
produced predominantly by macrophages.   
 FMF was associated with mutations in Mefv (Mediterranean Fever) based on linkage 
analysis and was confirmed by positional cloning (5, 6).  Mefv encodes the protein Pyrin.  
Consistent with IL-1β-mediated inflammatory responses and neutrophil accumulation in FMF, 
Pyrin expression is highest in macrophage and neutrophil cells (7, 8).  Thus, the symptoms of 
FMF, clinical tests, and the properties of the Pyrin protein indicate that the innate immune 
system mediates disease.  Specifically, neutrophils and macrophages, are likely to play an 
important role in FMF-associated inflammation that is caused by mutations in the Mefv gene.  
Accordingly, previous laboratory research demonstrates a role of Pyrin in macrophage-mediated 
IL-1β production and in survival, chemotaxis, and phagocytosis processes of neutrophils.  In this 
chapter, I will summarize previous research on the regulation of IL-1β production and neutrophil 
functions, as they pertain to Mefv and FMF, and then discuss the features of the MEFV gene 
and Pyrin protein.  These data fit together nicely to provide support for a role of Pyrin in IL-1β 
production and neutrophil physiology, although the specific contribution of Pyrin is unclear.  One 
of the complications in interpreting the contribution of Pyrin is the limited understanding of the 
genetic inheritance of FMF and the consequences of FMF-associated mutations on Pyrin’s 
function.  Conflicting data suggests that mutations cause a loss-of-function or a gain-of-function.  
This will be presented later in this chapter.  The central aim of this work was to use the mouse 
as a model organism, capable of genetic manipulation, to isolate and differentiate Pyrin’s role in 
innate immune responses in an endogenous system. 
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Regulation of the innate immune system 
 Immune responses are normal physiological processes that are required for defense 
against invading pathogens, but must be limited to prevent excessive tissue damage.  
Appropriate activity is partially accomplished by coordinated processes of two phases of the 
immune response:  the innate immune response and the adaptive immune response.  The 
innate immune system orchestrates a relatively non-specific response against pathogens.  This 
phase begins immediately at the initial sensing of infection or tissue damage and clears most 
pathogens.  Protection is conferred by production and release of molecules such as proteases 
and free oxygen radicals that damage pathogens and through coordinated death of infected 
cells by apoptosis or phagocytosis.  Although critical to protect the organism as a whole, the 
innate immune response is damaging to local healthy tissue at the site of infection.  It is 
important for the immune response to be as weak as possible in order to limit healthy tissue 
damage while effectively preventing pathogenesis.  When the pathogen is persistent, and 
perhaps a less immediate threat to survival of the whole organism, activation of the adaptive 
immune system complements the limitations of the innate immune system.  The adaptive 
response phase is slower, but responds very specifically to the pathogen so that a more robust 
defense against the pathogen is possible without causing too much damage to healthy tissues.  
Disruptions to the mechanisms controlling these responses can cause either unproductive 
responses that allow the spread of infection, or overactive immune responses that damage 
healthy tissue.  These are referred to as autoinflammatory disorders, allergy, autoimmune 
disorders, or tissue graft rejection, depending on the tissues mediating the immune system 
activity.  Since FMF is an autoinflammatory disorder caused by misregulation of the innate 
immune system, the innate immune system will be the focus for the rest of this work.   
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 Appropriate pathogen recognition is critical for the prevention of autoinflammatory 
disorders.  The innate immune system must make quick decisions about whether or not a 
pathogen or foreign particle threatens the survival of the organism.  To confer this ability, cells 
often have co-stimulatory requirements or two independent pathways that converge and 
activate an immune response.  In 1994, Polly Matzinger proposed “the danger hypothesis” to 
account for some of the gaps in the current model describing the process of self versus non-self 
decisions.  “The danger hypothesis” proposes that the immune system does not directly detect 
self versus non-self stimuli to guide appropriate immune responses, but instead detects and 
protects against danger.  Indications of danger are provided by a network of extrinsic 
communication signals from damaged tissues and intrinsic cell stress signals.  Thus, the 
presentation of a pathogen in the context of a danger signal triggers the innate immune 
response.  These independent signals come together to tailor the breadth and magnitude of the 
response (9-11).  
 
Interleukin-1β production 
 Cytokine and chemokine signaling molecules circulate throughout the body and coordinate 
the strength and timing of pathogen responses.  The cytokine IL-1β is released very early during 
the innate immune response and is an important mediator of the overall magnitude of the 
immune response.  Its importance in the immune response is underscored by its contribution to 
sepsis, the autoimmune disorders rheumatoid arthritis, Crohn’s disease, and multiple sclerosis, 
and the autoinflammatory disorders CAPS, PAPA syndrome, and FMF.  Controlled experiments 
implicate Pyrin, the protein mutated in FMF, in the regulation of IL-1β production.  IL-1β is 
produced and secreted, predominantly by macrophages, in response to pathogen and danger 
signals.  For example, in response to simulation with sterile agents, such as necrotic cells which 
are a source of cellular damage or danger signals, IL-1β mediates a pro-inflammatory response 
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that can be quantified by neutrophil recruitment (12).  IL-1β binds to the IL-1 receptor (IL-1R) on 
the external surface of cells and promotes further downstream pro-inflammatory cytokine 
signaling, cell recruitment, fever, and overall metabolic changes (13).   
 IL-1β production involves two signaling pathways:  1) Pro-IL-1β transcripts are produced in 
a pathogen-stimulated and NF-kB-dependent manner, and 2) Caspase-1 processes pro-IL-1β 
protein to mature, or active, IL-1β cytokine (14).  Another IL-1 family cytokine, IL-18, is cleaved 
by Caspase-1 in an analogous manner.  Caspase-1, a cysteine-aspartic acid protease, is 
activated by autocatalytic cleavage, which is promoted by inflammasome complexes in 
response to cellular damage (15, 16).  The vast majority of IL-1β is produced in a Caspase-1-
dependent manner, although other proteases, produced by neutrophils and mast cells, can 
generate an active form of IL-1β with relatively low efficiency.  Pyrin is implicated in the 
regulation of IL-1β production during both the transcriptional and the inflammasome-dependent 
processing stages. 
 
The inflammasome complexes 
 There are at least six inflammasome complexes that activate Caspase-1.  Five are 
nucleated by a NLR family protein and the last contains the HIN-200 family member Absent in 
Melanoma 2 (AIM2).   The NLR/AIM2 protein binds either directly or indirectly to Caspase-1 
through their pyrin domain (PYD) or caspase activation and recruitment domain (CARD) 
domain.  Unfolding of the NLR protein is the “ignition switch” to inflammasome complex 
formation, and each is triggered by different stimuli.  In other words, the preferred 
inflammasome complex is dictated by the stimulus initiating the immune response, in order to 
allow some tailoring of the innate immune response.  Immune stimuli have been tested primarily 
in vitro using overexpression or knock-out experimental systems to access the contribution of 
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the indicated protein to IL-1β production.  It is unclear whether heterocomplexes with multiple 
NLRs form functional inflammasomes to further tailor a response to different stimuli.  Table 1.1 
shows the functional domain structures of the four proteins that nucleate inflammasomes, the 
predicted inflammasome complex structures, and the stimuli known to activate each of them.   
 
 
7 
Table 1.1 Inflammasome complexes. 
 
PYD, pyrin domain; LRR, leucine-rich repeat; FIIND, function to find; HIN, HIN-200/IF120x. 
The inflammasome structures are depicted as dimers, but also form higher-order molecular complexes. 
The indicated stimuli have been tested primarily in vitro, using a readout of Caspase-1 cleavage, Caspase-1 activity, or IL-1β 
production as a readout of inflammasome-mediated immune system activation. 
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 The protein domain structure of the NLRs is critical to their function.  NLRP1 – 3 and 6 and 
NLRC4 are members of the NLR protein family, based upon the presence of two domains for 
which they are named: the nucleotide-binding domain (NBD or NATCH) and the leucine-rich 
repeat (LRR).  These proteins also contain a pyrin domain (PYD) and/or a caspase recruitment 
domain (CARD).  NLRP1 contains an additional domain, a function to find (FIIND) domain.  
AIM2 contains a PYD and HIN-200/IF120x domain (HIN) and thus shows little structural 
similarity to the NLRs, but functional analysis indicates that it nucleates inflammasome 
complexes.  Unfolding of the NLR/AIM2 exposes the binding surfaces of the PYD and CARD 
domains and is regarded as the “ignition switch” for inflammasome complex formation.  The 
PYD and CARD form homodimers with cognate domains present in ASC (apoptosis-associated 
speck-like protein containing a CARD) or Caspase-1 to bring the inflammasome complexes 
together.  The inflammasome complexes are often depicted as dimers, but electron micrographs 
of in vitro reconstituted NLRP1 protein complexes show that they actually form higher order 
complexes, similar to apoptosomes, with 7 NLRP1 proteins forming a circular perimeter around 
the ASC and Caspase-1 proteins at the core (17).   
 The NLRP1 inflammasome was the first inflammasome to be described (18), and it remains 
the only inflammasome complex verified by reconstitution using purified human recombinant 
proteins (17).  The Nlrp1 gene was identified in mice based upon differential susceptibility of 
inbred mouse strains to Bacillus anthrax lethal toxin (LT) induced death.  The susceptibility 
region was mapped to a locus containing three orthologs analogous to the human NLRP1 gene: 
Nlrp1a, Nlrp1b, and Nlrp1c (19).  Further studies using genetically-deficient mice have verified 
that Nlrp1b is indeed necessary for LT-induced Caspase-1 activation and IL-1β production. 
 NLRP3, formerly referred to as NALP3, Cias1, Cryopyrin, and PYPAF1, responds to the 
broadest range of stimuli tested so far (20), and signaling through the NLRP3 inflammasome is 
most well-characterized.  Deletion of the NLRP3 gene in mice provides confirmation that NLRP3 
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is required for IL-1β production in response to pathogens and toxins (20).  NLRP3 mediates IL-
1β production following exposure to a diverse set of stimuli, including some bacteria, ATP, uric 
acid crystals common in gout, the vaccine adjuvant alum, antiviral drug compounds, reactive 
oxygen species, and cell membrane permeabilizing toxins.  It remains unclear how such a 
diverse set of stimuli can activate NLRP3, and it will be interesting for future studies to 
determine where the danger response pathways converge to trigger NLRP3 inflammasome 
complex formation.  Under physiological conditions, NLRP3 folds upon itself to prevent 
activation.  NLRP3 unfolds in response to low intracellular potassium levels induced by 
hypotonic cell medium or treatment with a toxin that permeabilizes the cell membrane.  These 
treatments favor potassium efflux (21-23).  It is likely that NLRP3 unfolding requires interaction 
between a phosphorylated nucleotide and the NACHT domain to transfer energy that enables 
protein unfolding.  Once unfolded, NLRP3 forms an inflammasome complex that brings together 
NLRP3 and Caspase-1 through the adaptor protein ASC (gene: Pycard).  Inflammasomes 
aggregate to form larger protein complexes called ASC specks.  Proximity of multiple Caspase-
1 molecules causes autocatalytic cleavage and activation of Caspase-1.  Active Caspase-1 
cleaves pro-IL-1β (and pro-IL-18) to their mature forms, and these molecules are released from 
the cell (24).  The NLRP3-mediated response to a combined exposure of LPS and ATP is well 
described.  LPS activates NF-κB-dependent transcription of IL-1β, and ATP triggers NLRP3 
unfolding (Figure 1.1).  Current research efforts also continue to delineate the role of NLRP3 
inflammasomes in inflammation-induced cell death and in shaping the adaptive immune 
response. 
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Figure 1.1. LPS and ATP stimulated IL-1β production.  IL-1β production is mediated by 1) 
NF-κB dependent transcription, and 2) Caspase-1 mediated cleavage of pro-IL-1β to form a 
mature protein capable of signaling. The pathogen-associated molecular pattern (PAMP) 
endotoxin (LPS) is recognized by Toll-like receptor 4 (TLR4).  Signaling through TLR4 results in 
NF-κB activation and induced transcription of IL-1β.  IL-1β production is also regulated at the 
protein level by the NLRP3 inflammasome.  The NLRP3 inflammasome is activated by the 
danger-associated molecular pattern (DAMP) of high extracellular ATP (concentrations >500 
times the physiological level) (25).  ATP binds to P2rX7 (purinergic receptor P2X, ligand-gated 
ion channel, 7), which is an ATP-dependent potassium channel.  P2rX7 allows rapid efflux of K+ 
from the cell.  Subsequently, NLRP3 unfolds, and its exposed pyrin domain forms homodomain 
interactions with the pyrin domain of ASC.  ASC is an adaptor protein that also binds pro-
Caspase-1 through CARD homodomain interactions. Pro-Caspase-1 is autocatalytically cleaved 
and activated Caspase-1 then cleaves pro-IL-1β inside of intracellular vesicles. IL-1β and 
Caspase-1 are released from the cell when the vesicles fuse with the plasma membrane (24). 
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 NLRC4, or Ipaf, responds to intracellular bacterial virulence factors and nucleates an 
inflammasome that contains either NLRC4 and Caspase-1 with ASC, or NLRC4 and Caspase-1 
alone and requires NAIP5 for activation.  Salmonella typhimurium, Pseudomonas aeruginosa, 
and Shingella flexneri activate a ASC-dependent NLRC4 inflammasome, whereas Caspase-1 
activation in response to Legionella pneumophila requires NAIP5, but not ASC (26).  Purified 
recombinant flagellin has also been shown to increase IL-1β production in an NLRC4-
dependent manner, indicating that flagellin alone can activate the NLRC4 inflammasome.  
Correspondingly, S. typhimurium and L. pneumophila that are deficinent in flagellin have a 
reduced ability to activate Caspase-1.  However, S. flexneri does not express flagellin; its 
recognition factor is unknown.  The intracellular delivery of virulence factors through a Type III 
or Type IV secretion system is critical for NLRC4 activation.  This finding helps to separate the 
NLRC4 inflammasome pathway as a virulence factor-sensing pathway that is independent of 
TLR5, which senses flagellin that is presented extracellularly (21, 27). 
 AIM2 is not an NLR protein, but nevertheless it contains a PYD that is capable of binding 
ASC and forming an inflammasome complex involved in both IL-1β and IL-18 production, as 
well as inflammasome-mediated cell death.  Elicited peritoneal and bone marrow-derived 
macrophages from AIM2-deficient mice have impaired Caspase-1 cleavage and IL-1β and IL-18 
release, and they are protected from cell death following transfection with double-stranded DNA 
(dsDNA).  Biologically, this translates to AIM2 mediating inflammasome activation in response 
to some bacteria and viruses, specifically Francisella tularensis, L. monocytogenes, vaccinia 
virus, and mouse cytomegalovirus (28).  Immunofluorescence micrographs of macrophages 
infected with F. tularensis brilliantly show cellular localization between dsDNA, AIM2, and ASC 
(29).  This result provides initial evidence that an inflammasome complex can directly perceive 
pathogen virulence factors (30).  The absence of the NACHT and LRR domain also confirms the 
capacity for the PYD to mediate inflammasome complex formation, at least for AIM2. 
12 
 
 The NLRP6 inflammasome was recently described.  NLRP6 complexes with ASC and 
Caspase-1 to form an inflammasome which mediates pro-IL-18 cleavage (31, 32).  In vivo, 
Nlrp6-deficient mice have exacerbated intestinal inflammation and an increased propensity for 
tumors in dextran sodium sulfate models of colitis (31-33).  Phenotypes are similar to those of 
Pycard-deficient mice (31). 
 The inflammasomes differ slightly between humans (depicted in Table 1.1) and mice.  The 
PYD of mouse NLRP1b is non-functional, and instead the C-terminal CARD binds directly to 
Caspase-1, whereas the CARD of human NLRP1 binds to caspase-5, another pro-inflammatory 
caspase.  Human NLRP3 inflammasome complex may also contain CARD8/CARDINAL.  The 
molecular contribution of CARD8 towards Caspase-1 activation and IL-1β production is not well-
described, and CARD8 is absent from the mouse genome (34).  However mutations in CARD8 
are associated with increased risk for Crohn’s disease and ulcerative colitis and increased IL-1β 
levels in some populations (35, 36).  However, despite these differences, the function of the 
inflammasomes is well-conserved between humans and mice. 
 The inflammasome complex provides a unique signaling pathway that is amendable to 
manipulation to specifically affect IL-1β and IL-18 production without affecting production of 
other cytokines.  Previous research indicates that both endogenous and pathogen-derived 
molecules can interfere with this pathway.  This is important on a clinical level, because it 
suggests that continued research will help to direct production of pharmaceutical agents that 
can interfere with IL-1β production in a more specific manner.  In theory, the inhibition of 
aberrant, disease-associated IL-1β production will be possible without limiting crucial pathogen-
stimulated IL-1β and IL-18 signaling.  Pyrin regulates inflammasome-mediated IL-1β production.  
Contradictory models suggest that pyrin nucleates its own Caspase-1-activating inflammasome, 
or that Pyrin inhibits activity of the NLRP3, or perhaps all, inflammasome complexes.  Directed 
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therapies to influence Pyrin’s molecular functions are a promising avenue for improved 
therapies for immune disorders. 
Inflammasome-mediated autoinflammatory disorders 
 Autoinflammatory disorders, by definition, are innate immune responses in the absence of 
an identifiable stimulus.  Familial Mediterranean Fever (FMF) is part of a group of hereditary 
autoinflammatory disorders.  It was originally identified as a unique disorder in 1948, and named 
benign paroxysmal peritonitis (37) and later periodic disease (38), periodic fever, and Siegal-
Cattan-Mamou syndrome.  Today, periodic disease describes a family  of genetic 
autoinflammatory disorders that include:  Cryopyrin-Associated Periodic Syndromes (CAPS), 
PAPA syndrome (Pyogenic sterile arthritis, pyoderma gangrenosum, and acne), Blau 
Syndrome, early-onset Sarcoidosis, Familial Hibernian Fever (also known as TNF-Receptor 
Associated Periodic Syndrome, or TRAPS), Hyperimmunoglobulinemia D with recurrent fever 
syndrome (also known as mevalonate kinase deficiency), PFAPA syndrome (Periodic fever, 
aphthous stomatitis, pharyngitis, and adenitis), and Deficiency of the Interleukin-1–receptor 
antagonist syndrome. 
 FMF, CAPS, and PAPA diseases are all characterized by spontaneous inflammation or 
inflammation in response to innocuous stimuli, such as cold temperatures (39), and have similar 
symptoms, including elevated levels of IL-1β and neutrophil deposition within inflamed tissues 
(Table 1.2).  Mutations in Pyrin, NLRP3, and PSTPIP1 cause FMF, CAPS, and PAPA 
syndrome, respectively, and have all been shown to influence IL-1β production.  NLRP3 
enhances IL-1β production.  The vast majority of CAPS-related mutations in NLRP3 are 
missense mutations within the NATCH domain, and it is hypothesized that they result in 
constitutive unfolding of NLRP3 and increased sensitivity to stimuli.  Thus, these mutations 
provide a gain-of-function with respect to IL-1β production (34).  Studies have contradictorily 
shown that Pyrin increases or decreases IL-1β production.  How mutations affect Pyrin’s 
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function, and why there are discrepancies in the results of various studies, is unclear.  The 
proposed mechanisms by which Pyrin alters IL-1β production will be discussed further in the 
following sections.  PSTPIP1 (also known as CD2BP1) binds to Pyrin, and this interaction 
influences the binding of Pyrin to ASC.  Mutations in PSTPIP1 increase PSTPIP1’s binding 
affinity for Pyrin (40, 41).  In one model, an interaction between Pyrin and PSTPIP1 leads to 
decreased binding between Pyrin and ASC.  In this model, Pyrin and ASC interaction functions 
to decrease IL-1β production (41).  However, an alternative model depicts that PSTPIP1-Pyrin 
interaction unfolds Pyrin and reveals the domains necessary for Pyrin to bind ASC.  In this 
model, Pyrin and ASC interaction forms a pyroptosome that promotes IL-1β production and cell 
death (40).  Despite the differences in these two models, they both posit that PAPA syndrome-
associated mutations in PSTPIP1 increase IL-1β production through a mechanism mediated by 
Pyrin and the inflammasome.   
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Table 1.2. Symptoms and genetic alterations of the inflammasome-mediated 
autoinflammatory disorders. .   
Disorder Symptoms Genetic Alteration 
Familial Mediterranean 
Fever (FMF) 
Fever, Peritonitis, pleuritis, Arthritis, 
Skin rashes, polymorphonuclear 
infiltration at sites of inflammation, 
Amyloidosis, Elevated IL-1β 
Missense mutations in 
Mefv; 
Autosomal recessive 
Cryopyrin-associated 
Periodic Syndromes (CAPS) 
• Familial cold autoinflammatory 
syndrome 
• Muckle-Wells syndrome 
• Neonatal-onset multisystem 
inflammatory disorder 
Skin rashes (uticaria) in response to 
cold, polymorphonuclear infiltration at 
uticarial sites, Fever, Hearing loss, 
Arthritis, Amyloidosis, Meningitis, 
Inflammation of the eyes, Elevated IL-
1β 
Missense mutations in 
NLRP3 (formerly 
Cryopyrin); 
Autosomal dominant 
PAPA syndrome (Pyogenic 
sterile arthritis, pyoderma 
gangrenosum, and acne) 
Arthritis, polymorphonuclear 
infiltration at sites of inflammation, 
Skin rashes with ulcerative lesions, 
cystic acne, Elevated IL-1β 
Point mutations in 
PSTPIP1; 
Autosomal dominant 
 
 
 The similarities among these diseases, and especially the common pathologies of elevated 
IL-1β and neutrophilia support a model that NLRP3, Pyrin, and PSTPIP1 function within the 
same signaling pathway to affect innate immune responses.  Further evidence to support a 
function for Pyrin in IL-1β production and neutrophil dynamics will be discussed later in this 
chapter.  First, I will provide a conceptual framework for these function of Pyrin by describing the 
expression pattern of Mefv and the molecular interactions previously reported for Pyrin. 
 
The FMF-associated gene, Mefv, encodes the protein Pyrin 
 The Mefv gene is part of chromosome 16 in the human (5, 6), chimpanzee, and mouse 
genomes, chromosome 6 in the dog, and chromosome 10 in the rat genome.  In both mouse 
and human, the genomic region contains 10 exons, which are all part of the coding region 
(Figure 1.2).  The corresponding human and mouse Pyrin proteins are also of similar length: 
781 and 767 amino acids, respectively.   
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The promoter region of human Mefv contains regulatory elements associated with 
inflammation-dependent transcription.  Specifically, C/EBPα and NF-κB response elements are 
necessary for mediating the increase in MEFV expression induced by tumor necrosis factor 
(TNF)-α (42).  In mice, cytokine-induced Pyrin expression is prevented by the genetic loss of 
Stat6 and NF-κB, indicating that these elements are critical to the regulation of Mefv expression 
(43), although the regulation of Mefv may be a downstream effect of another cytokine that is 
regulated by Stat6 and NF-κB elements, such as IL-4 or IFNγ.  Thus, it appears that Mefv 
expression is regulated somewhat differently in humans and mice. 
 Alternative splicing of both the human and mouse transcripts has been detected.  In 
humans, there are isoforms lacking one or more exons: exon 2 (del2), exons 3 and 4 (del34), 
exons 2,3,4 (del234), exons 2,3,4,5 (del2345), exon 7 (del7), and exon 7 and 8 (del78).  These 
are found in both FMF-patients and healthy controls, suggesting that mutations in MEFV may 
not influence splicing, and that alternative splicing may not have a pathological effect (44).  In 
peripheral blood leukocytes and sonovial fibroblasts, splice variants with alternative exons 2a 
and 4a in place of 2 and 4, respectively, have been identified.  The 4a exon substitution creates 
a frame-shift and a predicted truncated protein ending in exon 5.  A transcript that contains an 
extended version of exon 8 (8ext) and lacks exons 9 and 10 is induced by LPS and accounts for 
27% of transcripts in sonovial fibroblasts.  Transcripts with del2 or 2a combined with 4a or 8ext 
were also detected (45).  In mice, alternative splicing replaces exon 9 with 9a.  It remains 
unclear if these splice variants provide wild-type function in a similar, increased, or decreased 
capacity, or if they have novel function or no function at all.   
 Structural analysis of the Pyrin protein places it in several protein families.  The human 
Pyrin protein, also known as tripartite motif-20 (TRIM20) and marenostrin, contains five 
functional domains: a pyrin domain (PYD), a bZip domain (bZ), a B-box domain (BB), a coiled-
coiled domain (C-C), and a B30.2 domain (Figure 1.2).  The PYD is common to death-domain 
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family proteins (46).  Within this family are NLRs, several of which function in innate immunity, 
and specifically, IL-1β production.  As previously mentioned, the PYD mediates homodomain 
interactions that are essential to the formation of the inflammasome complexes (47).  However, 
in contrast to NLRs which contain a NBD and a LRR domain, the only common domain of Pyrin 
is the PYD.  Thus, Pyrin is part of a family of POPs (PYD-only proteins) that inhibit 
inflammasome-dependent IL-1β production (48).  Pyrin also has a B30.2 region with a PRY-
SPRY domain, which places it in the TRIM (tripartite motif) protein family.  Nearly 150 proteins 
contain a SPRY domain.  It forms an immunoglobulin-like structure that mediates protein-ligand 
and protein-protein interactions and is implicated in pathogen detection.  For example, allelic 
differences in TRIM5α change the capacity for TRIM5α to recognize the HIV viral capsid (49).  
The majority of FMF-associated mutations are found in the SPRY domain, suggesting that the 
SPRY domain provides an essential function.  However, conservation of the Pyrin protein 
between mice and rats, which both lack the PRY-SPRY domain (7), indicate that genetic 
selection pressure remains, despite the loss of this region.  Therefore, the PRY-SPRY domain is 
unlikely to account for all of the functions of Pyrin. 
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Figure 1.2.  Mefv encodes Pyrin.  The orthologous Mefv genes of the human and mouse 
genomes both contain ten exons and encode proteins with a high degree of homology.  Gene 
exons are shown as unfilled boxes and align with protein domains (filled boxes) as indicated.  
Exons 1-8, except exon 2, are especially similar between humans and mice.  The B30.2 domain 
of the human protein is missing from the mouse.  The mouse protein contains the bZip domain 
(bZ) sequence, but it is unclear if its function is conserved.  PYD, pyrin domain; BB, B-box; C-C, 
coiled-coiled domain. 
 
 The human and mouse proteins contain a high degree of similarity:  47.6% identity, 65.5% 
similarity.  The PYD is encoded by the first exon and is especially well-conserved between 
human and mouse, providing further evidence of the importance of the PYD in overall Pyrin 
function.  The BB and CC are also conserved between human and murine Pyrin, and the bZ is 
likely present in the mouse protein as well as the human protein.  The B30.2 domain that is 
present in human Pyrin, is however, absent from the mouse and rat protein (7).  Based upon the 
high degree of identity at the nucleotide level, 59%, it is believed that the B30.2 domain is 
absent due to a pre-mature stop codon created by an ancient frame-shift mutation (7).  As will 
be discussed in detail later, most of the common FMF-associated mutations in Pyrin cluster 
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within the B30.2 region of the human protein, creating a conundrum as to how function is 
conserved between mice and humans.  It is, however, clear that there are disease associated 
mutations which lie outside of the B30.2 region (50-54). 
 
Expression of Mefv 
Mefv expression is highest in immune tissues in both humans and mice.  In humans, 
significant expression can be detected in the spleen, lung, and muscle tissues and very low 
levels of expression are detected in several other human organs by RT-PCR (8).  At the cellular 
level, expression is highest in neutrophils and macrophages, and there is low expression in 
B220+ B cells, CD3+ T cells, eosinophils, dendritic cells, and epithelial cells of the lung, 
peritoneum, and synovium (8, 45, 55).  Rodents may have a more restricted expression pattern 
of Mefv in immune tissues.  By northern blot analysis, expression was detected in the spleen of 
mice and rats and also in the lung and kidney of rats.  Expression was not detected during 
mouse embryonic development.  In the murine spleen, in situ hybridization showed that 
expression was concentrated in the primary follicle and marginal zone regions, which contain 
mostly granulocytes and B cells.  At the cellular level, Pyrin is expressed in granulocytes and 
macrophages, but not lymphocytes (7).   
 At the sub-cellular level, human Pyrin has been detected in both the nucleus and cytoplasm 
of cells.  The intracellular localization of Pyrin appears to be affected by cell type, differential 
splicing, and Caspase-1 cleavage (45, 56, 57).  Full-length Pyrin is predominantly found in the 
cytosol (8), and it co-localizes with perinuclear ASC-specks (47), and cytoskeletal elements (58, 
59).  The del2 splice variant (56), and the N-terminal Caspase-1-mediated cleavage fragment of 
Pyrin, however, appears to localize to the nucleus.  It is unclear if any mutations within the 
coding region, such as those associated with FMF, affect Pyrin localization.  In COS-7 cells 
20 
 
overexpressing human Pyrin, localization was unaffected by M694V or V726A mutations (8).  
Less is known about the cellular localization of murine Pyrin.  Since there are fewer splice 
variants described for the mouse transcript and protein cleavage is not described, protein 
localization may be less complex in mouse cells. 
 Pyrin expression in humans and rodents is regulated by sterile immune stimuli and 
cytokines.  Lipopolysacchride (LPS), interferon (IFN)-γ, and IFN-α increase expression of MEFV 
in human macrophages (55), while IL-4, IL-10, and transforming growth factor (TGF)-β can 
abrogate the effect of increased expression following a combined treatment of LPS and IFN-γ 
(55).  There are some differences between humans and mice in the induction of Pyrin 
expression.  IFN-γ dose-dependently increases expression at the transcript and protein level in 
human macrophages (55, 57).  In mice, IFN-γ increases Mefv expression at the transcript level, 
although it has also been reported that a difference in Pyrin expression was not seen at the 
protein level in murine macrophages (43).  LPS, TNF-α, IL-1β, IL-2, IL-4, IL-6, IL-10, and IL-12 
increase expression of Pyrin in murine macrophages.  The TH2-inducing cytokines IL-4 and IL-
10 are the strongest inducers of mouse Pyrin expression (43), but perhaps not human Pyrin.  
Instead, IL-4 treatment inhibits expression at the transcript level, and IL-10 induces cleavage of 
the human Pyrin protein (57).  In vivo intratracheal administration of LPS or silica increased 
levels of Mefv in rats (60).  Thus, Pyrin expression is regulated by endogenous and exogenous 
immune stimulants, both in vitro and in vivo.  Mutations in Mefv that are associated with FMF 
may increase, decrease, or have no effect on levels of Pyrin expression.  
 
Molecular interactions 
 Previous research has demonstrated binding between Pyrin and several other proteins, 
cytoskeletal elements, and itself (Figure 1.3).  These interactions have fueled multiple 
21 
 
hypotheses for the function of Pyrin.  In this section, I will describe the previously-reported 
molecular interactions of Pyrin.  The functional relevance of these interactions will be discussed 
in subsequent sections, as they pertain to IL-1β production and neutrophil physiology. 
 
 
Figure 1.2. Pyrin’s molecular interactions.  Through co-immunoprecipitation experiments 
and/or co-localization experiments using cells overexpressing Pyrin, the human Pyrin protein 
has been shown to interact with several proteins, itself, and cytoskeletal elements.  These are 
shown as unfilled boxes placed under the domains in Pyrin that are necessary for the molecular 
interaction.  This figure summarizes findings from several groups using four different antibodies 
(43, 47, 57, 59, 61-65).  The interaction of Pyrin with ASC, NLRP3, and Caspase-1 is reported 
by more than one laboratory.  Published work indicates that the mouse Pyrin protein also 
interacts with ASC, but the other interactions have not been demonstrated for the mouse 
protein.  Murine Pyrin does not contain the B30.2 domain, so these interactions are especially 
unclear.  PYD, pyrin domain; bZ, bZip domain; C-C, coiled-coiled domain.  
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Protein interactions 
An interaction between Pyrin and ASC was demonstrated through a yeast two-hybrid screen 
of the human genome and through immunofluorescence microscopy and coimmunoprecipitation 
of endogenous human and mouse Pyrin with ASC proteins (47).   Several studies indicate that 
Pyrin’s interaction with ASC affects production of IL-1β (40, 43, 61, 66, 67) and inflammation-
associated cell death (40, 43, 47). 
 The SPRY domain of Pyrin interacts with the NACHT domain of NLRPs 1-3 the pro domain 
of pro-IL-1β, and Caspase-1 based upon co-immunoprecipitation experiments (61, 62).  These 
interactions support multiple models of ASC-independent contributions of Pyrin to IL-1β 
regulation. 
An interaction between Pyrin and 14-3-3 has also been shown.  14-3-3 is implicated in 
multiple signal transduction pathways and in protein shuttling across the nuclear membrane 
(64).  It is reasonable to hypothesize that 14-3-3 mediates cytoplasmic-nuclear shuttling of 
Pyrin. 
A co-immunoprecipitation experiment identified an interaction between Pyrin and Siva1.  
Siva1 is proapoptotic protein, and its interaction with Pyrin reduced the ability of Siva1 to induce 
apoptosis (63).  However, in a screen of gene networks involved in FMF pathogenesis, Siva1-
mediated apoptosis was not linked to FMF.  Gene network analysis in THP-1 human monocytes 
supports an interaction of Mefv with Pycard, Caspase-1, Nlrp3, Pstpip1, NF-κB, and Interferon-
α, but the gene networks for Mefv and Siva1 do not overlap (68). 
Cytoskeletal interactions 
In an initial yeast two-hybrid screen for proteins that interact with Pyrin, human Pyrin was 
shown to interact with a novel protein, dubbed Pyrin/marenostrin interacting protein 1 (P/M-IP1).  
M694V and V726A mutations decreased, but did not eliminate, protein interaction in yeast cells.  
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P/M-IP1 and Pyrin co-localized to perinuclear structures in Cos-7 cells (69).  Based upon these 
findings, Pyrin was believed to have a role in Golgi-mediated transport.  A direct interaction in 
human cells has not been demonstrated by coimmunoprecipitation experiments.  Further 
experiments have failed to demonstrate co-localization of Pyrin with Golgi structures.  In fact, 
paclitaxel or colchicine treatment of Cos-7 cells, at a dose capable of diffusing Golgi structures, 
did not disrupt the cellular distribution of Pyrin (58).   
Immunofluorescent co-localization and an in vitro binding assay were used to show that 
Pyrin associates with microtubules.  However, the common FMF-associated mutations M680I, 
M694V and V726A mutations did not affect binding, which limits support for the hypothesis that 
Pyrin’s association with microtubules has functional consequences that are important in FMF 
pathophysiology.  In the same study, Pyrin also co-localized with actin depolymerization ends 
located at cell membrane ruffles on the lagging end of HeLa cells (58).  Subsequently, another 
group found that Pyrin co-localized with actin, but not microtubules, and α-actin 
coimmunoprecipitated with Pyrin (59).  Furthermore, the toxin Cytochalasin D, which inhibits 
actin polymerization, disrupted the cellular distribution of both actin and Pyrin.  However, in this 
study, Pyrin and ASC co-localized in HeLa cells to the leading edge of cell membrane ruffles 
that are rich in polymerizing actin.  VASP and Arp3 proteins are important in actin 
polymerization, and a coimmunoprecipitation experiment using myc-labeled Pyrin and GFP 
labeled VASP or Arp3 showed that these proteins can bind to Pyrin.  VASP and Arp3 also co-
localized to ASC specks in the presence but not the absence of Pyrin (59).  Thus, these studies 
suggest that Pyrin may coordinate interaction between ASC specks and the polymerizing tails of 
actin at an immunological synapse.   
Pyrin binds to proline-serine-threonine phosphatase interacting protein 1 (PSTPIP1), which 
is associated with PAPA syndrome, as previously mentioned.  The B box and coiled-coiled 
region of Pyrin is necessary and sufficient for an interaction with PSTPIP1 (40, 41).  PSTPIP1 
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may influence Pyrin’s function with cytoskeletal elements.  PSTPIP1 binds to PTP-PEST, which 
is a scaffolding protein that associates with actin through the protein WASP (70).  Pyrin can co-
localize with actin even in the absence of ASC and PSTPIP1, indicating that Pyrin’s interaction 
with actin is not mediated by ASC or PSTPIP1 (59).  Rather, Pyrin recruited PSTPIP1 to ASC 
specks.  The PAPA-associated mutation W232A in PSTPIP1 prevented its recruitment to ASC 
specks (59), but the A230T and E250Q mutations caused an increase in recruitment (71).  In 
summary, through both direct interactions and indirect protein-protein mediated interactions, 
Pyrin is implicated in cytoskeletal function and could influence cell shape, cell migration, and 
organization of an immunological synapse (70).   
Intramolecular interactions 
 In one study, IL-1β interacted more strongly with independent domains of Pyrin compared 
to full-length Pyrin.  Further research based upon this observation showed that the SPRY 
domain interacts with the BB and C-C domains of Pyrin, and masks the interaction of the SPRY 
domain with pro-IL-1β in coimmunoprecipitation studies.  However, M694V mutation did not 
affect intermolecular binding or intramolecular binding, so the functional significance of these 
interactions remains unclear (62).  The BB region of Pyrin has also been shown to bind the PYD 
of Pyrin and interactions of these domains forms Pyrin homotrimers (40).  In contrast, however, 
a yeast two-hybrid assay failed to detect intramolecular interactions of human Pyrin, when 
expressed in yeast cells (69). 
 
Previous research implicates Pyrin in IL-1β production 
 Several lines of evidence indicate that Pyrin affects IL-1β production.  First, some FMF 
patients have elevated serum IL-1β during inflammatory attacks and blocking IL-1β signaling is 
an effective prophylactic treatment (61).  Second, controlled experiments indicate a role of Pyrin 
25 
 
in IL-1β production in human and mouse experimental systems.  Third, Pyrin interacts with 
proteins of the inflammasome complex, NF-κB and IκB-α, and IL-1β itself.  However, there are 
still outstanding questions.  First, it is unclear if WT Pyrin acts to positively or negatively regulate 
IL-1β production.  Second, do mutations in Pyrin cause a loss or gain of function relative to WT 
Pyrin that affects IL-1β production?  Does the mutant Pyrin protein also have novel functions?  
Third, does Pyrin affect IL-1β transcription, pro-IL-1β protein processing that is either dependent 
or independent of inflammasome complexes, and/or IL-1β cytokine release from the cell?   
In the sections below, I will detail the evidence that supports several hypotheses as to how 
Pyrin affects IL-1β production.  Some of the proposed models directly conflict with one another 
as to the function of Pyrin, and are thus unlikely to occur simultaneously.  The validity of these 
models is not necessarily mutually exclusive and may be context (i.e. pathogen) dependent.  It 
is also possible that more than one of these mechanisms facilitate concurrent and/or synergistic 
effects.   
Pyrin is a POP that negatively regulates IL-1β production 
 Based upon a high percent of amino acid sequence identity within predicted CARD and 
pyrin (PYD) domains, a group of proteins was identified within the human proteome which 
contain a CARD or PYD, but lack other domains necessary to propagate inflammasome activity.  
These proteins are predicted to bind ASC, Caspase-1 or the NLR protein through cognate 
domain interactions, and sequester them to prevent formation of productive inflammasomes.  
These proteins are called COPs (CARD-only proteins) and POPs (PYD-only proteins).  
Structurally, Pyrin is considered a POP.  Results using in vitro overexpression experimental 
systems support the COP and POP model for the CARD-containing inhibitors COP (CARD-only 
protein), INCA (inhibitory CARD) and ICEBERG (72-74) and the pyrin-containing inhibitor 
cPOP2 (cellular pyrin-only protein 2).  POP1 (pyrin-only protein 1) was originally shown to 
increase IL-1β production, but a recent protein binding study suggests that POP1 may also 
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decrease NLR-dependent IL-1β production (75-78).  The in vivo function of these genes has not 
been examined, because they are absent from the mouse genome.  Conversely, Caspase12 
deficient mice display increased IL-1β cytokine production, suggesting that it negatively 
regulates inflammasome activity in vivo.  Thus, there is support for the model of COPs in an in 
vivo system.  However, the significance of Caspase-12 in humans is questioned because the 
gene structure varies between mouse, dog, and human genomes (79).  Pyrin is the only COP or 
POP that has been shown to negatively regulate IL-1β production in vitro and in vivo in both 
humans and mice. 
More specifically, the POP model proposes that Pyrin competes with NLRs, specifically 
NLRP3, for interaction with ASC, resulting in less Caspase-1 activity and less mature IL-1β 
production.  In a mixed lymphyocyte system using lysates from PT67 mouse epithelial cells 
overexpressing human Pyrin, ASC, and CASP-1, CASP-1 interacted with ASC in the absence, 
but not the presence of Pyrin.  Pyrin coimmunoprecipitated with ASC regardless of CASP-1 
expression.  Together, these findings indicate that Pyrin competes with CASP-1 for binding to 
ASC (43). Using reconstituted HEK293T human epithelial cells, Pyrin was also shown to 
compete with NLRP3 for binding to ASC (65).  In another study, Pyrin was shown to dose-
dependently reduce IL-1β production in transiently-transfected HEK293T (80).  U937 human 
monocytes overexpressing Pyrin also had decreased IL-1β production in response to LPS 
compared to cells treated with empty vector.  The M694V mutation reduced but did not eliminate 
the regulatory effect of Pyrin (43).  Correspondingly, a knockdown of endogenous Pyrin 
expression by THP-1 cells was shown to increase IL-1β production in response to LPS (61), 
peptidoglycan (PGN) and uric acid crystals (MSU) (62). 
Pyrin forms an inflammasome which positively regulates IL-1β production 
 An antithetical model proposes that Pyrin’s interaction with ASC enables the formation of a 
Pyrin inflammasome that activates Caspase-1 and leads to increased IL-1β production.  This 
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model draws upon the similarity in structure between Pyrin and NLR proteins.  The PRY/SPRY 
domain of human Pyrin forms an immunoglobulin receptor-like structure that could facilitate 
pathogen recognition in a manner analogous to the predicted receptor function of the LRR of 
NLR proteins.  In a HEK293T cell overexpression system, increasing levels of Pyrin dose-
dependently increased Caspase-1 processing and IL-1β cleavage.  SPRY domain mutants 
M694V and V726A were also able to increase Caspase-1 processing at levels similar to WT 
Pyrin.  Overexpression of WT or M694V, but not the PYD mutant L16P/F24S, also induced ASC 
oligomerization.  Furthermore, a Pyrin-ASC complex was shown to coimmunoprecipitate 
Caspase-1.  These data are consistent with a model in which PYD-PYD interactions between 
Pyrin and ASC mediate the formation of an inflammasome complex (67).  Another group also 
showed that Pyrin dose-dependently increased Caspase-1 activity and IL-1β release from 
HEK293T cells reconstituted with Pyrin, ASC, and Caspase-1, with or without IL-1β, and without 
an NLR.  A knock-down of Pyrin expression in the human monocytic cell line THP-1 and in 
human peripheral blood mononuclear cells resulted in decreased IL-1β release in response to 
LPS (66).  In support of this model, there is positive selection for mutations within the B30.2 
domain that is likely to function as a ligand receptor, suggesting that mutations in Pyrin may 
provide some selective advantage against a pathogen.  The biggest caveat of this model is a 
lack of evidence to support a pathogen that requires Pyrin for an efficient immune response, 
and specifically, IL-1β production.  
 It is also reasonable to imagine that Pyrin self-regulates its function by masking functional 
domains through intramolecular interactions.  In this model, Pyrin increases IL-1β production 
through its PYD domain, but the PYD domain must be exposed.  The B30.2 domain inhibits this 
function by hiding the PYD domain until a ligand causes unfolding of Pyrin.  If this were true, a 
mutation in the B30.2 domain could permanently expose the PYD domain and lead to increased 
IL-1β production in the absence of a ligand.  This model follows a paradigm proposed for 
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NLRP3 that suggests that mutations in the NATCH domain cause its PYD domain to be 
permanently exposed.  It is important to note that NLRP3 is a positive regulator of IL-1β 
production.  By analogy then, it is also possible to explain how Pyrin could be a positive 
regulator of IL-1β production, and mutations in Pyrin lead to increased IL-1β production. 
Pyrin forms a pyroptosome 
 The Pyrin-ASC interaction is the central evidence for yet a third model.  In this model, Pyrin 
and ASC complex into a “pyroptosome” that increases apoptosis during inflammation-induced 
cell death processes.  IL-1β release may increase during this process, but is not produced in an 
active process, and is instead a by-product of cell death (40).  HEK293T cells transfected with 
full-length Pyrin or the PYD only, but not Pyrin with a deleted PYD, showed increased apoptosis 
(65).  In another sudy, however, Pyrin increased ASC-speck formation, which is associated with 
inflammasome-mediated cell death, but the ASC-speck positive cells actually had increased 
survival (47).  Additionally, Pyrin has been shown to interact with Siva, a proapoptotic protein 
(63); however, there is no evidence to support a functional outcome of this interaction (68).   
Pyrin’s interaction with Caspase-1 could lead to multiple outcomes  
 Pyrin has been shown to interact with the catalytic subunits of Caspase-1 in the absence or 
presence of ASC (61, 62).  This interaction is suggested to have three different outcomes.  First, 
it may function to sequester Caspase-1 and prevent Caspase-1-mediated IL-1β cleavage.  This 
model is similar to the POP model, except in this case Pyrin binds Caspase-1 rather than ASC, 
and the interaction could occur before or after inflammasome-mediated Caspase-1 cleavage.  In 
HEK293T cells overexpressing proIL-1β and Caspase-1, the addition of full-length Pyrin 
expression inhibited inflammasome-dependent IL-1β production induced by cold temperature 
(30°C).  Deletion of the PYD did not prevent the inhibitory effect, and the SPRY domain alone 
was sufficient for Pyrin’s inhibitory effect.  In a dose-dependent manner, expression of the 
SPRY domain alone increased the amount of pro-IL-1β that co-immunoprecipitated with 
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Caspase-1, but decreased the amount of processed IL-1β.  Therefore, Pyrin probably does not 
compete with proIL-1β for binding to Caspase-1, but inhibits the catalytic activity required for 
Caspase-1 to process proIL-1β (62).  Correspondingly, another group showed in a PT67 
overexpression system that deletion of the B30.2 region made the inhibitory effect of Pyrin on 
IL-1β production less pronounced than the inhibitory activity of full-length Pyrin.  FMF-
associated mutations in the B30.2 domain reduced binding of the C-terminal region to Caspase-
1.  Crystal structure modeling indicated that amino acids 680 and 694 are important in Pyrin-
Caspase-1 interaction (61).   
 Alternatively, in the second model, Pyrin does not inhibit Caspase-1 activity, but instead is a 
substrate for Caspase-1-mediated cleavage (57, 67).  The cleavage site was mapped to amino 
acids 330-331 in human Pyrin, which is between the PYD and BB, but the C-terminal B30.2 
region was important in mediating the interaction of Pyrin with Caspase-1.  FMF-associated 
mutations M690I, M694V, and V726A in the B30.2 domain increased Pyrin cleavage (57).  
However, another group demonstrated that the M694V mutation does not affect the ability of 
Pyrin to bind Caspase-1 (62).  IFNγ, IL-4, and IL-10 induce cleavage of Pyrin (57).  A panel 
comparing 10 healthy and 10 FMF patients showed an increased relative abundance of cleaved 
versus uncleaved Pyrin in FMF patients, and this correlated with increased IκB-α proteolysis.  
Treatment of HeLa cells with colchicine dose-dependently reduced IκB-α proteolysis (57). 
 The N-terminal 330 amino acid Caspase-1 cleavage fragment of Pyrin localizes to the 
nucleus, and the bZip domain and a short, adjacent C-terminal region bind to NF-κB and IκB-α, 
respectively.  These interactions result in NF-κB and IκB-α translocation to the nucleus, and IκB-
α proteolysis (57).  In theory, this should result in increased NF-κB-dependent transcription, and 
since the IL-1β promoter contains an NF-κB response element, the end result should be 
increased IL-1β transcription.  However, in a HEK293T cell overexpression system, neither WT 
nor M694V or V726A Pyrin expression had an effect on NF-κB-dependent luciferase activity 
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(67).  In another study using HEK293T cells, full-length Pyrin and the PYD alone actually 
decreased NF-κB-dependent luciferase activity, but expression of Pyrin with a PYD deletion had 
no effect (65).  Thus, an interaction between Pyrin and Caspase-1 has been investigate by 
several group and findings suggest that there are two functional outcomes.  The first is 
sequestration of Caspase-1 to prevent cleavage of IL-1β by Caspase-1.  This interaction 
depends on the B30.2 domain of Pyrin.  The second is Caspase-1-mediated cleavage of Pyrin.  
Cleaved Pyrin has a subsequent function of increasing NF-κB translocation to the nucleus.  
Importantly, cleaved Pyrin inself is also translocated to the nucleus, which would limit 
interactions of the PYD of cleaved Pyrin and elements, such as inflammasome complexes and 
the cytoskeleton, which are found in the cytoplasm.  The different functions of Pyrin could have 
context-dependent actions, or they could occur simultaneously.  It is important to note that the 
first and second functions require different sub-cellular locations of the N-terminal, but not the C-
terminal, region of Pyrin.  Since the SPRY domain mediates Pyrin’s interaction with Caspase-1, 
it is possible for the Caspase-1 inhibitory function of Pyrin to occur before, after, and/or 
simultaneously to Pyrin cleavage. 
Pyrin’s interaction with the cytoskeleton may mediate IL-1β production 
 Pyrin’s interaction with cytoskeletal elements may also mediate IL-1β production.  
Colchicine and nacodazole, cytoskeletal disrupting agents, inhibit the ability of Pyrin to activate 
Caspase-1 (40).  Pyrin may also regulate formation or stability of an immunological synapse of 
inflammasome complexes and the actin cytoskeleton.  This provides a nice explanation for the 
therapeutic benefit of colchicine in FMF patients. 
Evidence using mouse models support conflicting hypotheses 
 So far, the evidence detailed above comes from in vitro experiments, mostly using 
overexpression systems in immortalized cell lines.  There is also evidence to support a role of 
Pyrin in vivo using three mouse model systems.  In the first mouse model (Mefvtrunc/trunc), a 
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disruption of Pyrin in exon 3 leaves the PYD intact while removing the BB and C-C domains, 
and the C-terminal region corresponding to the B30.2 domain of human Pyrin.  The mutation 
was designed to mimick FMF-associated mutations in the human B30.2 domain, and is based 
upon the assumption that the function of the B30.2 domain is lost as a result of FMF-associated 
point mutations.  These mice were reported to display exacerbated innate immune responses.  
Macrophages had increased Caspase-1 cleavage and production of IL-1β following treatment 
with LPS or LPS and IL-4.  Macrophages also had impaired apoptosis following LPS/IL-4 
treatment.  Furthermore, Mefvtrunc/trunc mice displayed exacerbated hypothermia and an 
increased susceptibility to septic shock induced by LPS.  Importantly, IL-1β release, 
macrophage apoptosis, and LPS-induced lethality of heterozygotes was similar to WT, 
indicating that two mutant alleles are necessary to produce an altered phenotype.  The authors 
concluded that the truncation of the Pyrin protein resulted in hypomorphic Pyrin function that let 
to heightened sensitivity and response to pathogens.  Thus, a biological basis for selection of 
allelic variants is an increased resistance to pathogens.  A significant conclusion was made 
based upon these studies:  FMF-associated mutations are hypomorphic.  However, there are 
two major caveats to this study.  First, the Mefvtrunc allele expresses a partial protein, and 
furthermore, expression of the PYD domain appears to be increased in these mice (43).  
Therefore, the Pyrin truncation mouse could represent a functional hypermorph, rather than a 
hypomorph, as the authors suggest.  Second, the endogenous mouse protein lacks the B30.2 
domain, so correlating the function of mouse Pyrin back to humans is a controversial matter. 
 Another mouse model system, reported recently, was designed to specifically address the 
role of the B30.2 domain.  Knock-in mouse lines were constructed to add the B30.2 domain of 
human Pyrin onto the end of the mouse Pyrin protein.  Specifically, exons 7–10 of mouse Mefv 
were replaced with exons 7–10 of human Mefv.  Four mouse lines were created to introduce the 
WT B30.2 sequence and 3 FMF-associated B30.2 domain mutants:  M964V, M680I, and 
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V726A.  The system was designed to test the hypothesis that mutations in the B30.2 region 
cause a gain-of-function that leads to FMF disease.  Mice with two B30.2 mutant alleles showed 
severe spontaneous inflammation and even developmental retardation.  Pathology indicated a 
substantial increase in CD11b+ innate immune cells in the peripheral blood and spleen of naïve 
homozygous V726A mutants compared to WT mice.  Furthermore, homozygous mice showed 
aberrant Caspase-1 cleavage and IL-1β production in response to LPS alone.  Pycard (ASC) 
deficiency largely rescued the phenotype of homozygous Pyrin B30.2 mutant mice so that 
CD11b+ populations and IL-1β production was similar to WT mice.  NLRP3-deficiency, however, 
did not rescue mice from spontaneous inflammation.  Thus, the inflammatory phenotype in 
these mice was dependent upon inflammasome-mediated IL-1β production, but not the NLRP3 
inflammasome in particular. 
 However, heterozygous MefvV726A/+ mice were healthy and had CD11b+ cell populations and 
IL-1β production similar to WT mice, which is inconsistent with a model in which mutations 
promote FMF via a gain-of-function.  Even more puzzling, mice homozygous for WT B30.2 were 
not born, suggesting that developmental retardation is too severe to be compatible with life.  
Interestingly, another group has observed that THP-1 cells infectected with retrovirus to express 
only the SPRY domain of Pyrin were not viable, whereas, in the same system, full-lenth Pyrin 
was not toxic (62).  Furthermore, the severity of homozygous B30.2 mutant mice is inversely 
proportional to the severity of FMF-phenotypes for the three mutations tested.  These findings 
are actually consistent with the hypothesis that murine Pyrin containing a wild-type B30.2 
domain causes aberrant function that is incompatible with life, and mutations in the B30.2 
domain cause a loss-of-function of these aberrant wild-type B30.2 domain mutations.  Thus, 
FMF is inherited in a phenotypically recessive manner, which is typical of diseases caused by a 
loss of protein function.  To address this possibility, Mefv-deficient mice were generated.  Mefv-/- 
mice did not display spontaneous inflammation nor statistically significant increases in CD11b+ 
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cell populations or in IL-1β production detected by western blot analysis.  The conclusion of this 
work was that B30.2 mutations cause a gain-of-function, but in a dose-dependent manner.  It is 
important to recognize that the inability to characterize mice homozygous for the WT B30.2 
domain means that this conclusion is predicated on a lack of a phenotype of the Mefv-deficient 
mice.  While the severe spontaneous inflammation of the homozygous B30.2 domain mutant 
mice is an overt phenotype that would be easily identified in the Mefv-/- mice if it were present, it 
remains possible that Mefv-/- mice have an innate immune system phenotype that could not be 
distinguished by the experiments chosen to test these mice. 
 In summary, evidence from these studies support conflicting models of Pyrin’s function, and 
further experiments are necessary to clarify both the contribution of Pyrin to the innate immune 
system and the inheritance pattern of FMF. 
 
Evidence from human patients supports conflicting hypotheses 
 Evidence shows that IL-1β production is altered during FMF-associated inflammatory 
attacks in at least some patients.  PBMC from patients with FMF have increased IL-1β 
production (43).  Treatment with IL-1β blockers helps prevent and lessen the severity of 
inflammatory attacks.  However, the role that mutations in Pyrin play in IL-1β production in FMF 
patients is less clear.  The expression level of Pyrin in patients compared to healthy controls is 
increased, decreased, or unchanged, depending upon the patient, and is not correlated with 
specific mutations within Mefv in a qualitative or quantitative way.  Moreover, mutations may 
affect alternative splicing, post-translational modifications, cellular localization, and/or Caspase-
1 cleavage of Pyrin, and one or more of these effects indirectly changes IL-1β levels.  It is most 
likely, however, that mutations directly affect the functional activity of Pyrin, since the majority of 
mutations are located in functionally significant exonic regions.  In summary, it is uncertain if 
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mutations mediate a gain or loss of Pyrin expression, localization, or function, and thus it is 
unclear if WT Pyrin positively or negatively regulates IL-1β production. 
 
The role of neutrophils in FMF 
 Early studies to determine the pathophysiology of FMF focused on neutrophils for three 
reasons:  1) Inflamed tissues in FMF patients have considerable neutrophil deposition (81), 
indicating that the autoinflammatory response in these patients is mediated, at least in part, by 
neutrophils.  2) Colchicine drug therapy can prevent FMF attacks, and while its mechanism of 
action in FMF is unclear, previous research indicates that colchicine is sequestered mainly by 
neutrophils (82, 83), so its therapeutic effects are likely to be on this cell type.  3) Neutrophils 
express Mefv at high levels (7, 55).  These data support the hypothesis that mutations in Mefv 
cause altered neutrophil physiology, and the correlative nature of these data leave open many 
possible processes of neutrophils that could be affected by Pyrin.  In the next section, the 
normal functions of neutrophils are reviewed, and in the following section, I will detail some of 
the previous research to assess the function of neutrophils in FMF patients.  
  
Neutrophil physiology 
Neutrophil Production 
 Neutrophils differentiate in the bone marrow from hematopoietic stem cells, through the 
myeloid lineage, and into the terminally-differentiated neutrophil cell type.  Concurrent with 
development, neutrophils migrate from the marrow region across sinusoidal endothelium into 
sinusoid vessels within the bone.  From there, neutrophils enter general circulation through the 
bloodstream (84).  The cytokine granulocyte-colony stimulating factor (G-SCF) regulates both 
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the differentiation of neutrophils from myeloid precursor cells and release of neutrophils from the 
bone marrow (85).  Neutrophils are maintained in high numbers (2.0 – 7.5 x 109 cells/L) within 
the blood under normal physiological conditions (86), but their circulatory half-life averages only 
6 hours in humans and 8 hours in mice (85).  The average human body produces greater than 5 
– 10 x 1010 neutrophils each day to counter the rapid turnover (87).  Neutrophil production is 
amplified during inflammation, in response to the cytokines G-CSF, GM-CSF, and IL-3 produced 
in the bone marrow, and GM-CSF, IL-6, and IL-17 produced by peripheral tissues (85).  The cell 
surface marker Gr-1 is used to detect the differentiation of myeloid precursor cells to 
neutrophils.  Gr-1 belongs to the Ly-6 gene family of adhesion molecules, and its expression is 
restricted to differentiated granulocytes, whereas it is absent from myeloid precursor cells and 
other hematopoietic-lineage cells (88).  
Neutrophil recruitment 
 In the absence of infection, the location of neutrophils is limited to the bone marrow, 
bloodstream, spleen, and liver.  Neutrophils are rapidly recruited to sites of inflammation by 
cytokine/chemokine concentration gradients.  TNF-a, IL-1β, Leukotriene B4 (LTB4), IL-8, and 
monocyte chemoattractant protein-1 (MCP-1) have all been shown to promote neutrophil 
recruitment to peripheral tissues (89-91).  Chemotactic stimuli activate signaling pathways to 
alter cell surface marker expression and to facilitate cytoskeletal rearrangements.  These 
changes result in migration of neutrophils from the bone marrow through the bloodstream and 
into peripheral tissues, where they help control local infections (87).  In vitro studies to mimic the 
movement of neutrophils in the bloodstream have shown that neutrophils begin rolling along an 
endothelial cell layer within two minutes of thrombin-induced endothelial cell damage (92).  In 
vivo, neutrophils can be visualized within infected tissues by 2 hours post-infection.  The 
presence of neutrophils in peripheral tissues is typically accompanied by signs of their 
activation. 
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Neutrophil effector functions  
 When neutrophils reach the source of the chemoattractant, (i.e. the pathogen or the highest 
cytokine/chemokine concentration), their cellular profile changes.  The once-migratory cells are 
immobilized and neutrophil effector functions initiate (87).  Neutrophils propagate a localized 
host response at infected or damaged tissues through several effector mechanisms:  1) the 
release of microbicidal agents and proteolytic enzymes, including myeloperoxidase, defensins, 
and hydrolases, from cytoplasmic granules, 2) the release of pro-inflammatory cytokines such 
as IL-8 and TNFα, which recruit and activate immune cells, 3) a respiratory burst that produces 
reactive oxygen species that kill pathogens, 4) the phagocytosis of pathogens, and 5) the 
extrusion of neutrophil extracellular traps (NETs), which help immobilize pathogens.   
Neutrophil lifespan 
 Neutrophils are short lived cells.  Non-activated neutrophils survive in the bloodstream for 
an average of 5.4 days (86), and activated neutrophils which have migrated to peripheral 
tissues survive for an even briefer time period of 1 – 3 days.   
 As human neutrophils age, they show signs of reduced chemotaxis in vivo, and reduced 
phagocytosis and respiratory burst in vitro.  This is likely caused by a reduction in several 
receptor-mediated signaling pathways, including protein kinase B, phosphoinositide-3-kinase, 
and JAK-STAT (Janus kinase – signal transducers and activators of transcription) signaling 
(93).  Non-activated neutrophils are removed from circulation by migrating to the bone marrow, 
spleen, or liver, where they apoptose.  It is suggested that age-dependent removal is important 
for maintaining adequate overall anti-microbial function (87).   
 Removal of activated, peripheral neutrophils is an important step in the resolution of 
inflammation.  While neutrophil functions mitigate risk of the spread of infection, their release of 
oxidizing agents and proteases is also damaging to neighboring healthy tissue.  Neutrophil 
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clearance from peripheral tissues occurs via apoptosis, necrosis, or phagocytosis by 
neighboring macrophages.  Neutrophils also die via uncontrolled necrosis induced by the 
pathogen.  A balance in the rate and extent of neutrophil influx, anti-microbial activity, and tissue 
clearance is critical to allow pathogen defense and prevent extensive tissue damage and 
chronic inflammation (94). 
Evidence for altered neutrophil physiology in FMF 
Neutrophil activation is altered in FMF patients 
 Differences have been detected in the ex vivo activation of neutrophils from patients with 
FMF compared to healthy controls. Oxidative burst in response to either phorbol myristate 
acetate (PMA) or monosodium urate crystals (MSU) is increased in neutrophils from FMF 
patients compared to healthy controls (95).  Furthermore, spontaneous free radical production 
and chemotaxis-, phagocytosis-, and PKC- induced respiratory burst by neutrophils from FMF 
patients is greater compared to neutrophils from healthy controls (96).  Neutrophils from FMF 
patients are also more effective at phagocytosing bacteria than neutrophils from healthy controls 
(97).  Interestingly, activation of the oxidative burst and phagocytosis in neutrophils 
demonstrates a biphasic phenotype in which activation of neutrophils collected from FMF 
patients in remission is more intense than in neutrophils harvested from FMF patients during an 
attack period (97-99).  This suggests that the inflammatory actions of neutrophils are quite 
variable during the course of FMF disease. 
Neutrophil survival is altered in FMF patients 
 As previously mentioned, extreme neutrophilia at inflamed tissues during FMF attacks has 
been observed by histological staining, and it could be a result of increased neutrophil 
production, chemotaxis, survival, or retention at sites of inflammation.  It is interesting to note 
that FMF attacks last 1 – 3 days, which corresponds to the deposition and clearance of 
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neutrophils from inflamed tissues.  This begs the question of whether or not resolution of FMF 
attacks is influenced by direct alterations of the kinetics of neutrophil apoptosis.  Indeed, 
circulating neutrophils from FMF patients have altered survival in experimental systems.  
Neutrophils from humans or rodents quickly die in culture.  Exposure to cytokines or endotoxin 
(LPS) reduces the rate at which neutrophils from healthy human donors or wild-type mice 
spontaneously apoptose (100, 101).  Neutrophils from FMF patients, however, show an 
increase in apoptosis following exposure to endotoxin (100).  If anything, these data suggest 
that the accumulation of neutrophils in FMF patients is not due to increased survival or impaired 
apoptosis of neutrophils, but data are too limited to make a clear statement regarding the 
survival kinetics of neutrophils FMF patients compared to healthy controls. 
Treatment of FMF with colchicine 
 Some of the most convincing evidence that neutrophils are directly altered in FMF is 
actually based on successful treatment of FMF with colchicine.  Colchicine is the main 
therapeutic agent prescribed for patients with FMF. Colchicine is sequestered mainly by 
neutrophils in vivo, suggesting that its beneficial effects are through modulation of neutrophil 
physiology (82, 83).  Colchicine treatment modulates chemotaxis, oxidative burst, and 
phagocytosis functions of neutrophils.  Colchicine inhibits neutrophil chemotaxis by decreasing 
expression of both E- and L- selectin, which are required for neutrophil migration to inflamed 
tissues (102).  Colchicine also inhibits release of chemotactic substances from neutrophils 
following phagocytosis of urate crystals (103).  In neutrophils from FMF patients, colchicine 
blocks initiation of the spontaneous respiratory burst.  Once induced, however, colchicine 
actually increases the intensity of the respiratory burst (104).  Colchicine inhibits phagocytosis of 
bacteria by neutrophils from FMF patients in a dose-dependent and time-dependent manner. 
Suppression of phagocytosis becomes more effective as the bacterial burden decreases (97).  
Evidence that colchicine alters neutrophil physiology suggests that FMF inflammatory attacks 
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are mediated at least in part by neutrophils, and thus mutations in Mefv may directly affect 
neutrophil function.   
 
The genetics of FMF 
 Polymorphisms within Mefv were identified by linkage analysis and positional cloning as the 
underlying genetic defect associated with FMF.  Mutations M680V, M694I, M694V and V726A 
were identified in the initial analysis and are all associated with one founding haplotype (5, 6).  
In a later study, another founding haplotype containing the mutation E148Q was associated with 
FMF, adding further support for Mefv’s association with FMF (105).  To date, these five 
mutations account for the vast majority of FMF patients.  The first four, as well as the majority of 
all polymorphisms, lie within the B30.2 domain, which suggests that this domain is especially 
important for Pyrin’s function.  Figure 1.4 summarizes the polymorphisms within the Mefv gene.  
There are 211 sequence variants within a relatively small 2.3 kb mRNA.  Ninety-one are 
associated with a phenotype.  The polymorphisms are all missense mutations or deletion point 
mutations (51-54) and infers that non-sense mutations or copy number variations either have no 
phenotype, or conversely, are incompatible with life.   
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Figure 1.4.  Mefv sequence variants.  Polymorphisms within the Mefv gene are found primarily 
within exons, especially exon 10, and are single nucleotide polymorphisms that cause missense 
mutations or single amino acid deletions or duplications. 
 
 Molecular and pedigree analyses support a pattern of predominantly recessive inheritance 
of FMF.  Most patients have mutations within the coding region of both Mefv alleles, however 
some individuals that fulfill Tel-Hashomer criteria (106) for FMF disease have only one mutated 
allele.  There is a wide breadth of phenotypic variation among patients in both the severity of 
FMF and the penetrance of FMF-associated mutations.  For example, pedigree analysis of one 
family indicates that 1 asymptotic grandmother and 1 asymptotic father carry the same allelic 
variants (M694V/V726A) as 4 grandchildren with childhood disease onset (107).  M694V and 
41 
 
ΔM694 are associated with aggressive renal amyloidosis and poor prognosis in patients with 
two allelic variants, especially M694V/M694V (2).  These mutations also exhibit some dominant 
penetrance.  At least two patients with one V726A mutation and no other detectable mutations 
also have FMF symptoms (108).  In a population genetics study in Crete, 83.1% (59/71) of 
patients carried 2 mutant alleles (109), but in a more recent study with 2,067 Turkish patients, 
only 23.7% (490/2,067) had 2 mutant alleles (110).  Evidence of dominant penetrance is limited, 
however, by the ability to detect a second allelic variant.  Genetic testing is largely confined to 
detection of the common mutations and/or sequencing of exon 10, which encodes the B30.2 
domain (111).  The studies in Crete and Turkey, for example, were limited to the 12 most 
common MEFV mutations.  Many patients are compound heterozygotes, so there is an 
extended range of potential activity of Pyrin created by a large number of possible genotype 
combinations. 
 The five most common FMF-associated mutations originated 3,000 – 30,000 years ago in 
people descendent from ethnic groups originating from the Mediterranean region, especially 
Iraqi and Ashkenazi Jews, Armenians, and Druze populations, and have been maintained 
through a founding effect (112).  Accordingly, FMF primarily affects ethnic groups that originate 
from the Mediterranean region, especially: Armenians, Sephardic Jews, Turks, North Africans, 
Arabs, and, less commonly, Greeks and Italians.  The incidence of FMF in Armenians is 1:500.  
The carrier frequency is especially high in these populations as well (1).  A clear association 
between the prevalence of disease-associated haplotypes and geographic origin suggests that 
an environmental stress caused the founding mutations (6). 
 Evolution studies indicate that there is positive selection for allelic variants of Mefv.  
Statistical analysis of the ratio of the frequency of nonsynonymous to synonymous mutations 
confirms a model of episodic positive selection for allelic variants of MEFV  (113).  Increased 
incidence of carriers in the Mediterranean area compared to other parts of the world suggests 
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that positive selection pressure maintains heterozygous carriers within this region due to an 
environmental stressor.  Carrier frequencies are astonishingly high, reaching 1:3 in some sub-
populations within the Mediterranean region.  While the five most common FMF-associated 
mutations show a founding affect in genetically-isolated populations, mutations also repeatedly 
arise de novo, indicating that there is a selection for allelic variants.  
 Genetic evidence clearly defines Mefv as the FMF-associate gene, but complexities of the 
underlying genetics makes interpretations of functional studies difficult.  Recessive inheritance 
of FMF suggests that a functional loss of both Mefv alleles is necessary for disease pathology.  
However, reports of dominant penetrance of disease argues that mutations lead to a gain-of-
function.  This implication is limited, however, by confined genetic testing to identify a second 
allelic variant.  In summary, further molecular genetic, population, and functional studies are 
fundamental to elucidate what appears to be a complex role for Mefv in innate immunity. 
 
Mice and Man:  Using the mouse as a model organism 
 The immune response is generally well-conserved between human and mice, which allows 
the mouse to be used as a small animal model system for inflammation that is amenable to 
genetic manipulations and in vivo studies.  Cross-species infection models allow for direct 
comparison of the dynamics of the immune response between mice and humans.  Inflammatory 
mediators that regulate the innate immune response to these pathogens are fairly well-
conserved on both a genetic and functional level.  Specifically, IL-1β production and signaling 
can be correlated between mice and humans.  For example, mouse models implicating IL-1β in 
disease progression have been translated to successful treatment of the corresponding disease 
in humans using IL-1β blocking therapies (13). 
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 The in vivo immune response is an orchestrated effort of many cell types that involves cell 
migration, extravasation, activation, and resolution.  The dynamics of these processes cannot 
be appreciated by any in vitro experiment.  It is especially important to recognize the overall in 
vivo process of the immune system in the case of an autoinflammatory disorder such as FMF.  
Since these disorders stem from unprovoked responses in the absence of a pathogen, it is 
necessary to develop a mouse model system in which aberrant immune activation can be tested 
in the context of an endogenous system.  By harnessing the power of manipulation to the 
mouse genome, we were able to create a system to allow for removal of the Mefv gene and 
stable Mefv expression.  Specifically for Mefv, this is an important point since various 
overexpression and knock-down experimental systems have provided inconclusive results. 
 
Summary and Significance of this work 
 The literature described above details some of the incredible work that has shaped our 
understanding of the recognition stage of the innate immune response and how danger signals 
can help guide the magnitude and duration of the immune response in order to promote 
necessary immune system activation and prevent autoinflammatory disorders such as FMF.  
Familial Mediterranean Fever (FMF) is an autosomal recessive autoinflammatory disease 
characterized by unprovoked fevers and acute inflammation leading to peritonitis, arthritis, 
pleuritis, skin rashes, and amyloidosis.  In the Mediterranean region, the incidence of FMF is 
estimated at 1:500 Armenians (1) and between 1:3000 and 1:6000 Iranian Jews (114), 
indicating that FMF is a major health concern in some populations.   
 Current therapeutic regimes for FMF patients involve nonsteroidal anti-inflammatory drugs 
to alleviate acute inflammatory episodes and life-long prophylactic treatment with colchicine or 
IL-1β blockers (2).  Colchicine drug therapy is the treatment of choice for FMF patients.  Its 
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mechanism of action is unclear, and some patients do not respond to colchicine treatment or 
cannot tolerate its side effects.  A better understanding of the function of Pyrin may shed light on 
the mechanism of action of colchicine and lead to the ability to predict whether or not colchicine 
will be beneficial to individual patients.  Furthermore, the IL-1β blocker anakinra has been 
successfully used to treat colchicine-nonresponsive patients (115).  This indicates that IL-1β is 
at least partially responsible for the symptoms of FMF.   
 IL-1β is a critical mediator of not just in FMF pathology, but of many innate immune 
responses.  Its production is regulated by the inflammasome signaling pathway, which is 
activated by danger signals.  IL-1β/IL-1R interaction drives a pro-inflammatory immune 
response, and approaches to block this interaction effectively decrease inflammation.  Lifelong 
therapeutic use of IL-1β-blockers has dangerous side effects, as long-term, broad immune 
suppression leaves the body susceptible to dangerous pathogens.  Further knowledge of the 
regulation of the inflammasome pathway should help in the design of tailored therapeutic 
approaches to more precisely control aberrant IL-1β production.  Several chronic autoimmune 
disorders, including rheumatoid arthritis and multiple sclerosis, as well as the autoinflammatory 
CAPS and FMF, are treated with IL-1β blockers.  While this proposal focuses primarily on 
characterizing the function of Pyrin in disease symptoms related to FMF, delineating the role of 
Pyrin will provide insight into the causes and potential treatments of all inflammatory disorders.  
 The overall aim of this dissertation was to assess the role of Pyrin in regulating innate 
immune responses.  Our approach was to generate Pyrin-deficient mice and characterize these 
mice in a naïve state and during innate immune responses.  We addressed the contribution of 
Pyrin to immune cell development, recruitment, activation, and survival.  The first specific aim 
focused on determining if Pyrin modulates inflammasome-mediated IL-1β production.  Although 
previous work has indicated that Pyrin can modulate IL-1β production, its contribution as a 
positive or negative regulator of IL-1β production is controversial.  Here, we address this 
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question using a genetic approach and in vitro and in vivo experimental systems.  The second 
specific aim of this work addresses the direct contribution of Pyrin to neutrophil physiology.  We 
used a genetic approach and in vitro and in vivo studies to detect differences in neutrophil 
development, recruitment, and/or survival in vitro and in vivo.  Our findings provide a framework 
for us to think about how mutations in Pyrin lead to misregulation of the inflammatory responses 
and contribute to spontaneous activation of the innate immune system in FMF. 
 
Research presented in this dissertation 
  In this dissertation, I present our investigations into how Pyrin regulates innate immune 
responses.  We generated Mefv-deficient mice, as described in chapter 2, that we used 
throughout this study to provide a novel in vitro and in vivo genetic system for assessing the 
consequences of a loss of Pyrin function.  Chapter 3 describes our studies to characterize the 
naïve state of Pyrin-deficient mice in order to determine if these mice had altered immune cell 
development or indications of spontaneous inflammation.  Chapter 4 details the role of Pyrin in 
IL-1β production.  Chapter 5 discusses our work to characterize the contribution of Pyrin to 
neutrophil physiology.  In chapter 6, we describe in vivo experimental models that we used to 
ascertain a role of Pyrin in fever and peritonitis, common symptoms of FMF.  Together, this 
work demonstrates that a loss of Pyrin function can alter the innate immune response, and 
specifically, inflammasome-dependent IL-1β production.  This finding suggests that a loss of 
Pyrin function is responsible for at least some of the pathological phenotypes seen in FMF 
patients. 
46 
 
References 
1. Rosenberg, P. M., and S. E. Goldfinger. 2011. Pathophysiology of familial Mediterranean 
fever. In UpToDate.com, 2011 ed. 
2. Shohat, M., and G. J. Halpern. 2011. Familial Mediterranean fever-A review. Genet Med 
13:487-498. 
3. Manukyan, G., K. Ghazaryan, Z. Ktsoyan, Z. Khachatryan, D. Kelly, M. Tatyan, M. 
Agababova, and R. Aminov. 2010. Comparative analysis of cytokine profiles in 
autoinflammatory and autoimmune conditions. Cytokine 50:146-151. 
4. Kallinich, T., H. Wittkowski, R. Keitzer, J. Roth, and D. Foell. 2010. Neutrophil-derived 
S100A12 as novel biomarker of inflammation in familial Mediterranean fever. Ann 
Rheum Dis 69:677-682. 
5. Consortium, F. F. 1997. A candidate gene for familial Mediterranean fever. Nat Genet 
17:25-31. 
6. Consortium, T. I. F. 1997. Ancient missense mutations in a new member of the RoRet gene 
family are likely to cause familial Mediterranean fever. Cell 90:797-807. 
7. Chae, J. J., M. Centola, I. Aksentijevich, A. Dutra, M. Tran, G. Wood, K. Nagaraju, D. W. 
Kingma, P. P. Liu, and D. L. Kastner. 2000. Isolation, genomic organization, and 
expression analysis of the mouse and rat homologs of MEFV, the gene for familial 
mediterranean fever. Mamm Genome 11:428-435. 
8. Tidow, N., X. Chen, C. Muller, S. Kawano, A. F. Gombart, N. Fischel-Ghodsian, and H. P. 
Koeffler. 2000. Hematopoietic-specific expression of MEFV, the gene mutated in familial 
Mediterranean fever, and subcellular localization of its corresponding protein, pyrin. 
Blood 95:1451-1455. 
9. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu Rev Immunol 
12:991-1045. 
10. Kono, H., and K. L. Rock. 2008. How dying cells alert the immune system to danger. Nat 
Rev Immunol 8:279-289. 
11. Shi, Y., J. E. Evans, and K. L. Rock. 2003. Molecular identification of a danger signal that 
alerts the immune system to dying cells. Nature 425:516-521. 
12. Chen, C. J., H. Kono, D. Golenbock, G. Reed, S. Akira, and K. L. Rock. 2007. Identification 
of a key pathway required for the sterile inflammatory response triggered by dying cells. 
Nat Med 13:851-856. 
13. Hallegua, D. S., and M. H. Weisman. 2002. Potential therapeutic uses of interleukin 1 
receptor antagonists in human diseases. Ann Rheum Dis 61:960-967. 
14. Chin, J., and M. J. Kostura. 1993. Dissociation of IL-1 beta synthesis and secretion in 
human blood monocytes stimulated with bacterial cell wall products. J Immunol 
151:5574-5585. 
47 
 
15. Pomerantz, B. J., L. L. Reznikov, A. H. Harken, and C. A. Dinarello. 2001. Inhibition of 
caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-
1beta. Proc Natl Acad Sci U S A 98:2871-2876. 
16. Westphal, E., M. Herzberg, I. Neumann, L. Beibei, C. Pilowski, C. Li, K. Werdan, and H. 
Loppnow. 2006. Neutrophils process interleukin-1beta and interleukin-18 precursors in a 
caspase-1-like fashion--processing is inhibited by human vascular smooth muscle cells. 
Eur Cytokine Netw 17:19-28. 
17. Faustin, B., L. Lartigue, J. M. Bruey, F. Luciano, E. Sergienko, B. Bailly-Maitre, N. 
Volkmann, D. Hanein, I. Rouiller, and J. C. Reed. 2007. Reconstituted NALP1 
inflammasome reveals two-step mechanism of caspase-1 activation. Mol Cell 25:713-
724. 
18. Hlaing, T., R. F. Guo, K. A. Dilley, J. M. Loussia, T. A. Morrish, M. M. Shi, C. Vincenz, and 
P. A. Ward. 2001. Molecular cloning and characterization of DEFCAP-L and -S, two 
isoforms of a novel member of the mammalian Ced-4 family of apoptosis proteins. J Biol 
Chem 276:9230-9238. 
19. Martinon, F., A. Mayor, and J. Tschopp. 2009. The inflammasomes: guardians of the body. 
Annu Rev Immunol 27:229-265. 
20. Mariathasan, S., D. S. Weiss, K. Newton, J. McBride, K. O'Rourke, M. Roose-Girma, W. P. 
Lee, Y. Weinrauch, D. M. Monack, and V. M. Dixit. 2006. Cryopyrin activates the 
inflammasome in response to toxins and ATP. Nature 440:228-232. 
21. Martinon, F., K. Burns, and J. Tschopp. 2002. The inflammasome: a molecular platform 
triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 
10:417-426. 
22. Kostura, M. J., M. J. Tocci, G. Limjuco, J. Chin, P. Cameron, A. G. Hillman, N. A. Chartrain, 
and J. A. Schmidt. 1989. Identification of a monocyte specific pre-interleukin 1 beta 
convertase activity. Proc Natl Acad Sci U S A 86:5227-5231. 
23. Petrilli, V., S. Papin, C. Dostert, A. Mayor, F. Martinon, and J. Tschopp. 2007. Activation of 
the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell 
Death Differ 14:1583-1589. 
24. Wewers, M. D. 2004. IL-1beta: an endosomal exit. Proc Natl Acad Sci U S A 101:10241-
10242. 
25. Martinon, F. 2008. Detection of immune danger signals by NALP3. J Leukoc Biol 83:507-
511. 
26. Lightfield, K. L., J. Persson, N. J. Trinidad, S. W. Brubaker, E. M. Kofoed, J. D. Sauer, E. A. 
Dunipace, S. E. Warren, E. A. Miao, and R. E. Vance. 2011. Differential requirements for 
NAIP5 in activation of the NLRC4 inflammasome. Infect Immun 79:1606-1614. 
27. Lamkanfi, M., T. D. Kanneganti, L. Franchi, and G. Nunez. 2007. Caspase-1 
inflammasomes in infection and inflammation. J Leukoc Biol 82:220-225. 
48 
 
28. Rathinam, V. A., Z. Jiang, S. N. Waggoner, S. Sharma, L. E. Cole, L. Waggoner, S. K. 
Vanaja, B. G. Monks, S. Ganesan, E. Latz, V. Hornung, S. N. Vogel, E. Szomolanyi-
Tsuda, and K. A. Fitzgerald. 2010. The AIM2 inflammasome is essential for host defense 
against cytosolic bacteria and DNA viruses. Nat Immunol 11:395-402. 
29. Jones, J. W., N. Kayagaki, P. Broz, T. Henry, K. Newton, K. O'Rourke, S. Chan, J. Dong, Y. 
Qu, M. Roose-Girma, V. M. Dixit, and D. M. Monack. 2010. Absent in melanoma 2 is 
required for innate immune recognition of Francisella tularensis. Proc Natl Acad Sci U S 
A 107:9771-9776. 
30. Kanneganti, T. D. 2010. Central roles of NLRs and inflammasomes in viral infection. Nat 
Rev Immunol 10:688-698. 
31. Elinav, E., T. Strowig, A. L. Kau, J. Henao-Mejia, C. A. Thaiss, C. J. Booth, D. R. Peaper, J. 
Bertin, S. C. Eisenbarth, J. I. Gordon, and R. A. Flavell. 2011. NLRP6 inflammasome 
regulates colonic microbial ecology and risk for colitis. Cell 145:745-757. 
32. Chen, G. Y., M. Liu, F. Wang, J. Bertin, and G. Nunez. 2011. A functional role for Nlrp6 in 
intestinal inflammation and tumorigenesis. J Immunol 186:7187-7194. 
33. Normand, S., A. Delanoye-Crespin, A. Bressenot, L. Huot, T. Grandjean, L. Peyrin-Biroulet, 
Y. Lemoine, D. Hot, and M. Chamaillard. 2011. Nod-like receptor pyrin domain-
containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal 
carcinogenesis upon injury. Proc Natl Acad Sci U S A 108:9601-9606. 
34. Agostini, L., F. Martinon, K. Burns, M. F. McDermott, P. N. Hawkins, and J. Tschopp. 2004. 
NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-
Wells autoinflammatory disorder. Immunity 20:319-325. 
35. Yang, S. K., H. Kim, M. Hong, J. Lim, E. Choi, B. D. Ye, S. K. Park, and K. Song. 2011. 
Association of CARD8 with inflammatory bowel disease in Koreans. J Hum Genet 
56:217-223. 
36. Franke, A., P. Rosenstiel, T. Balschun, O. Von Kampen, S. Schreiber, C. Sina, J. Hampe, 
T. H. Karlsen, M. H. Vatn, and C. Solberg. 2007. No association between the TUCAN 
(CARD8) Cys10Stop mutation and inflammatory bowel disease in a large retrospective 
German and a clinically well-characterized Norwegian sample. Gastroenterology 
132:2080-2081. 
37. Siegal, S. 1949. Benign paroxysmal peritonitis. Gastroenterology 12:234-247. 
38. Reimann, H. A. 1948. Periodic disease; a probable syndrome including periodic fever, 
benign paroxysmal peritonitis, cyclic neutropenia and intermittent arthralgia. J Am Med 
Assoc 136:239-244. 
39. Inohara, N., and G. Nunez. 2003. NODs: intracellular proteins involved in inflammation and 
apoptosis. Nat Rev Immunol 3:371-382. 
40. Yu, J. W., T. Fernandes-Alnemri, P. Datta, J. Wu, C. Juliana, L. Solorzano, M. McCormick, 
Z. Zhang, and E. S. Alnemri. 2007. Pyrin activates the ASC pyroptosome in response to 
engagement by autoinflammatory PSTPIP1 mutants. Mol Cell 28:214-227. 
49 
 
41. Shoham, N. G., M. Centola, E. Mansfield, K. M. Hull, G. Wood, C. A. Wise, and D. L. 
Kastner. 2003. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial 
Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl 
Acad Sci U S A 100:13501-13506. 
42. Papin, S., C. Cazeneuve, P. Duquesnoy, I. Jeru, D. Sahali, and S. Amselem. 2003. The 
tumor necrosis factor alpha-dependent activation of the human mediterranean fever 
(MEFV) promoter is mediated by a synergistic interaction between C/EBP beta and NF 
kappaB p65. J Biol Chem 278:48839-48847. 
43. Chae, J. J., H. D. Komarow, J. Cheng, G. Wood, N. Raben, P. P. Liu, and D. L. Kastner. 
2003. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to 
endotoxin and a defect in macrophage apoptosis. Mol Cell 11:591-604. 
44. Medlej-Hashim, M., N. Nehme, E. Chouery, N. Jalkh, and A. Megarbane. 2010. Novel 
MEFV transcripts in Familial Mediterranean fever patients and controls. BMC Med Genet 
11:87. 
45. Diaz, A., C. Hu, D. L. Kastner, P. Schaner, A. M. Reginato, N. Richards, and D. L. 
Gumucio. 2004. Lipopolysaccharide-induced expression of multiple alternatively spliced 
MEFV transcripts in human synovial fibroblasts: a prominent splice isoform lacks the C-
terminal domain that is highly mutated in familial Mediterranean fever. Arthritis Rheum 
50:3679-3689. 
46. Harton, J. A., M. W. Linhoff, J. Zhang, and J. P. Ting. 2002. Cutting edge: CATERPILLER: 
a large family of mammalian genes containing CARD, pyrin, nucleotide-binding, and 
leucine-rich repeat domains. J Immunol 169:4088-4093. 
47. Richards, N., P. Schaner, A. Diaz, J. Stuckey, E. Shelden, A. Wadhwa, and D. L. Gumucio. 
2001. Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-
induced apoptosis. J Biol Chem 276:39320-39329. 
48. Stehlik, C., and A. Dorfleutner. 2007. COPs and POPs: modulators of inflammasome 
activity. J Immunol 179:7993-7998. 
49. Woo, J. S., J. H. Imm, C. K. Min, K. J. Kim, S. S. Cha, and B. H. Oh. 2006. Structural and 
functional insights into the B30.2/SPRY domain. Embo J 25:1353-1363. 
50. Topaloglu, R., F. Ozaltin, E. Yilmaz, S. Ozen, B. Balci, N. Besbas, and A. Bakkaloglu. 2005. 
E148Q is a disease-causing MEFV mutation: a phenotypic evaluation in patients with 
familial Mediterranean fever. Ann Rheum Dis 64:750-752. 
51. 2011. Infevers: an online database for autoinflammatory mutations. In Infevers.com, 2008 
ed. 
52. Milhavet, F., L. Cuisset, H. M. Hoffman, R. Slim, H. El-Shanti, I. Aksentijevich, S. Lesage, 
H. Waterham, C. Wise, C. Sarrauste de Menthiere, and I. Touitou. 2008. The infevers 
autoinflammatory mutation online registry: update with new genes and functions. Hum 
Mutat 29:803-808. 
50 
 
53. Sarrauste de Menthiere, C., S. Terriere, D. Pugnere, M. Ruiz, J. Demaille, and I. Touitou. 
2003. INFEVERS: the Registry for FMF and hereditary inflammatory disorders 
mutations. Nucleic Acids Res 31:282-285. 
54. Touitou, I., S. Lesage, M. McDermott, L. Cuisset, H. Hoffman, C. Dode, N. Shoham, E. 
Aganna, J. P. Hugot, C. Wise, H. Waterham, D. Pugnere, J. Demaille, and C. Sarrauste 
de Menthiere. 2004. Infevers: an evolving mutation database for auto-inflammatory 
syndromes. Hum Mutat 24:194-198. 
55. Centola, M., G. Wood, D. M. Frucht, J. Galon, M. Aringer, C. Farrell, D. W. Kingma, M. E. 
Horwitz, E. Mansfield, S. M. Holland, J. J. O'Shea, H. F. Rosenberg, H. L. Malech, and 
D. L. Kastner. 2000. The gene for familial Mediterranean fever, MEFV, is expressed in 
early leukocyte development and is regulated in response to inflammatory mediators. 
Blood 95:3223-3231. 
56. Papin, S., P. Duquesnoy, C. Cazeneuve, J. Pantel, M. Coppey-Moisan, C. Dargemont, and 
S. Amselem. 2000. Alternative splicing at the MEFV locus involved in familial 
Mediterranean fever regulates translocation of the marenostrin/pyrin protein to the 
nucleus. Hum Mol Genet 9:3001-3009. 
57. Chae, J. J., G. Wood, K. Richard, H. Jaffe, N. T. Colburn, S. L. Masters, D. L. Gumucio, N. 
G. Shoham, and D. L. Kastner. 2008. The familial Mediterranean fever protein, pyrin, is 
cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood 
112:1794-1803. 
58. Mansfield, E., J. J. Chae, H. D. Komarow, T. M. Brotz, D. M. Frucht, I. Aksentijevich, and D. 
L. Kastner. 2001. The familial Mediterranean fever protein, pyrin, associates with 
microtubules and colocalizes with actin filaments. Blood 98:851-859. 
59. Waite, A. L., P. Schaner, C. Hu, N. Richards, B. Balci-Peynircioglu, A. Hong, M. Fox, and D. 
L. Gumucio. 2009. Pyrin and ASC co-localize to cellular sites that are rich in 
polymerizing actin. Exp Biol Med (Maywood) 234:40-52. 
60. Rao, K. M., and T. Meighan. 2006. Exposure in vivo to silica or lipopolysaccharide produces 
transient or sustained upregulation, respectively, of PYPAF7 and MEFV genes in 
bronchoalveolar lavage cells in rats. J Toxicol Environ Health A 69:481-490. 
61. Chae, J. J., G. Wood, S. L. Masters, K. Richard, G. Park, B. J. Smith, and D. L. Kastner. 
2006. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts 
directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A 
103:9982-9987. 
62. Papin, S., S. Cuenin, L. Agostini, F. Martinon, S. Werner, H. D. Beer, C. Grutter, M. Grutter, 
and J. Tschopp. 2007. The SPRY domain of Pyrin, mutated in familial Mediterranean 
fever patients, interacts with inflammasome components and inhibits proIL-1beta 
processing. Cell Death Differ 14:1457-1466. 
63. Balci-Peynircioglu, B., A. L. Waite, C. Hu, N. Richards, A. Staubach-Grosse, E. Yilmaz, and 
D. L. Gumucio. 2008. Pyrin, product of the MEFV locus, interacts with the proapoptotic 
protein, Siva. J Cell Physiol 216:595-602. 
51 
 
64. Jeru, I., S. Papin, S. L'Hoste, P. Duquesnoy, C. Cazeneuve, J. Camonis, and S. Amselem. 
2005. Interaction of pyrin with 14.3.3 in an isoform-specific and phosphorylation-
dependent manner regulates its translocation to the nucleus. Arthritis Rheum 52:1848-
1857. 
65. Dowds, T. A., J. Masumoto, F. F. Chen, Y. Ogura, N. Inohara, and G. Nunez. 2003. 
Regulation of cryopyrin/Pypaf1 signaling by pyrin, the familial Mediterranean fever gene 
product. Biochem Biophys Res Commun 302:575-580. 
66. Seshadri, S., M. D. Duncan, J. M. Hart, M. A. Gavrilin, and M. D. Wewers. 2007. Pyrin 
levels in human monocytes and monocyte-derived macrophages regulate IL-1beta 
processing and release. J Immunol 179:1274-1281. 
67. Yu, J. W., J. Wu, Z. Zhang, P. Datta, I. Ibrahimi, S. Taniguchi, J. Sagara, T. Fernandes-
Alnemri, and E. S. Alnemri. 2006. Cryopyrin and pyrin activate caspase-1, but not NF-
kappaB, via ASC oligomerization. Cell Death Differ 13:236-249. 
68. Goulielmos, G. N., E. Petraki, D. Vassou, E. Eliopoulos, D. Iliopoulos, P. Sidiropoulos, I. 
Aksentijevich, D. Kardassis, and D. T. Boumpas. 2010. The role of the pro-apoptotic 
protein Siva in the pathogenesis of Familial Mediterranean fever: A structural and 
functional analysis. Biochem Biophys Res Commun 402:141-146. 
69. Chen, X., Y. Bykhovskaya, N. Tidow, M. Hamon, Z. Bercovitz, O. Spirina, and N. Fischel-
Ghodsian. 2000. The familial mediterranean fever protein interacts and colocalizes with 
a putative Golgi transporter. Proc Soc Exp Biol Med 224:32-40. 
70. Badour, K., J. Zhang, F. Shi, M. K. McGavin, V. Rampersad, L. A. Hardy, D. Field, and K. 
A. Siminovitch. 2003. The Wiskott-Aldrich syndrome protein acts downstream of CD2 
and the CD2AP and PSTPIP1 adaptors to promote formation of the immunological 
synapse. Immunity 18:141-154. 
71. Waite, A. L., P. Schaner, N. Richards, B. Balci-Peynircioglu, S. L. Masters, S. D. Brydges, 
M. Fox, A. Hong, E. Yilmaz, D. L. Kastner, E. L. Reinherz, and D. L. Gumucio. 2009. 
Pyrin Modulates the Intracellular Distribution of PSTPIP1. PLoS One 4:e6147. 
72. Druilhe, A., S. M. Srinivasula, M. Razmara, M. Ahmad, and E. S. Alnemri. 2001. Regulation 
of IL-1beta generation by Pseudo-ICE and ICEBERG, two dominant negative caspase 
recruitment domain proteins. Cell Death Differ 8:649-657. 
73. Lamkanfi, M., G. Denecker, M. Kalai, K. D'Hondt, A. Meeus, W. Declercq, X. Saelens, and 
P. Vandenabeele. 2004. INCA, a novel human caspase recruitment domain protein that 
inhibits interleukin-1beta generation. J Biol Chem 279:51729-51738. 
74. Lee, S. H., C. Stehlik, and J. C. Reed. 2001. Cop, a caspase recruitment domain-containing 
protein and inhibitor of caspase-1 activation processing. J Biol Chem 276:34495-34500. 
75. Bedoya, F., L. L. Sandler, and J. A. Harton. 2007. Pyrin-only protein 2 modulates NF-
kappaB and disrupts ASC:CLR interactions. J Immunol 178:3837-3845. 
76. Dorfleutner, A., N. B. Bryan, S. J. Talbott, K. N. Funya, S. L. Rellick, J. C. Reed, X. Shi, Y. 
Rojanasakul, D. C. Flynn, and C. Stehlik. 2007. Cellular pyrin domain-only protein 2 is a 
candidate regulator of inflammasome activation. Infect Immun 75:1484-1492. 
52 
 
77. Srimathi, T., S. L. Robbins, R. L. Dubas, H. Chang, H. Cheng, H. Roder, and Y. C. Park. 
2008. Mapping of POP1-binding site on pyrin domain of ASC. J Biol Chem 283:15390-
15398. 
78. Stehlik, C., M. Krajewska, K. Welsh, S. Krajewski, A. Godzik, and J. C. Reed. 2003. The 
PAAD/PYRIN-only protein POP1/ASC2 is a modulator of ASC-mediated nuclear-factor-
kappa B and pro-caspase-1 regulation. Biochem J 373:101-113. 
79. Saleh, M., J. C. Mathison, M. K. Wolinski, S. J. Bensinger, P. Fitzgerald, N. Droin, R. J. 
Ulevitch, D. R. Green, and D. W. Nicholson. 2006. Enhanced bacterial clearance and 
sepsis resistance in caspase-12-deficient mice. Nature 440:1064-1068. 
80. Stehlik, C., S. H. Lee, A. Dorfleutner, A. Stassinopoulos, J. Sagara, and J. C. Reed. 2003. 
Apoptosis-associated speck-like protein containing a caspase recruitment domain is a 
regulator of procaspase-1 activation. J Immunol 171:6154-6163. 
81. Ben-Zvi, I., and A. Livneh. 2011. Chronic inflammation in FMF: markers, risk factors, 
outcomes and therapy. Nat Rev Rheumatol 7:105-112. 
82. Ben-Chetrit, E., and M. Levy. 1998. Does the lack of the P-glycoprotein efflux pump in 
neutrophils explain the efficacy of colchicine in familial Mediterranean fever and other 
inflammatory diseases? Med Hypotheses 51:377-380. 
83. Nuki, G. 2008. Colchicine: its mechanism of action and efficacy in crystal-induced 
inflammation. Curr Rheumatol Rep 10:218-227. 
84. Yin, T., and L. Li. 2006. The stem cell niches in bone. J Clin Invest 116:1195-1201. 
85. Rankin, S. M. 2010. The bone marrow: a site of neutrophil clearance. J Leukoc Biol 88:241-
251. 
86. Contributors, W. 2011. Neutrophil granulocyte. Wikipedia, The Free Encyclopedia. 
87. Cowburn, A. S., A. M. Condliffe, N. Farahi, C. Summers, and E. R. Chilvers. 2008. 
Advances in neutrophil biology: clinical implications. Chest 134:606-612. 
88. Fleming, T. J., M. L. Fleming, and T. R. Malek. 1993. Selective expression of Ly-6G on 
myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-
differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol 151:2399-
2408. 
89. Monteiro, A. P., C. S. Pinheiro, T. Luna-Gomes, L. R. Alves, C. M. Maya-Monteiro, B. N. 
Porto, C. Barja-Fidalgo, C. F. Benjamim, M. Peters-Golden, C. Bandeira-Melo, M. T. 
Bozza, and C. Canetti. 2011. Leukotriene B4 mediates neutrophil migration induced by 
heme. J Immunol 186:6562-6567. 
90. Ribeiro, R. A., C. A. Flores, F. Q. Cunha, and S. H. Ferreira. 1991. IL-8 causes in vivo 
neutrophil migration by a cell-dependent mechanism. Immunology 73:472-477. 
91. Ajuebor, M. N., A. M. Das, L. Virag, R. J. Flower, C. Szabo, and M. Perretti. 1999. Role of 
resident peritoneal macrophages and mast cells in chemokine production and neutrophil 
migration in acute inflammation: evidence for an inhibitory loop involving endogenous IL-
10. J Immunol 162:1685-1691. 
53 
 
92. Ostrovsky, L., J. Carvalho-Tavares, R. C. Woodman, and P. Kubes. 2000. Translational 
inhibition of E-selectin expression stimulates P-selectin-dependent neutrophil 
recruitment. Am J Physiol Heart Circ Physiol 278:H1225-1232. 
93. Shaw, A. C., S. Joshi, H. Greenwood, A. Panda, and J. M. Lord. 2010. Aging of the innate 
immune system. Curr Opin Immunol 22:507-513. 
94. Reddy, R. C., and T. J. Standiford. 2010. Effects of sepsis on neutrophil chemotaxis. Curr 
Opin Hematol 17:18-24. 
95. Gogus, F., I. Fresko, Y. Elbir, E. Eksioglu-Demiralp, and H. Direskeneli. 2005. Oxidative 
burst response to monosodium urate crystals in patients with Behcet's syndrome. Clin 
Exp Rheumatol 23:S81-85. 
96. Avetisian, S. A., T. K. Davtian, G. S. Akopian, A. M. Manukian, and D. A. Pogosian. 2006. 
[Spontaneous and inducible respiratory burst of monocytes and neutrophils in periodic 
autoinflammatory fever]. Patol Fiziol Eksp Ter:11-12. 
97. Akopian, V. P., S. A. Avetisian, and T. K. Davtian. 2005. [The effect of colcichine and 
iodine-lithium-alpha-dextrin on the phagocytosis of granulocytes and monocytes in 
patients with familial Mediterranean fever]. Eksp Klin Farmakol 68:36-39. 
98. Davtian, T. K., S. A. Avetisian, G. S. Akopian, and V. M. Arutiunian. 2005. [A respiratory 
splash of monocytes and neutrophils in familial Mediterranean fever]. Ter Arkh 77:39-43. 
99. Davtyan, T. K., G. S. Hakopyan, S. A. Avetisyan, and N. R. Mkrtchyan. 2006. Impaired 
endotoxin tolerance induction in patients with familial Mediterranean fever. Pathobiology 
73:26-39. 
100. Davtyan, T. K., V. A. Harutyunyan, G. S. Hakobyan, and S. A. Avetisyan. 2008. Heightened 
endotoxin susceptibility of monocytes and neutrophils during familial Mediterranean 
fever. FEMS Immunol Med Microbiol 52:370-378. 
101. Ledford, J. G., M. Kovarova, and B. H. Koller. 2007. Impaired host defense in mice lacking 
ONZIN. J Immunol 178:5132-5143. 
102. Cronstein, B. N., Y. Molad, J. Reibman, E. Balakhane, R. I. Levin, and G. Weissmann. 
1995. Colchicine alters the quantitative and qualitative display of selectins on endothelial 
cells and neutrophils. J Clin Invest 96:994-1002. 
103. Phelps, P. 1970. Polymorphonuclear leukocyte motility in vitro: IV. Colchicine inhibition of 
chemotactic activity formation after phagocytosis of urate crystals. Arthritis Rheum 
13:S25-33. 
104. Akopian, V. P., S. A. Avetisian, and T. K. Davtian. 2005. [The effect of colchicine on the 
periodicity of the spontaneous and induced respiratory burst of granulocytes and 
monocytes during familial Mediterranean fever]. Eksp Klin Farmakol 68:36-39. 
105. Bernot, A., C. da Silva, J. L. Petit, C. Cruaud, C. Caloustian, V. Castet, M. Ahmed-Arab, C. 
Dross, M. Dupont, D. Cattan, N. Smaoui, C. Dode, C. Pecheux, B. Nedelec, J. 
Medaxian, M. Rozenbaum, I. Rosner, M. Delpech, G. Grateau, J. Demaille, J. 
Weissenbach, and I. Touitou. 1998. Non-founder mutations in the MEFV gene establish 
54 
 
this gene as the cause of familial Mediterranean fever (FMF). Hum Mol Genet 7:1317-
1325. 
106. Mor, A., Y. Shinar, N. Zaks, P. Langevitz, A. Chetrit, S. Shtrasburg, E. Rabinovitz, and A. 
Livneh. 2005. Evaluation of disease severity in familial Mediterranean fever. Semin 
Arthritis Rheum 35:57-64. 
107. Gershoni-Baruch, R., M. Shinawi, H. Shamaly, L. Katsinetz, and R. Brik. 2002. Familial 
Mediterranean fever: the segregation of four different mutations in 13 individuals from 
one inbred family: genotype-phenotype correlation and intrafamilial variability. Am J Med 
Genet 109:198-201. 
108. Medlej-Hashim, M., E. Chouery, N. Salem, V. Delague, G. Lefranc, J. Loiselet, and A. 
Megarbane. 2010. Familial Mediterranean fever in a large Lebanese family: multiple 
MEFV mutations and evidence for a Founder effect of the p.[M694I] mutation. Eur J Med 
Genet 54:50-54. 
109. Fragouli, E., E. Eliopoulos, E. Petraki, P. Sidiropoulos, I. Aksentijevich, E. Galanakis, H. 
Kritikos, A. Repa, G. Fragiadakis, D. Boumpas, and G. N. Goulielmos. 2008. Familial 
Mediterranean Fever in Crete: a genetic and structural biological approach in a 
population of 'intermediate risk'. Clin Genet 73:152-159. 
110. Dundar, M., E. F. Emirogullari, A. Kiraz, S. Taheri, and M. Baskol. 2010. Common Familial 
Mediterranean Fever gene mutations in a Turkish cohort. Mol Biol Rep. 
111. Berdeli, A., S. Mir, S. Nalbantoglu, N. Kutukculer, B. Sozeri, Y. Kabasakal, S. Cam, and M. 
Solak. 2011. Comprehensive Analysis of a Large-Scale Screen for MEFV Gene 
Mutations: Do They Truly Provide a "Heterozygote Advantage" in Turkey? Genet Test 
Mol Biomarkers. 
112. Jalkh, N., E. Genin, E. Chouery, V. Delague, M. Medlej-Hashim, C. A. Idrac, A. Megarbane, 
and J. L. Serre. 2008. Familial Mediterranean Fever in Lebanon: founder effects for 
different MEFV mutations. Ann Hum Genet 72:41-47. 
113. Schaner, P., N. Richards, A. Wadhwa, I. Aksentijevich, D. Kastner, P. Tucker, and D. 
Gumucio. 2001. Episodic evolution of pyrin in primates: human mutations recapitulate 
ancestral amino acid states. Nat Genet 27:318-321. 
114. Shinar, Y., I. Kuchuk, S. Menasherow, M. Kolet, M. Lidar, P. Langevitz, and A. Livneh. 
2007. Unique spectrum of MEFV mutations in Iranian Jewish FMF patients--clinical and 
demographic significance. Rheumatology (Oxford) 46:1718-1722. 
115. Guz, G., M. Kanbay, and M. A. Ozturk. 2009. Current perspectives on familial 
Mediterranean fever. Curr Opin Infect Dis 22:309-315. 
 
 
 
CHAPTER 2  
Expression of Mefv 
 
 Familial Mediterranean Fever (FMF) is characterized by aberrant activation of the immune 
system.  Thus, it not surprising that MEFV expression levels are high in immune tissues in both 
humans and mice.  To further clarify which immune tissues of the mouse express Mefv, real-
time PCR was used to assess expression.  Mefv expression was detected in several organs and 
it was particularly high in bone marrow.   High expression was found in cells of the myeloid 
lineage and increased as cells matured along this lineage.  Expression of Mefv in macrophages 
was induced after exposure to lipopolysaccharide (LPS) and Interleukin-4 (IL-4).  The detection 
of Mefv in immune tissues of naïve mice, and the increased expression of Mefv during immune 
cell maturation and activation suggests that Pyrin function is important to the immune system 
during normal physiological states and is increasingly important during activation of the immune 
system.  
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Introduction 
 FMF is characterized by sudden inflammatory episodes associated with neutrophil influx 
and elevated acute response proteins and cytokines (1).  Previous research suggests that FMF 
is, at least in part, due to problems with intrinsic neutrophil and monocyte/macrophage functions 
(2-5). Accordingly, expression of MEFV can be detected in neutrophils and macrophages from 
humans and mice (6, 7).  However, several conundrums in the proposed models by which 
mutations in Pyrin causes FMF leave open the possibility that Pyrin may contribute to processes 
in additional cell types that have not been examined.   
 Neutrophils and macrophages differentiate from a common myeloid precursor cell in the 
bone marrow.  The profile of neutrophils and macrophages changes as they mature and 
following exposure to immune stimuli and cytokines.  For example, the expression of surface 
antigen receptors changes during the 24 h lifespan of neutrophils, and the expression profiles 
correlates with the extent of activation, extravasation, recruitment, and apoptosis of neutrophils 
(8).  Macrophages develop from immature macrophages, or monocytes, give rise to other cell 
types:  dendritic cells and osteoclasts, and to 4 subsets of macrophages:  innate activated, 
classically activated, alternatively activated, and deactivated.  Each of these cell types differs in 
immune function (9).  Differences between monocytes and macrophages are particularly well-
characterized and include differences in phagocytosis, cytokine release, cell migration, and cell 
survival mechanisms (9-11).  Specifically, the magnitude and kinetics of IL-1β cytokine release 
varies with monocyte/macrophage cell maturity (11).  This is of particular interest since human 
MEFV expression changes following maturation of and activation of neutrophils and 
macrophages (2, 11, 12). 
 We examined the expression levels of Mefv in immune tissues collected from mice.  Mefv 
expression was high in the spleen and bone marrow, but was also detected, at a much lower 
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level, in other immune organs.  Mefv expression was high in neutrophils and macrophages and 
was increased by cell maturation and activation. 
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Materials and Methods 
Sources of RNA 
 Whole organs (lung, iguanal lymph nodes, thymus, and spleen) were snap-frozen and 
smashed to collect tissue for RNA preparation.  Whole bone marrow was collected by flushing 
femurs and tibias with phosphate-buffered saline (PBS; Gibco).  Bone marrow was cultured with 
appropriate cytokines to derive mast cells (interleukin-3, stem-cell factor) and macrophages (L-
cell conditioned media as a source of M-CSF).  Bone-marrow neutrophils were isolated from 
total bone marrow by centrifugation through a Histopaque density gradient (density 1.083 g/mL 
and 1.119 g/mL; Sigma-Aldrich) per manufacturer’s instructions.  Greater than 90% of cells 
were classified as neutrophils based upon morphological analysis of cytospun cells stained with 
Hema-3 (Protocol, Fisher Scientific).  Resident peritoneal macrophages were collected by PBS 
lavage from the peritoneal cavity of naïve mice.  Peritoneal cells were cultured in media without 
serum for 2 h to isolate adherent macrophages from other cell types.  Recruited/elicited 
peritoneal macrophages were collected by peritoneal lavage, as above, from mice treated 3 d 
prior with intraperitoneal (i.p.) injection of 3 mLs of 3% Brewer’s thioglycolate medium.  Elicited 
neutrophils were collected from the peritoneal cavity of mice at 4 h following i.p. injection of 1 
mL of 1 mg/mL Zymosan-A in PBS. 
 Total RNA was isolated using RNA Bee (Tel-test) as instructed by the manufacturer.  RNA 
was eluted in nuclease-free water.  The optical density (OD) at 260 nm was used to determine 
RNA concentration, and the 260/280 nm ratio was 1.7 – 2.0 for all samples.   
Real-time PCR  
 Total RNA was converted to cDNA per manufacturer’s protocol (high capacity cDNA 
Reverse Transcription Kit; Applied Biosystems).  For neutrophils, 500 ng of total RNA was used.  
Expression of Mefv, Nlrp3, Pycard, Il1b, Gapdh, β-actin, and Hprt were detected with TaqMan 
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universal PCR master mix and probes Mm00490258_m1 (Mefv), 4352932-070313 (Gapdh), 
4352664-0608007 (β-actin), and Mm00446968_m1 (Hprt) by an ABI Prism 7900HT detection 
system according to manufacturer protocol (all from Applied Biosystems).  The Mefv probe 
detects all known splice variants.  Relative gene expression values were calculated from the 
cycle number (Ct) data by the equations below. 
1. Ct Mefv – Ct Gapdh = Δ Ct  (normalizes Mefv to the Gapdh internal sample control) 
2. Δ Ct of sample - Δ Ct of control sample = ΔΔ Ct  (normalizes values to control sample) 
3. 2 ^ -ΔΔ Ct = fold change  (converts values to relative expression ratio) 
Northern blot expression analysis 
 Total neutrophil RNA was electrophoresed on a 1.1% formaldehyde, 1.2% agarose gel 
containing formamide and transferred to a nylon membrane (Bright Star Plus Positively-charged 
nylon membrane, Ambion).  Full-length cDNA corresponding to Mefv was radiolabeled with [α-
32P]dCTP per manufacturer’s instructions (Random Primed DNA Labeling Kit; Roche 
AppliedScience).  RNA blots were probed with radiolabled cDNA probe in hybridization buffer 
following manufacter’s protocol (ULTRAhyb Ultrasensitive Hybridization Buffer, Applied 
Biosystems).  Membranes were hybridized and washed at 42°C.  RNA was visualized on 
autoradiography film (BioMax, Kodak) following overnight storage with the membrane at -80°C.  
Membranes were probed with a β-actin probe following the same protocol.   
Statistical Analyses 
 One-way ANOVA and Tukey’s post-test were used to determine significance. 
Animal Care and Use 
 All experiments were conducted in accordance with the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals as well as the Institutional Animal Care and Use 
Committee guidelines of UNC Chapel Hill. 
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Results 
Cells of the myeloid lineage express high levels of Mefv 
 Broader expression of MEFV has been detected in humans by RT-PCR (12) than in mice 
by northern blot (7).  We reasoned that Mefv might have a broader expression pattern in mice at 
a low-level that limits detection by northern blot.  Mefv expression in immune tissues was 
analyzed using real-time PCR.  Expression was detected in spleen as expected, but also in 
lymph node and bone marrow and to a lesser extent in lung and thymus (Figure 2.1A).  Based 
upon northern blot analysis, expression was highest in myeloid cells, and expression in 
neutrophils was markedly increased compared to macrophages (Figure 2.1B).  Expression of 
Mefv was undetectable in bone marrow-derived mast cells (data not shown).   
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Figure 2.1.  Mefv is expressed in immune tissues.  A, Real-time PCR analysis of Mefv 
expression in WT tissues.  Ct values are normalized to Gapdh and expressed as fold change 
relative to bone marrow.  The raw Ct value of Mefv in all tissues was below 32 for all tissues 
shown.  The Ct value of neutrophils from Mefv-/- mice was undetermined (>40).  B, Northern blot 
analysis to detect Mefv transcripts in bone marrow, recruited peritoneal neutrophils, and 
recruited peritoneal macrophages.  Full-length Mefv cDNA was used as a probe.  Equal 
amounts of RNA for each sample were loaded.   
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Mefv expression is increased upon maturation of neutrophils and macrophages 
 To further characterize the expression of Mefv in myeloid cells, neutrophils and 
macrophages were harvested from different tissues within the mouse.  Neutrophils were 
isolated from total bone marrow or peritoneal cells were collected at 4 h following treatment with 
Zymosan A.  At the mRNA transcript level, Mefv expression was 23-fold higher in neutrophils 
recruited to the peritoneal cavity than in neutrophils isolated from the bone marrow (Figure 
2.2A).  In macrophages, Mefv expression was easily detected in bone marrow-derived 
monocyte/macrophages.  Bone marrow-derived macrophages were cultured for 8 – 12 days 
before expression analysis, and no significant differences were seen in Mefv expression.  
However, Mefv expression was markedly higher in both resident peritoneal macrophages 
(rpMΦ) and in macrophages collected from the peritoneal cavity at 72 h after the induction of 
peritonitis with the sterile immunostimulant, thioglycolate (Figure 2.2B).   
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Figure 2.2.  Mefv expression increases upon matuaration of neutrophils and 
macrophages collected from mice.  Relative expression of Mefv was determined by real-time 
PCR analysis for neutrophils, A, and macrophages, B.  A, Neutrophils were isolated from bone 
marrow or peritoneal cells were harvested at 4 h after treatment with 1 mg of Zymosan-A i.p.  
Greater than 90% of cells were considered neutrophils by differential cell staining.  Data are 
expressed as fold change relative to bone marrow neutrophils.  RNA from several wild-type 
B6;129S6 mice was pooled.  Results are representative of two experiments.  B, Macrophages 
were derived from whole bone marrow (BMMΦs) or were collected from the peritoneal cavity of 
naïve mice (resident peritoneal macrophages, rpMΦs) or mice at 72 h after treatment with 
thioglycolate (elic pMΦs).  Expression of myeloperoxidase, a gene expressed in neutrophils but 
not macrophages, was measured to ensure that differences in expression were not due to the 
presence of neutrophils.  Data are expressed as fold change relative to BMMΦs. 
 
Mefv expression is increased upon activation of macrophages 
 Previous reports indicate that Pyrin expression is affected by treatment of macrophages 
with LPS and cytokines.  However, previous studies show that Interleukin (IL)-4 and Interferon-
gamma (IFN-γ) have opposing affects on Mefv expression in mice and humans.  Whereas IL-4 
increases Pyrin protein expression in mice, it inhibits expression in humans.  IFN-γ does not 
affect expression of mouse Pyrin but increases Pyrin protein levels in humans (2, 5).  Here, the 
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abundance of Mefv transcripts was measured in macrophages cultured for 24 h in the presence 
of LPS, LPS and IL-4, or left untreated.  Consistent with previous findings at the protein level 
(5), Mefv expression increased after treatment with LPS and LPS and IL-4.  Expression levels of 
inflammasome proteins Nlrp3 and Pycard, which are involved in IL-1β production, and 
expression of Il1β itself were also determined.  Similar to Mefv, Nlrp3, and Il1β expression were 
increased after treatment with LPS.  The addition of IL-4 resulted in a further increase in Nlrp3 
and Il1β expression (Figure 2.3).     
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Figure 2.3.  Mefv expression in macrophages is increased after pathogen and cytokine 
treatment.  Thioglycolate-elicited peritoneal macrophages were cultured for 22 h with 1 µg/mL 
lipopolysaccharide (LPS) and 12.5 ng/mL as indicated.  Relative expression of A, Mefv, B, 
Nlrp3, C, Pycard, and D, Il1β was detected by real-time PCR.  Results are expressed as fold 
change compared to PBS-treated samples.  n = 3.  *, p < 0.05 for LPS or LPS + IL-4 treatment 
compared to PBS treatment.  #, p < 0.05 for LPS + IL-4 treatment compared to LPS. 
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Discussion 
 Here, we describe our analysis of Mefv expression in wild-type mice.  Previous studies 
indicate that Mefv is expressed in a broad set of tissues in humans (12), and we hypothesized 
that expression in the mouse might be broader than previously appreciated due to the detection 
limit of northern blot analyses.  The pathology of FMF is especially complex and many different 
tissue and cell types may be involved in inflammatory attacks.   
 Our studies indicate that Mefv expression is highest in the bone marrow, spleen, and lymph 
nodes, but can also be detected at low levels in the lung and thymus.  On a cellular level, 
expression was highest in neutrophils and macrophages and was undetectable in bone marrow-
derived mast cells.  By using cDNA derived from Mefv-null neutrophils as a negative control, a 
difference between low-level expression and no expression could be resolved.  Our findings 
extend the panel of tissues in mice that express Mefv, although these results should be 
confirmed at the protein level once a Pyrin antibody is commercially available.  Among the panel 
of tissues previously characterized by northern blot analysis, expression was detected in the 
spleen but not the thymus, lung, brain, heart, kidney, liver, muscle, ovary, or testis (7).  In 
humans, significant expression of MEFV can be detected in the spleen, lung, consistent with the 
profile of mouse Mefv.  In contrast, human MEFV is also expressed in muscle, and previous 
results of semi-quantitative RT-PCR analysis also showed a low number of MEFV transcripts in 
cDNA collected from heart, kidney, and liver organs.  MEFV transcripts were not detected in the 
small intestines, brain, prostate, or ovary (12), and the later three organs in the mouse also lack 
Mefv expression (7).  At the cellular level, human MEFV expression is highest in neutrophils and 
macrophages, and there is low expression in B220+ B cells, CD3+ T cells, eosinophils, dendritic 
cells, and epithelial cells of the lung, peritoneum, and synovium (6, 12, 13).  Previous reports 
suggest that murine Mefv expression is limited to neutrophils and monocytes/macrophages.  
Expression of Mefv in whole bone marrow or lymph nodes was not examined previously.  High 
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expression in bone marrow was expected, since a large portion of bone marrow cells are 
developing/maturing neutrophils.  It is not surprising to see low level of expression in the lung, 
since expression of Mefv in the lung has been reported for rats and humans.  The low level of 
expression in that was detected in the lung and thymus in our studies using real-time PCR is 
likely below the detection limit of northern blot analysis that was used in the previous study (7).  
Low expression in human T cells may correspond with the low level of Mefv expression that we 
detected in the thymus of mice. 
 We found that Mefv expression was increased in neutrophils and macrophages from the 
peritoneal cavity in comparison to neutrophils collected from the bone marrow or 
monocytes/macrophages derived from bone marrow precursors.  Since expression is also 
increased in resident or resting peritoneal macrophages compared to bone marrow-derived 
macrophages, the increased expression is likely to be a function of cell maturity in the myeloid 
lineage.  In humans, on the other hand, the expression of Pyrin decreases as peripheral blood 
mononuclear cells are differentiated from monocytes to macrophages (11).  However, our 
findings for neutrophils are consistent with previous reports that expression of MEFV increases 
in HL-60 promyeloblast cells and peripheral blood hematopoietic precursors as they differentiate 
along a granulocytic lineage (12).  The influence of cell maturity on Mefv expression may be a 
species and/or cell type –specific contribution, but further research is necessary to examine this 
possibility. 
 Consistent with previous reports (5), our results indicate that expression of the mouse Mefv 
gene is enhanced following exposure to LPS and IL-4, at least in macrophages.  Expression 
levels of inflammasome complex genes and Il1β were also assessed in parallel to provide 
context for future studies to assess the role of Pyrin in inflammasome-dependent IL-1β 
production, which will be discussed in Chapter 4.  Expression of the human MEFV gene is also 
increased after exposure of monocytes and macrophages to LPS (2, 6, 11), however, IL-4 does 
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not increase human MEFV expression in peripheral blood mononuclear cells and instead 
decreases MEFV expression (2).  IL-4 stimulates an alternative activation phenotype of 
macrophages (14) and polarizes T cells towards a T helper type 2 response (9, 15).  
Interestingly, Interferon-gamma, which polarizes T cells towards T helper type 1, increases 
MEFV expression in humans and mice (2, 5, 9).  One previous study found that FMF patients 
have higher levels of cytokines associated with T helper type 1 responses (16).  Further studies 
are needed to clarify the role of wild-type and mutant Pyrin proteins in T cell polarization and 
alternative versus classical activation of macrophages.   
 It is unclear whether or not FMF-associated mutations within MEFV have an effect on 
MEFV expression levels.  Since the majority of these mutations lie within the coding region 
rather than the promoter or intronic regions, they are more likely to affect protein function or 
protein stability rather than transcript or protein expression levels.  Previous studies have 
demonstrated increased, decreased, or unchanged expression of MEFV in FMF patients 
compared to healthy controls (17, 18).  Alternative splicing of the MEFV transcript has been 
well-described (19), so conclusions regarding the effect of mutations on expression levels are 
complicated by the ability to detect splice variants of the MEFV transcript or isoforms of the 
Pyrin protein they encode.  A recent study has also shown that non-sense mediated decay is 
involved in the regulation of expression of MEFV transcripts (18). 
Information from these expression analyses extends the rationale for future studies using Mefv-
deficient mice.  Since a difference due to the loss of Mefv will be more apparent in cells with 
high levels of expression, future studies will focus on neutrophils and macrophages isolated 
from the peritoneal cavity. 
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CHAPTER 3 
Creation of Mefv null mice and characterization of naïve mice 
 
 The ability to engineer mouse lines with mutations in genes suspected to contribute to a 
particular signaling pathway has facilitated our understanding of the immune response.  In 
particular, mice with mutations in genes involved in inflammasome signaling have extended our 
knowledge of the involvement of these genes during in vivo pathogen responses.  In this 
chapter, I describe the creation of a mouse line that lacks the Mefv gene, which encodes the 
Pyrin protein.  We used a unique targeting strategy to remove the coding region and all known 
regulatory elements.  The loss of Mefv did not impact the growth or survival of mice, nor did it 
impact the size or cellular composition of immune organs.  These results suggest that mice in a 
naïve state can compensate for the loss of Pyrin function. 
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Introduction 
 Genetically altered mice provide a system to isolate the contribution of a gene in a 
physiologically relevant in vivo system.  The development of constitutive knock-out, conditional 
knockout, and transgenic mouse models, as well as selective breeding strategies to maintain 
spontaneous mutations, have helped to elucidate the contribution of a gene or cell type towards 
inflammation.  Specific to the inflammasome pathway, mice deficient in Nlrp1b, Nlrp3, Nlrc4, 
Aim2, Pycard (ASC), and Caspase-1 have been developed (1-4).  Bone marrow-derived 
macrophages and macrophages collected from the peritoneal cavities of these animals have 
impaired IL-1β production, demonstrating that these proteins enhance IL-1β production (1-5).  
Caspase-12 deficient mice, on the other hand, display elevated levels of IL-1β, indicating that 
Caspase-12 negatively regulates IL-1β production in mice (6).  Treatment of genetically deficient 
mice provides evidence that the importance of these proteins for IL-1β production and pathogen 
resistance is maintained in vivo. (1-4, 6-9).  Thus, it is reasonable to anticipate that a 
contribution of Mefv (Pyrin) towards inflammasome-dependent IL-1β production, either 
enhancing or inhibiting IL-1β production, will be detectable using in vitro and in vivo 
experimental systems. 
 Targeting constructs designed to generate null alleles can result in modified loci, which 
because of alternative splicing, continue to direct the production of a protein with some activity.  
Perhaps even more problematic, in some cases, integration of a targeting vector generates an 
allele that produces transcripts encoding proteins with novel function.  These possibilities are of 
particular concern when alternative splicing has been well documented, as is the case for the 
Mefv gene (10, 11).  Alternative splicing of Mefv transcripts may significantly alter Pyrin function 
(10). 
 The inflammatory attacks of Familial Mediterranean Fever (FMF) occur in the apparent 
absence of a pathogen, thus, stimulation of the immune response with a pathogen is not 
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required to detect the immune system defect in these patients.  Consistent with this, as 
previously described in Chapter 2, Mefv is expressed in immune organs of naïve, or untreated 
mice, which suggests that Pyrin functions in the development or maintenance of the immune 
system in a naïve, or homeostatic, state.   
 To enable further study of the contribution of Pyrin to IL-1β production and FMF 
pathophysiology, we created a Mefv-defecient mouse line.  A targeting construct capable of 
removing the entire coding sequence and the promoter region of the gene was developed to 
ensure that the mutation introduced into the Mefv locus creates a null allele.  The survival and 
growth of these mice, and the cell profiles of immune organs were maintained despite the loss 
of Pyrin. 
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Materials and Methods 
Creation of MefvDel targeting plasmid 
 A bacterial artificial chromosome (BAC) containing the Mefv genomic region of the mouse 
strain 129S7/SvEv (clone ID bMQ133e1, Geneservice, United Kingdom) was altered by Red/ET 
recombination in bacteria to generate a targeting vector (MefvDel).  The entire coding region and 
5 kb upstream and downstream was removed and replaced with a deletor cassette.  
Bioinformatic websites http://genome.ucsc.edu/ and http://genome.lbl.gov/vista/index.shtml were 
used to assign the gene region and assess possible regulatory regions within the promoter and 
3’ intergenic region.  The deletor cassette contains a Neor,Kanr gene that was used for 
selection, a loxP site and the 3’ end of the Hprt gene that were used for a later genetic 
manipulation of the Mefv locus, and Bam HI and Xba I restriction digest sites that allowed for 
screening of targeting events by Southern blot.  The region downstream of the Mefv gene in the 
BAC was shortened and replaced with an ampicillin resistance cassette (Ampr), but proper 
recombination in ESCs prevents incorporation of Ampr into the mouse genome.  MefvDel was 
linearized and electroporated into embryonic stem cells (ESCs) derived from 129Sv/Ev mice.  
Table 2.2 lists the PCR primers used in construction of MefvDel. 
Detection of ESC transformants and mice carrying a targeted allele 
 ESC transformants were isolated by selection using standard methodologies (12) ESC 
lysates were prepared and used for PCR analysis with the primers listed in Table 2.2.  For 
Southern blotting, DNA was isolated from ESCs using standard methodologies.  DNA was 
digested with Bam HI or Xba I and electrophoresed through a 0.8% agarose gel and transferred 
to a Nitrocellulose (Hybond-N) membrane.  A 527-bp genomic fragment, created by PCR using 
the primers shown in Table 2.2, hybridizes downstream of the targeted region and was used as 
a probe.  The probe was radiolabeled with [α-32P]dCTP per manufacturer’s instructions 
(Random Primed DNA Labeling Kit; Roche AppliedScience) and hybridized to the nylon 
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membrane as instructed (Rapid-hyb, GE Healthcare Life Sciences).  DNA fragment length was 
visualized on autoradiography film (BioMax, Kodak) following overnight storage with the 
membrane at -80°C.  A custom-made real-time PCR probe (Applied Biosystems) was 
engineered to detect the copy numbers of exon 1 of Mefv in the genome relative to the number 
of copies of the Hprt gene.  ESCs that contained a targeted Mefv allele were injected into 
C57BL/6 blastocysts, and the chimeric blastocysts were implanted into C57BL/6 foster moms.  
Chimeric mice were identified by coat color and mated with both C57BL/6 and 129/SvEv mice.  
Transmission of the targeted allele was identified by Southern blot. 
Northern blotting 
 Total RNA was isolated from neutrophils using RNA Bee (Tel-test) as instructed by the 
manufacturer.  RNA was electrophoresed through a 1.1% formaldehyde, 1.2% agarose gel 
containing formamide and transferred to a nylon membrane (Bright Star Plus Positively-charged 
nylon membrane, Ambion).  Full-length cDNA corresponding to Mefv was radiolabeled with [α-
32P]dCTP per manufacturer’s instructions (Random Primed DNA Labeling Kit; Roche 
AppliedScience).  RNA blots were probed with radiolabled cDNA probe in hybridization buffer 
following manufacter’s protocol (ULTRAhyb Ultrasensitive Hybridization Buffer, Applied 
Biosystems).  Membranes were hybridized and washed at 42°C.  RNA was visualized on 
autoradiography film (BioMax, Kodak) following overnight storage with the membrane at -80°C.  
Membranes were probed with a β-actin probe following the same protocol.   
Real-time PCR to detect Mefv expression 
 Total RNA was isolated from the bone marrow and spleen, and the optical density (OD) at 
260 nm was used to determine RNA concentration.  RNA was converted to cDNA per 
manufacturer’s protocol (high capacity cDNA Reverse Transcription Kit; Applied Biosystems).  
TaqMan universal PCR master mix and probes corresponding to Mefv and β-actin mRNA 
transcripts were used to quantify fluorescence intensity by an ABI Prism 7900HT detection 
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system according to manufacturer protocol (all from Applied Biosystems).  The Mefv probe 
detects all known splice variants.  Relative expression values were calculated from the cycle 
number (Ct) data. 
Mouse genotyping 
 Mice used in experiments were genotyped by PCR and/or Southern blot.  PCR primer 
sequences listed in Table 2.2.  PCR product sizes were 351 bases for the WT allele and 594 
bases for the targeted allele. 
Flow cytometry 
 Single-cell suspensions of thymocytes, splenocytes, and lymph node cells were prepared 
using standard methodologies.  Cells were incubated in PBS containing 0.1% BSA during 
staining.  Fc-block, Gr-1-APC, CD11b-PE, CD-11c-FITC, CD-3-FITC, CD-4-PE, CD-8-PE Abs 
(BD Biosciences) were used as recommended by the manufacturer and compared with isotype-
matched Ab controls.  Samples were scanned using a Beckman Coulter CyAn ADP Analyzer, 
and data were analyzed using FloJo (TreeStar) software. 
Peritoneal lavage 
The peritoneal cavity was lavaged with 4 mL phosphate-buffered saline (PBS) and the 
concentration of cells was determined using a hemocytometer. 
Blood analysis 
 Blood was collected by cardiac puncture.  Whole blood containing 5mM EDTA was used for 
analysis on the Heska Hematology Analyzer by the Animal Clinical Chemistry and Gene 
Expression Laboratory at UNC-Chapel Hill.   
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Use of animals   
 All experiments were conducted in accordance with the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals as well as the Institutional Animal Care and Use 
Committee guidelines of UNC Chapel Hill. 
 
Table 2.1. PCR primers. 
Construction of MefvDel vector: 
 3’ Red/ET arm upper (56624): gagaggtacCAAGAGGGGCAAGATTTGAA 
 3’ Red/ET arm 5’ junx lower (56621): 
GTGCTCGAAGGAGTTTCCTGcaattggctagc
acgcgtggatcctctagaGCCCTGTGTTGCCATA
ACTT 
 5’ Red/ET arm upper (56623): gagaggtacCTCATGGCTCTTGCTGCATA 
 5’ Red/ET arm lower (56622): CAGGAAACTCCTTCGAGCAC 
 Amp 3’ deletion (56719): 
CTTTGGCCGCCGCCCAGTCCTGCTCGCT
TCGCTACTTGGAGCCACTATCGATGATCT
TTTCTACGGGGTCTGACG 
Screen for targeted ESCs: 
 Upper Common BAC primer 
 Lower: AGATCCACGCCTAGCTTTCA 
3’ probe for Southern blot: 
 Upper: GTGGTGGGTCTTCCTGTGTT 
 Lower: GGTCTCTGTATGGGGTTGAAA 
Mouse genotyping primers: 
 Endogenous: CTTTGGAGATTGCTGGCTGT 
 Common: TCCAGGAAATGGAGAGATGG 
 Targeted: AAATGCCTGCTCTTTACTGAAGG 
PCR primers are listed in forward orientation. 
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Results 
Design of the Mefv targeting vector 
 The mouse Mefv gene is located within a 10 kb region on chromosome 16 in the mouse.  
The primary transcript contains 10 exons, with the translational start site located in exon 1.  To 
generate a mouse line carrying a null Mefv allele, we designed a targeting construct capable of 
deleting the entire Mefv locus.  Homologous recombination of this vector with the endogenous 
gene resulted in a 21 kb deletion at the Mefv locus, replacing the gene with a selectable marker 
gene. This deletion includes all identified exons as well as the 5 kb promoter region and the 
intergenic region immediately 3’ of the 3’UTR (Figure 3.1A).  A Vista plot of the genomic region 
was used to ensure that regions which are conserved between the human, mouse, and rat 
genomes and are likely to represent regulatory regions were removed upon homologous 
recombination (13).  The genomic region was replaced with a cassette containing: 1) a 
neomycin resistance gene (Neor) that was used for selection, 2) Bam HI and Xba I restriction 
digest sites that were used to screen for recombinants, and 3) elements for a later genetic 
manipulation at the targeted locus.   
Targeted mouse ESCs were identified 
 Correctly targeted ES cell lines were identified by three methods.  PCR was used as a 
preliminary screen and detected a fragment length consistent with incorporation of the targeting 
vector into the mouse genome in some cell lines.  These clones were screened by Southern blot 
analysis using the 3’ probe (Figure 3.1A).  Proper targeting of the Mefv locus created Bam HI 
and Xba I fragments that were shorter than those corresponding to the endogenous allele 
(Figure 3.1B).  Finally, real-time PCR detected a 50% decrease in the relative copy number of 
Mefv in the mouse genome (Figure 3.1C).  Proper recombination at the Mefv locus occurred at 
a frequency of 0.15% (2 of 672 ESC colonies screened).   
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Figure 3.1.  Targeting of the Mefv locus and screening of ESC clones.  A, Schematic 
showing the endogenous Mefv locus, gene-targeting construct, and targeted locus after 
homologous recombination with the targeting construct.  Upon homologous recombination, the 
entire coding region and 5 kb on either side of the Mefv gene was replaced with a selectable 
neomycin resistance (neor) gene.  Exons are depicted as filled boxes.  Arrow indicates 
directionality of the open reading frames.  Bam HI and Xba I restriction sites and the genomic 
fragment (3’ probe) used in Southern blot analysis are indicated.  B, Southern blot of DNA 
collected from ES cell lines and digested with Bam HI (top) or Xba I (bottom).  Labels identify 
individual ES cell lines.  C, Genomic copy number of the Mefv gene relative to the Hprt gene.  
Real-time PCR on genomic DNA collected from ES cell lines detects exon 1 of Mefv and a 
unique genomic region within Hprt.  Since Hprt is located on the X chromosome, a wild-type 
male has 2 copies of Mefv per Hprt.  Targeted male ES cell lines and wild-type female ES cell 
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lines have a 1:1 of Mefv to Hprt.  A comparison between DNA from a wild-type male and wild-
type female served as an assay control (checkered boxes).  Results are normalized to a wild-
type male.  Labels identify individual ES cell lines.  Results for clones 1072-3B4 and 1100-2A11 
were confirmed by at least two independent experiments. 
 
Mice carrying a null Mefv allele were generated 
 Chimeras generated from targeted 129S6 ES cell lines were crossed with both C57BL/6 
and 129S6 mice.  As the ES cells were generated from the 129 substrain, breeding with 129S6 
mice generated 129 Mefv-/- co-isogenic mice, which were used in all functional assays.  Mefv+/- 
mice were intercrossed, and DNA collected from the offspring was screened by Southern blot 
analysis and identifed pups that inherited the null allele (Figure 3.2A).  Inheritance of the null 
Mefv allele followed a Medelian pattern.  DNA from animals homozygous for the targeted locus 
(Mefv-/-) was subjected to additional Southern blot analysis to verify the absence of the Mefv 
gene.  As expected, DNA from these pups failed to hybridize with probes corresponding to 
various regions of the Mefv gene.    
 Consistent with our Southern analysis, northern blot analysis using a full length Mefv cDNA 
probe failed to detect Mefv transcripts in mRNA prepared from Mefv-/- neutrophils.  Mefv 
transcripts present in the wild type cells were absent, and no aberrant transcripts could be 
detected, confirming that the targeting strategy generated a null Mefv allele.  A β-actin cDNA 
probe was used to verify equivalent loading of RNA (Figure 3.2B). 
 To further define the mutation introduced into the Mefv locus, RNA was prepare from the 
bone marrow and spleen of Mefv+/+, Mefv+/- and Mefv-/- animals, and Mefv expression was 
assessed by quantitative PCR using primers specific for mRNA transcripts of the WT gene.  
Expression of Mefv is undetectable in Mefv-/- animals.  A 50% decrease in expression is 
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observed in heterozygous animals compared to Mefv+/+ animals, indicating that there is little or 
no compensatory transcription from the remaining wild-type Mefv allele (Figure 3.2C).    
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Figure 3.2. Verification of Mefv-/- mice.  A, Southern blot analysis of DNA from offspring 
generated by the intercross of mice heterozygous for the Mefv mutant allele.  The 8.6 kb BamHI 
restriction fragment is generated by the endogenous WT Mefv alelle and the 5.9 kb fragment is 
generated by the targeted Mefv null allele.  B, Northern blot analysis of RNA collected from 
recruited peritoneal neutrophils of Mefv+/+ and Mefv-/- mice.  A full-length Mefv cDNA probe was 
used to detect transcripts corresponding to the Mefv gene.  Several bands were detected in the 
WT sample, indicating the presence of multiple splice variants of Mefv.  All bands are absent in 
Mefv-/- mice.  A probe specific to β-actin confirms equal loading of the RNA samples.  C, 
Relative expression of Mefv in bone marrow and spleen tissues collected from Mefv+/+, Mefv+/-, 
and Mefv-/- mice. 
 
Naïve Mefv-deficient mice showed no developmental abnormalities 
 The loss of Pyrin did not impact the survival, growth, or reproductive performance of the 
mice.  Intercrossing heterozygous animals produced litters with Mefv-/- mice at expected 
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Mendelian ratios, and the size and frequency of litters from Mefv-/- mating pairs were similar 
compared to coisogenic Mefv+/+ (WT) 129/S6 mice.  Total body weight (Figure 3.3A) and organ 
weights (Figure 3.3B) were similar between age-matched 10-week-old WT and KO mice. 
Furthermore, Mefv-/- mice be distinguished from littermates based on morphological or 
behavioral criteria.  Mefv-deficient mice displayed no overt signs of acute or chronic disease, 
such as lethargy or sudden death.   
 
Mefv +/+ Mefv -/-
20
21
22
23
24
25
26
bo
dy
 w
ei
gh
t (
g)
Spleen Thymus Lung
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
Mefv +/+
Mefv -/-
%
 o
f b
od
y 
w
ei
gh
t
A B
 
Figure 3.3. Mefv-/- mice had normal body and organ weights.  A, Body weight of Mefv+/+ and 
Mefv-/- mice at 10 weeks of age.  n = 18 Mefv+/+, 19 Mefv-/- mice, p = 0.57.  B, Weight of spleen, 
thymus, and lung organs is expressed as percent of total body weight.  n = 3 mice per 
genotype. 
 
 Since Mefv expression was detected in immune organs of untreated mice, and FMF is an 
autoinflammatory disorder characterized by episodes of spontaneous inflammation, we 
hypothesized that the loss of Mefv might affect the resting, or naïve, state of the immune 
system.  We characterized naïve animals maintained in a sterile and pathogen-free environment 
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for indications of altered immune system development or signs of inflammation.  Cell 
populations within the primary immune organs of the thymus, spleen, and mesenteric lymph 
nodes from naïve mice were characterized by flow cytometry.  No change in cellularity of the 
thymus, spleen, or lymph nodes was apparent.  Furthermore, analysis of the cellular 
composition of these organs failed to identify a role for Mefv in the development of lymphocytes 
or cells of myeloid lineage, despite the high level of expression of Mefv in this later population 
(Figure 3.4A-C and data not shown).  To examine a large population of innate immune cells, 
cells residing in the peritoneal cavity were collected by lavage.  The total number of cells was 
similar between WT and KO animals (Figure 3.4D).  Additionally, blood collected from 6-month-
old WT and Mefv-/- animals also indicated a similar concentration of circulating lymphocytes, 
monocytes, and granulocytes between cohorts (Figure 3.4E).   
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WT 129 1.71 ± 0.28 8.29 ± 0.16 238.10 ± 29.55 73.47 ± 3.29 17.08 ± 2.13 10.50 ± 0.65 45.29 ± 0.98 13.79 ± 0.25
Mefv -/- 2.12 ± 0.35 8.34 ± 0.24 285.50 ± 31.61 67.25 ± 6.08 23.72 ± 6.97 10.03 ± 0.65 45.73 ± 1.09 13.90 ± 0.30
MONO HCT HGB
x103/uL x106/uL x103/uL % % % % g/dL
WBC RBC PLT LYMPH GRAN
 
Figure 3.4. Naïve Mefv-/- mice have a normal immune system profile.  A-C, FACS analysis 
shows the percentage of thymocytes, A, splenocytes B, and lymph node cells, C, that are 
positive for T lymphocyte (CD3/CD4 and CD3/CD8), B lymphocyte (B220), macrophage 
(CD11b), dendritic cell (CD11c), and neutrophil (Gr-1) cell receptors.  n = 3 – 6 mice per 
genotype for each tissue.  D, Total number of resident peritoneal cells collected in 4 mL of 
lavage fluid.  Each dot represents one mouse.  E, Analysis of blood collected from WT and 
Mefv-/- mice.  n = 13 mice per genotype. 
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Discussion 
 We describe here the generation of a mouse in which the entire Mefv gene is excised.  
Although a more difficult mutation to generate, this strategy ensures the loss of not only the 
primary Mefv transcript, but also transcripts initiated from internal promoters and splice variants 
from the Mefv locus.  Thus, proteins containing all or a subset of the many functional domains of 
Pyrin cannot be generated from this modified locus.  Pyrin null mice were born at a normal 
Mendelian ratio and displayed normal growth and development.  Immune system development 
was unaffected by the loss of Pyrin, and naïve mice showed no signs of inflammation or illness.  
Our results suggest that there may be a mechanism to prevent a functional deficit caused by the 
loss of Pyrin, at least in a naïve immune state.   
 Our northern blot analysis indicates that alternative splicing of murine Mefv is more 
extensive than previously described.  Although multiple splice variants of the human MEFV 
gene have been described (10), in mice and rats, only one transcript for the Mefv gene was 
detected by previous northern blot analysis (14).  Using RT-PCR, one splice variant of the 
mouse gene was identified in which exon 9 is replaced with an alternative exon a found in intron 
9 (11).  Nucleotide sequencing of the bands detected by our northern blot analysis is necessary 
to confirm the identity of these bands as transcripts of the Mefv gene, however their absence in 
Mefv null mice provides preliminary support. 
 It is not too surprising that naïve mice showed no signs of inflammation or illness.  The 
contribution of many genes cannot be detected in knock-out mice in a naïve state, but following 
treatments to induce an innate immune response, the contribution of these genes to 
inflammation is striking.  Many other mouse lines with deficiencies in genes that contribute to 
the innate immune response do not display a phenotype.  Specific to IL-1β production, Il1β, 
Caspase-1, Nlrp1b, and Nlrp3 –deficient mice do not show overt signs of spontaneous 
inflammation or developmental deficits.  Furthermore, immune cell composition of naïve mice 
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was unaltered by the loss of Aim2 (15).  Moreover, analogous to these previous studies, the 
lack of a detectable phenotype in naïve mice leaves open the possibility that a functional role of 
Pyrin may be distinguished following treatment to Pyrin-deficient mice to induce inflammation.   
 Mice carrying a disrupted Mefv allele were previously generated.  These mice carry an 
allele in which exon 3 is disrupted to place eGFP and pgk-Neor cassettes in frame, and a stop 
codon terminates translation within the altered third exon.  These mice produce a protein with 
an intact pyrin domain (PYD), but the rest of the protein is deleted.  Anecdotal notes of 
exacerbated immune function were reported in naïve mice and significant function differences 
were seen upon treatment of homozygous mutant mice with immune stimulants.  Immunological 
phenotypes including fever, increased IL-1β production, increased lethality in response to LPS, 
increased cellularity after the induction of peritonitis, and impaired apoptosis of macrophages 
were observed (11).  However, extrapolating the results of these studies to define the function of 
Pyrin is complicated by the presence of a truncated Pyrin protein in these animals, especially 
since individual domains within Pyrin appear to be functionally competent.  The authors based 
the interpretations of their studies on the idea that these mice express proteins with 
hypomorphic function.  However, expression of the truncated Pyrin protein appears to be 
greater than that of endogenous Pyrin.  This finding is more consistent with a model in which the 
disrupted gene produces a protein with increased function.  Furthermore, mutations in human 
Pyrin may not confer a loss-of-function to the Pyrin protein.  Intramolecular interactions between 
the domains of Pyrin have been seen (16), and it is reasonable to hypothesize that a mutation 
might alter these protein interactions and influence Pyrin to lead to a gain-of-function.  The PYD 
of the truncated mouse protein may function very differently than the wild-type Pyrin protein 
and/or mutant Pyrin generated by FMF-associated alleles.  Mutations could even result in 
hypermorphic function with respect to some interactions and hypomorphic function with respect 
to others.  Therefore, to address the overall function of Pyrin, we generated mice missing the 
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entire Pyrin protein.  Our strategy to remove the entire coding region and eliminate all potential 
splice variants will help to clarify what appears to be a quite complex contribution of Pyrin to 
innate immune responses. 
 A recent report describes the generation of mice expressing a chimeric Pyrin protein.  The 
majority of the protein is of endogenous origin, but a short region of the C-terminal end is 
removed and replaced with a mutated C-terminal region of human Pyrin, which includes the 
B30.2 domain.  Homozygous mice displayed delayed growth, visual signs of inflammation 
including dermatitis, and an increased number of innate immune cells, even in a resting state.  
Similar to studies using mice expressing a truncated Pyrin protein, work with these mice 
suggests that disruption to the Pyrin protein leads to inflammatory phenotypes.  However, again, 
discerning the contribution of Pyrin to the innate immune system is complicated by the presence 
of an altered protein which could have novel functions.  Consistent with this hypothesis, mice in 
which the wild-type B30.2 sequence was incorporated into the Mefv locus could not be 
generated, perhaps due to a novel protein function(s) that is incompatible with embryonic 
development. 
 While the majority of the Mefv gene is orthologous between mice and humans, a point 
mutation within the mouse gene forms a stop codon and causes early termination of 
transcription.  Thus, Pyrin encoded by the mouse gene lacks the C-terminal domain, termed 
B30.2, present in the human protein.  This complicates comparison of gene function, not only 
because numerous functions including interaction with Caspase-1, NLRPs1-3, and IL-1β have 
been assigned to this domain (16), but also because the majority of the FMF mutations are 
located in this C-terminal region (17).  In addition, major differences in the regulation of the gene 
have been noted between human and mouse: while the mouse gene is induced by IL-4 (11), 
this cytokine inhibits expression of the human ortholog (18).  These differences raise the 
possibility that one or more functions of Pyrin is unique to the human protein and is therefore 
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difficult to model in the mouse.  Thus, perhaps for no other autoinflammatory disorder is the 
validity of extrapolating results from mouse studies more subject to scrutiny than for FMF.  To 
address this problem, the targeted Mefv locus is designed to allow a further recombination event 
to introduce the human MEFV gene and its regulatory elements into the mouse genome.  Future 
studies, beyond the scope of this work, will examine the contribution of the B30.2 domain to the 
overall function of the Pyrin protein. 
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CHAPTER 4 
Genetic loss of murine Pyrin, the Familial Mediterranean Fever protein, 
increases Interleukin-1β levels 
 
 
 Familial Mediterranean Fever (FMF) is an inherited autoinflammatory disorder 
characterized by unprovoked episodes of fever and inflammation.  The associated gene, MEFV 
(Mediterranean Fever), is expressed primarily by cells of myeloid lineage and encodes the 
protein Pyrin/TRIM20/Marenostrin.  The mechanism by which mutations in Pyrin alter protein 
function to cause episodic inflammation is controversial.  To address this question, we have 
generated a mouse line lacking the Mefv gene by removing a 21 kb fragment containing the 
entire Mefv locus.  We show enhanced IL-1β release by Mefv-/- macrophages in response to a 
spectrum of inflammatory stimuli, including stimuli dependent on IL-1β processing by the 
NLRP1b, NLRP3 and NLRC4 inflammasomes.  These results are consistent with a model in 
which Pyrin acts to limit the release of IL-1β generated by activation and assembly of 
inflammasomes in response to subclinical immune challenges.  
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Introduction 
 Mutations in MEFV predispose humans to Familial Mediterranean Fever (FMF), a disease 
characterized by spontaneous activation of the innate immune system in the absence of a 
detectable pathogenic stimulus.  Fever and acute abdominal pain are the most common 
symptoms, but disease manifestations also include arthritis, pleuritis, localized erythema, and 
amyloidosis of the kidneys. The inflammation observed in FMF patients is characterized by 
neutrophil influx to peripheral tissues and increased serum levels of acute-phase reactant 
proteins and cytokines (1).  The efficacy of pharmacological inhibitors of IL-1β/IL-1 receptor 
signaling in treatment of some patients supports the hypothesis that pathophysiology of FMF is 
mediated in part by this cytokine (2).   
 MEFV encodes a 781 a.a. cytoplasmic protein comprised of 5 domains:  pyrin, b-Zip, B-
Box, coiled-coiled, and PRY/SPRY (B30.2), although this later domain is absent in the mouse 
protein. The pyrin domain is of particular interest since this domain is found in several proteins 
critical in IL-1β production (3). Similar to most cytokines, Il1β transcript levels are enhanced by 
cellular stimulation with cytokines or pathogen-associated molecular patterns (PAMPs) (4).  
However, the Il1β gene does not encode a leader peptide to facilitate transport and secretion of 
the protein (5).  Instead, it is synthesized as an inactive pro protein which is cleaved by the 
cysteine-aspartic acid protease Caspase-1 (CASP-1) to form mature IL-1β.  Catalytic activity of 
CASP-1 also requires removal of a regulatory domain, although in this case, this is achieved 
through autocatalytic cleavage.  Activation of CASP-1 is observed after exposure of cells to both 
host-derived signals of cellular stress or damage, called danger-associated molecular patterns 
(DAMPs) and to PAMPS.  These signals trigger the assembly of inflammasomes, protein 
scaffolds nucleated by a nucleotide-binding domain, leucine-rich repeat family (NLR) protein.  A 
number of NLRs are capable of assembling an inflammasome in response to unique but 
overlapping DAMPS and PAMPS.  To date, these include NLRP3, NLRP1b, NLRC4, NLRP2 
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and NLRP6 (6-11).  However, assembly of a CASP-1 activating  inflammasome complex is not 
restricted to the NLR family, as more recently, the protein absent in melanoma 2 (AIM2) has 
been shown to contribute to CASP-1 activation and IL-1β release in response to dsDNA (12).   
 In addition to the NLR/AIM2 protein, the inflammasome often contains the protein adaptor 
ASC which facilitates the recruitment of pro-Caspase-1 to the complex (3).  Interaction between 
the pyrin and card domains of various proteins is critical for inflammasome assembly, both the 
self association of the NLR proteins and the recruitment of ASC and CASP-1 to the complex.  It 
is, therefore, not surprising that it has been suggested that proteins which contain a PYD or 
CARD domain, yet lack other critical functional domains, act as dominant negative regulators of 
inflammasome assembly (13).  Furthermore, a number of studies indicate that Pyrin might 
function in a similar manner, with disease-associated mutations resulting in reduced ability to 
limit inflammasome assembly (14-17).  Such a model is consistent with the recessive pattern of 
inheritance of the disease (18, 19) and with previous findings that Pyrin can bind ASC, CASP-1, 
NLRPs 1-3, and IL-1β (15, 17, 20, 21). 
 Not all reports, however, support this model.  Molecular genetic reports of both the absence 
of individuals carrying null MEFV alleles and the observation of disease in some individuals 
believed to carry a wild-type allele, have led to the suggestion that FMF is an autosomal 
dominant disease with variable penetrance (22, 23).  It has been posited that Pyrin itself can 
assemble a CASP-1 activating inflammasome, with the assembly of the mutant Pyrin 
inflammasome triggered by lower, subclinical, levels of PAMPs/DAMPs (21, 24-27).  
Transfection and knockdown studies provide limited clarification of the function Pyrin, as in 
some studies, Pyrin increased IL-1β release, while in others, using similar strategies, cytokine 
production was decreased (14-17, 21, 25-27). 
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 To further examine the function of Pyrin, we generated a mouse carrying a null Mefv allele.  
This mouse lacks the entire 21 kb locus.  Using primary cells from this mouse line, we show that 
Pyrin negatively regulates IL-1β production in response to inflammasome-dependent stimuli. 
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Materials and Methods 
In vitro macrophage activation studies 
 Resident peritoneal cells were collected by lavage and cultured in RPMI media (Gibco) 
containing 10% FBS (Cellgro), 10 mM HEPES (Gibco) and supplements (L-glutamine, 
pen/strep, 2β-mercaptoethanol) at 106 cells/mL and 105 cells/well in a 96-well plate.  Cells were 
washed with phosphate-buffered saline (PBS, Gibco) to remove non adherent cells, primed with 
1 µg/mL crude lipopolysaccharide derived from Escherichia coli (LPS, Sigma) and then 
stimulated as indicated.  250 µg/mL Aluminum hydroxide (Alum), 250 µg/mL silica, 100 µg/mL 
calcium pyrophosphate dihydrate (CPPD), 1mM ATP, 250 ng/mL each of lethal factor and 
protective antigen from Bacillus anthracis (LT), 10 ug/mL muramyl dipeptide (MDP), 5 ug/mL 
titanium dioxide (TiO2).  For LT treatment, cells were cultured in DMEM without glutamine and 
containing 2 mM Glutamax (Invitrogen), 10% FBS, 2 mM HEPES, and 50 ug/mL gentamycin.  
For ATP stimulation, cells were incubated in BSSH buffer.  Cell culture supernatants were 
collected and stored at -80°C.  After collection of media, cells were lysed with and total protein 
was measured. 
Real-time PCR Analysis 
 Total RNA was converted to cDNA using High Capacity cDNA Reverse Transcription Kit.  
TaqMan universal PCR master mix and recommended probes were detected by ABI Prism 
7900HT detection system (Applied Biosystems).  Gene expression was calculated as the 
relative expression of Mefv, Il1β, or Il6 normalized by Gapdh or 18s.   
Protein analyses 
 IL-1β and IL-6 ELISA (eBioscience), lactate dehydrogenase (LDH, Clontech) and total 
protein (BCA protein assay, Thermo Scientific Pierce) protocols were followed.   
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LPS/ATP treatment in vivo 
 Mice were treated with 1 mg/mouse of crude LPS at time 0 h, followed by 500 µL/mouse of 
30 mM ATP at 2 h, and harvested at 2.5 h.  The peritoneal cavity was lavaged with PBS.  
Peritoneal cell concentrations and viability were assessed using a hemocytometer and trypan 
blue.  Samples were centrifuged to pellet cells and the supernatant was collected for IL-1β 
ELISA.   
Animal Care and Use 
 All experiments were conducted in accordance with the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals as well as the Institutional Animal Care and Use 
Committee guidelines of the University of North Carolina at Chapel Hill. 
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Results 
Pyrin-deficient mice displayed normal responses to LPS 
 The N-terminal cleaved fragment of Pyrin has been reported to interact with IκB-α and the 
p65 subunit of NF-κB, increasing the activity of this transcription factor (28).  If this model is 
correct, it is reasonable to expect that the induction of NF-κB transcripts after treatment of cells 
with inflammatory mediators such as LPS would be attenuated in Mefv-/- mice.  To test this 
hypothesis, we compared the mRNA levels of two NF-κB sensitive transcripts, Il1β and Il6, in 
macrophages before and after exposure to LPS.  Basal levels of mRNA for both of these 
cytokines were similar in the Mefv-/- and control macrophages.  As expected, treatment of the 
cells with LPS for 24 hours resulted in a robust increase in expression of these genes.  
However, the magnitude of the increase in expression of Il1β and Il6 was not altered in cells 
lacking Pyrin (Figure 4.1A).   
 To address this point further, we examined the level of IL-6 and IL-1β in the supernatant of 
cultures of rpMΦ before and after LPS treatment.  IL-6, similar to most cytokines, is released 
through a classical secretion pathway (4).  Consistent with the increase in mRNA levels, a 
dramatic increase in the level of IL-6 was observed in the supernatants from the LPS-treated 
cells.  No difference, however, was observed in IL-6 levels in samples from wild-type (WT) and 
Pyrin-deficient cell cultures (Figure 4.1B).   Similar to IL-6, LPS results in an increase in 
expression of Il1β mRNA, but efficient release of this cytokine requires processing of the 
immature protein by Caspase-1 (7).  Thus, not unexpectedly, the level of IL-1β in the 
supernatant collected from macrophage cultures is low, and while these levels increased 
significantly after LPS treatment, the magnitude of this increase was small.  Loss of Pyrin did 
not augment or attenuate the release of IL-1β by rpMΦ either left untreated or following 
treatment with LPS (Figure 4.1C).  Survival of the macrophages, either under control conditions 
or in the presence of LPS was not altered by the lack of Pyrin: levels of the cytoplasmic enzyme 
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LDH in the supernatant did not differ between samples collected from Mefv-/- and WT cultures 
(Figure 4.1D).       
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Figure 4.1.  Loss of Mefv does not affect the response to LPS.  rpMΦ from Mefv+/+ and 
Mefv-/- littermate mice were untreated or treated with 1 µg/mL LPS for 24 h.  A, Il1β and Il6 
expression at the transcript level is expressed as fold induced by LPS treatment.  n = 3 mice per 
genotype.  B and C, Concentration of IL-6 and IL-1β in supernatants from LPS-treated rpMΦ 
cultures as determined by ELISA.  n = 6 mice per genotype.  D, The concentration of lactate 
dehydrogenase (LDH) released into cell supernatants was used as an indicator of cell death. 
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NLRP3 Inflammasome-dependent IL-1β production is increased in Mefv-deficient 
macrophages 
 To determine if a loss of Pyrin modulates inflammasome-mediated IL-1β production, WT 
and Mefv-/- rpMΦ were exposed to a variety of elicitors that induce NLRP3 inflammasome-
dependent IL-1β production.  Cells were pre-treated with LPS to induce IL-1β transcription and 
then stimulated with one of the following NLRP3 inflammasome elicitors: titanium dioxide 
(TiO2), aluminum hydroxide (alum), calcium pyrophosphate dehydrate crystals (CPPD), silica, 
or ATP (6, 29).  IL-1β and IL-6 levels in the cell supernatants were determined  by ELISA.  As 
expected, treatment of cells with compounds that trigger assembly of the NLRP3 inflammasome 
resulted in substantial increase in the levels of extracellular IL-1β, compared to cultures treated 
with LPS alone.  In addition, in all cases, higher IL-1β cytokine levels were measured in 
supernatants collected from Mefv-/- cultures compared to those collected from similarly treated 
WT cultures.  The magnitude of the increase in the levels of IL-1β in Mefv-/- cultures compared 
to controls varied depending on the stimulus, ranging from an increase of 1.5-fold in cells 
exposed to silica to an increase of almost 5-fold in the response of Mefv-/- cells to Alum (Figure 
4.2A).  No difference was observed in the levels of IL-6 present in the samples from WT and 
Mefv-/- cultures (Figure 4.2B).  Both mature and pro-IL-1β can be released into the supernatant 
after cell death, and most ELISAs do not bind exclusively to the mature protein.  It is therefore 
possible that the increase in IL-1β in samples collected from Mefv-/- cultures reflects an increase 
in cell death.  To address this question, we measured levels of LDH in the supernatant.  Many of 
the agents used to stimulate NLRP3 assembly decrease cell viability (30), and the magnitude of 
this decrease was dependant on the agent used to elicit the inflammasome, but viability was not 
influenced by the absence of Pyrin: LDH levels did not differ significantly between Mefv-/- and 
WT macrophage cultures (Figure 4.2C).   
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Figure 4.2.  A loss of Pyrin causes 
increased IL-1β protein levels in 
response to NLRP3 inflammasome 
stimuli.  rpMΦs from Mefv+/+ and 
Mefv-/- littermate mice were exposed 
to LPS and the indicated stimuli.  The 
concentration of IL-1β, A, and IL-6, B, 
cytokines in cell culture supernatants 
was determined by ELISA.  C, LDH 
protein levels detected in cell 
supernatants.  The total protein of 
cell lysates was measured to verify 
equivalent plating of cells.  TiO2, 
titanium dioxide; Alum, aluminum 
hydroxide; CPPD, calcium 
pyrophosphate dihydrate; ATP, 
adenosine 5’ triphosphate.  n = 6 
mice per genotype.  Results are 
representative of at least 4 
independent experiments.  A 
student’s t test was used to calculate 
p values for WT versus Mefv-/- 
cultures.  **, p ≤ 0.001; ***, p < 
0.0001. 
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Negative regulation of IL-1β production is not limited to the NLRP3 inflammasome 
 Caspase-1 activation and IL-1β release is also observed after exposure of macrophages to 
agents that mediate the assembly of NLRC4 and NLPR1b -containing inflammasomes (7).  We 
therefore asked whether a loss of Pyrin impacts only NLRP3-mediated IL-1β release or whether 
it also modulates IL-1β release secondary to assembly of these inflammasomes.  WT and Mefv-
/- rpMΦ were treated with LPS and exposed to agents known to elicit the NLRC4 and NLRP1b 
inflammasomes.  The NLRC4 inflammasome is assembled in response to flagellin, while 
NLRP1b is required for IL-1β production in response to Bacillus anthracis (anthrax) lethal toxin 
(LT).  Muramyl dipeptide (MDP) alone and MDP plus titanium dioxide (TiO2) activate both 
NLRP1 and NLRP3 inflammasomes (7, 29).  Again, significantly higher levels were observed in 
samples collected from cultures of Mefv-/- macrophages compared to similarly treated WT 
controls (Figure 4.3A).  In contrast, IL-6 and LDH levels in supernatants collected from WT and 
Mefv-/- cultures were similar (Figure 4.3B and C). 
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Figure 4.3.  A loss of Pyrin causes 
increased IL-1β protein levels in 
response to NLRC4 and NLRP1b 
inflammasome stimuli.  rpMΦs from 
Mefv+/+ and Mefv-/- littermate mice were 
exposed to LPS and the indicated 
stimuli.  The concentration of IL-1β, A, 
and IL-6, B, cytokines in cell culture 
supernatants was determined by 
ELISA.  C, LDH protein levels detected 
in cell supernatants.  The total protein 
of cell lysates was measured to verify 
equivalent plating of cells.  MDP, 
muramyl dipeptide; LT, lethal toxin of 
Bacillus anthracis; TiO2, titanium 
dioxide.  n = 6 mice per genotype.  
Results are representative of at least 4 
independent experiments.  A student’s 
t test was used to calculate p values for 
WT versus Mefv-/- cultures. #, p < 0.05; 
*, p ≤ 0.01. 
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IL-1β levels after LPS/ATP treatment in vivo were not affected by the loss of Pyrin 
 To determine if Pyrin affected inflammasome-mediated IL-1β production in vivo, we 
exposed mice to LPS and ATP.  In contrast to the significant 2-fold increase in IL-1β levels in 
supernatants of macrophages treated with LPS/ATP in vitro (p < 0.0001), Mefv-/- and WT mice 
released similar amounts of IL-1β in vivo (Figure 4.4A).  The concentration and viability of 
peritoneal cells was also unaffected by the loss of Pyrin (Figure 4.4B and C).  Previous studies 
have demonstrated that systemic IL-1β levels are increased in vivo after LPS/ATP treatment by 
a NLRP3 inflammasome-dependent mechanism (31, 32), and we were able to verify these 
findings using our experimental system (Figure 4.4D and E).  However, given the variability 
which is inherent to this experimental system, it is unlikely that a 2-fold change in IL-1β levels 
would be detected.   
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Figure 4.4.  Loss of Pyrin does not affect the response to LPS/ATP treatment in vivo.  A – 
C, Mefv+/+, Mefv-/-, and Caspase-1-/- mice were treated with 1 mg/mouse of crude LPS at time 0 
h, followed by 500 µL/mouse of 30 mM ATP at 2 h, and harvested at 2.5 h.  The peritoneal 
cavity was lavaged with 4 mL of PBS.  A, IL-1β concentration in lavage fluid as detected by 
ELISA.  B, Cell concentrations were determined using a hemocytometer and C, trypan blue to 
assess viability.  Each dot represents one mouse in A – C.  D, Nlrp3+/+ and Nlrp3-/- mice were 
treated as in A.  n = 3 mice per genotype.  p < 0.05.  E, WT B6 and P2rX7-/- mice were treated 
with LPS followed by either PBS or ATP and harvested as in A using 3 mLs of PBS.  n = 3 and 
3 for LPS/PBS and 4 and 7 for LPS/ATP.  *, p < 0.05. 
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Discussion 
 Using Pyrin null mice, we show a marked change in the response of primary macrophages 
to a number of inflammatory stimuli; specifically, a significant increase in the release of IL-1β 
observed in cultures derived from Mefv-/- mice in comparison to WT mice.  
 Since the discovery of the genetic lesions which cause FMF, numerous models have 
emerged that attempt to incorporate information gleaned from the genetic and clinical 
characteristics of the disease, from the structure of the protein and its pattern of expression, and 
from studies of the gene in model systems.  One model suggests that Pyrin is a substrate for 
Caspase-1, and the N-terminal fragment of Pyrin potentiates inflammation by interacting with 
proteins of the NF-κB pathway.  An increased ratio of cleaved to intact protein was detected in 
clinical samples from FMF patients (28).  However, other investigators have not observed 
increased NF-κB-dependent luciferase activity following overexpression of full-length MEFV (16, 
21).  Our studies of mouse macrophages lacking Pyrin do not support a role for Pyrin in activity 
of the NF-κB pathway, although more extensive studies are required.  An increase in expression 
of NF-κB sensitive transcripts was not observed in Mefv-/- cells in a naïve state or after exposure 
to LPS.  As expected, i.p. injection of LPS resulted in an acute peritonitis characterized by a 
rapid drop in body temperature and accumulation of inflammatory cells in the peritoneal cavity. 
However, again, no difference was observed in the response of the mutant mice compared to 
control littermates.   
 The phenotype of the Mefv null mice differs in some aspects from those reported previously 
for mice carrying a disrupted Mefv locus. Macrophages from these mice were shown to release 
more IL-1β than wild type cells.  In addition, these animals displayed an exaggerated cryogenic 
response to low-dose LPS, and an increase in morbidity upon exposure to high-dose LPS or 
LPS and D-Gal.  An increase in the number of inflammatory cells recovered from peritoneal 
lavage fluid was observed in these mice after exposure to thioglycolate. Furthermore, apoptosis 
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was impaired in macrophages collected from animals homozygous for the targeted locus (14).  
In contrast, we did not observe an increase in the release of IL-1β from Mefv-/- cells treated with 
LPS alone, and as discussed above, the response of the Mefv-/- animals to LPS delivered i.p. 
could not be distinguished from that of the controls. We also failed to detect any change in the 
survival of Mefv null cells: no difference in the rate of cell death was observed in cultured 
macrophages, or in the number of cells surviving after stimulation of these cultures with 
inflammatory mediators.  In addition, ex vivo survival of recruited peritoneal neutrophils lacking 
Pyrin was not altered (data not shown).  One explanation for the differences between the mutant 
Mefv line characterized in this earlier report and the line described here is that in the former, a 
Mefv transcript and a truncated Pyrin protein were created by the targeted allele.  In fact, the 
level of this truncated protein, based on western analysis, appeared to be higher than that 
observed for the native protein.  It is possible that this truncated protein conferred unique 
functions not observed in mice carrying a null allele. 
 While we did not observe an increase in the IL-1β release by macrophages in response to 
LPS alone by cells lacking Pyrin, increased levels of IL-1β were detected in the culture media 
after stimulation of these mutant cells with agents that lead to inflammasome assembly.  The 
increase in IL-1β levels was observed in supernatants collected from cells stimulated with 
agents known to trigger assembly of NLRP1b, NLRP3, and NLRC4 inflammasomes.  Increased 
release of IL-1β from cells in response to all of the tested inflammatory stimuli is inconsistent 
with a model in which Pyrin modulates IL-1β production by regulating the assembly of a specific 
inflammasome, such as the NLRP3 inflammasome.  It is unlikely that Pyrin acts to block ASC or 
Caspase-1 association with the inflammasome, because no alteration in Caspase-1 activity was 
observed between Mefv-/- and wild-type cells (data not shown).  Our results differ from studies 
carried out with a human monocyte/macrophage cell line and PBMCs in which silencing of the 
MEFV transcript suppressed secretion of IL-1β (25, 26), and from transfection studies in which 
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overexpression of Pyrin increased Caspase-1 activity and IL-1β release (21).  However, our 
results are consistent with models in which Pyrin acts as a negative regulator of innate immune 
pathways, and with a genetic model in which Pyrin mutations causing FMF represent loss-of-
function mutations.  In opposition to the studies mentioned above, silencing of MEFV has been 
shown to increase IL-1β release from a human monocyte/macrophage cell line (15, 17).  This 
model is also supported by transfection studies in which wild-type Pyrin inhibited pro-IL-1β 
processing in macrophage cell lines, whereas the FMF-associated alleles proved less active in 
these assays (14, 15). 
 It is becoming increasingly apparent that production of IL-1β is regulated at many different 
levels, and that the relative importance of these mechanism(s) is likely dependant on many 
factors including the cell type, its local environment, and the nature of the stimuli (33). For 
example, recently, induction of autophagy by rapamycin was reported to result in degradation of 
pro-IL-1β and reduced secretion of IL-1β (34).  Interestingly, in one study, examination of PMNs 
from FMF patients revealed a gene expression pattern consistent with impaired basal 
autophagy (35), raising the possibility that increased IL-1β levels in FMF patients and the 
increase in IL-1β release by the Mefv-/- macrophages reflect a defect in regulation of cellular 
levels of pro-IL-1β.  Many other means by which Pyrin could modulate release of IL-1β are 
apparent.  For example, alteration in uptake of particulate matter and/or decrease in lysosomal 
stability or transport could increase IL-1β maturation in response to many stimuli (7).  It has 
been previously reported that mice with peritonitis induced by octacalcium phosphate (OCP) 
crystals had elevated IL-1β levels, and IL-1β release is was not impaired by the loss of the 
inflammasome components NLRP3 or ASC (36).  In another study, crystal-induced IL-1β 
production was blocked by colchicine, a prophylactic drug for FMF patients (37).  Furthermore, 
higher levels of reactive oxygen species have been reported in cells from FMF patients (38), 
and reactive oxygen species can increase IL-1β release (39-41).  Pyrin may regulate the 
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release of mature IL-1β from the cytoplasm, a process that is poorly understood (5).  Together, 
these data support a hypothesis that Pyrin regulates trafficking of vesicles containing IL-1β.  
Further studies will be required to identify at which of these many steps Pyrin acts to limit 
release of IL-1β.  
 Recently, an additional mouse line carrying a mutant Mefv-/- gene was reported.  No 
difference in the release of IL-1β by macrophages after treatment with LPS or LPS and ATP, 
after infection with Salmonella typhimurium, or after tranfection of DNA was reported (24).  A 
number of explanations for these differences are possible.  First, while our studies use mature 
peritoneal macrophages which express high levels of Pyrin (Figure 2.2B), Chae, et al. examine 
IL-1β production in bone marrow-derived macrophages.  As cultured bone marrow-derived 
macrophages express very low levels of Pyrin, the impact of the loss of this protein on IL-1β 
processing and/or release might not be as apparent with this cell type as on comparison of cells 
with higher levels of expression.  In addition, the two studies use mice of differing genetic 
backgrounds: those reported here carried out entirely with co-isogenic 129S6 mouse lines, while 
those of Chae and collegues use N6 B6.129 animals.  It is possible that the regulatory role of 
Pyrin might be more apparent on some genetic backgrounds.  Correspondingly, the severity of 
FMF can differ dramatically between individuals carrying the same mutation (1).  
 The demonstration here that loss of Pyrin can result in increase in IL-1β release is 
consistent with the original designation of FMF as a recessive genetic disorder.  However, 
perhaps for no other autoinflammatory disorder is the validity of extrapolating results from 
mouse studies more subject to scrutiny than for FMF.  Pyrin encoded by the mouse gene lacks 
the C-terminal domain, termed B30.2, that is present in the human protein.  This complicates 
comparison of gene function, not only because numerous functions including interaction with 
Caspase-1, NLRPs1-3, and IL-1β have been assigned to this domain (17), but also because the 
majority of the FMF mutations are located in this C-terminal region (14).  In addition, major 
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differences in the regulation of the gene have been noted between human and mouse: while the 
mouse gene is induced by IL-4 (14), this cytokine inhibits expression of the human ortholog 
(42).  These differences raise the possibility that one or more functions of Pyrin is unique to the 
human protein and is therefore difficult to model in the mouse.  Thus, until novel methods and 
reagents are developed for addressing this limitation, we can only ascertain that Pyrin can act to 
limit the activity of proinflammatory pathways, namely the release of IL-1β by macrophages, in 
at least some species. 
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CHAPTER 5 
The role of Pyrin in neutrophils 
 
 In FMF patients, neutrophils accumulate at sites of inflammation, implying that these 
immune cells may play a role in disease pathophysiology.  Neutrophils from patients with FMF 
are reported to have altered activity and survival in ex vivo assays.  We hypothesize that genetic 
lesions within the MEFV gene alter a primary function of Pyrin in neutrophils and promote FMF 
pathology.  To address this hypothesis, we created a mouse line lacking the Mefv gene and 
Pyrin protein.  We characterized the development, recruitment, and survival of neutrophils.  We 
did not detect any differences in neutrophils from Mefv-/- mice compared to neutrophils from 
wild-type mice using these criteria, despite high expression of Mefv in murine neutrophils.  While 
more extensive characterization is necessary, these results do not support the hypothesis that 
neutrophil phenotypes seen in FMF patients result from mutations to the MEFV gene. 
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Introduction 
 Neutrophils are very dynamic cells and are critical for the host pathogen response.  
Neutrophils are the first line of defense against bacterial, yeast, and fungal infections.  Their 
rapid recruitment to sites of tissue damage helps to prevent the early spread of infection and 
shape the overall immune response.  In addition to infection, neutrophils also respond to 
mechanical injury (such as cuts or burns), oxidative stress (brought on by ischemia/reperfusion), 
and thermal stress (brought on by overheating or excessive exercise).  Significant neutrophil 
deposition can be maintained in peripheral tissue during chronic inflammation.  
 Three pieces of correlative evidence support a model in which neutrophils play a role in 
FMF pathophysiology.  First, during inflammatory attacks, neutrophils accumulate at sites of 
inflammation.  Furthermore, the lifespan of neutrophils is 1–3 days (1), which correlates with the 
duration of symptoms and suggests that neutrophils mediate the onset and amelioration of 
inflammation.  While these data suggest that FMF-associated inflammation engages 
neutrophils, they do not clarify if mutations in Mefv directly affect neutrophils or if neutrophil 
accumulation is an indirect result of perturbations to immune signaling upstream of neutrophil 
recruitment, activation, and/or survival.  Second, colchicine can successfully ameliorate 
inflammatory episodes in many FMF patients.  As colchicine is sequestered mainly by 
neutrophils (2), this suggests that altering neutrophil function can alter the outcome of FMF.  
Colchicine modulates the oxidative burst, phagocytosis, and chemotaxis functions of neutrophils 
(3-5).  Still, the therapeutic effects of colchicine cannot distinguish between a direct reversal of 
the cause of FMF pathophysiology or an indirect bypass of exacerbated upstream signaling.  
Third, Mefv is expressed more highly in neutrophils than any other cell type tested.  This argues 
that Mefv could play a direct role in neutrophil function.   
 Previous studies with neutrophils from FMF patients demonstrate altered neutrophil 
physiology.  Oxidative burst and phagocytosis are increased in neutrophils from FMF patients 
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compared to controls (3-11).  Interestingly, neutrophils demonstrates a biphasic phenotype in 
which activation of neutrophils collected from FMF patients between attacks is more intense 
than in neutrophils harvested from FMF patients during an attack period (4, 8, 9).  Furthermore, 
previous work demonstrates that neutrophils from FMF patients are more susceptible to 
apoptosis.  Following endotoxin (LPS) exposure, neutrophils from healthy human donors show a 
decrease in apoptosis, while neutrophils from FMF patients show an increase in apoptosis 
compared to untreated neutrophils (10).   
 To test the hypothesis that Pyrin functions in neutrophils to mediate acute episodic 
inflammation associated with FMF, in vitro and in vivo experimental systems were used to 
determine if a deficiency of the Pyrin protein affected neutrophils.  In this chapter, studies 
designed to isolate and differentiate a role of Mefv in intrinsic neutrophil processes are 
presented.  The following chapter describes in vivo models of peritonitis that were designed to 
detect differences in not only neutrophil function, but also macrophage function and the overall 
immune response in Mefv-/- mice compared to WT mice.  The development, recruitment, and 
survival of neutrophils were not affected by the loss of Pyrin function. 
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Methods 
Isolation of bone marrow neutrophils 
 The polymorphonuclear fraction that contained bone-marrow neutrophils was isolated from 
total bone marrow by centrifugation through a density gradient per manufacturer’s instructions 
(density 1.083 g/mL and 1.119 g/mL; Histopaque, Sigma-Alrich).  Greater than 90% of cells 
were classified as bone-marrow neutrophils based upon morphological analysis of cytospun 
cells stained with Hema-3 (Protocol, Fisher Scientific).   
Peritoneal neutrophil recruitment 
 Wild-type (WT) and Mefv-/- mice were treated with 1 mL of 1 mg/mL zymosan-A (from 
Saccharomyces cerevisiae; Sigma-Aldrich) dissolved in PBS, by intraperitoneal (i.p.) injection 
using a 27G needle.  Zymosan-A solution was aspirated through a 30G needle before injections 
to ensure the solution was homogeneous.  Mice were sacrificed at 4 h after treatment, and the 
peritoneal cavity was lavaged with 4 mLs of Delbucco’s phosphate-buffered saline (PBS; Gibco) 
to collect peritoneal cells.  The majority of peritoneal cells were elicited neutrophils.  Cell 
numbers within the peritoneal lavage fluid were determined using a hemocytometer. 
In vitro neutrophil survival studies 
 WT and Mefv-/- thirteen-week-old female mice were used in these studies.  Elicited 
peritoneal neutrophils were collected in PBS at 4 h following zymosan-A treatment, as stated 
above.  Cells were kept on ice during harvest.  Samples were diluted 2-fold with PBS and then 
washed once with 10 mLs of PBS containing 10% fetal bovine serum.  Centrifuge steps were 
done at 230 x g for 10 minutes at 4°C.  Cells were eluted in 13 mLs of DMEM containing 10% 
FBS, 150 U/mL of penicillin, 150 µg/mL of streptomycin, 0.438 mg/mL of L-glutamine (all from 
Invitrogen), gentamicin, and 57.2 µM 2-Mercaptoethanol (Sigma-Aldrich).  Cell densities were 
determined using a hemocytometer, and cells were diluted to 1 x 106 cells/mL.  Cells were kept 
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at room temperature in a laminar flow hood while counting.  400 µL (4 x 105 cells) were plated 
into each well of 48-well plates.  Cell cultures were maintained in a constant environment 
(humidified 37°C, 5% CO2) for the indicated times.  When cultured in 10% serum, 80 – 90% of 
neutrophils are strongly or loosely -adherent to the culture dish.  At harvest, wells were pipette-
mixed in order to collect the majority of neutrophils in the well. 
Trypan Blue 
 Viability was assessed by hemocytometer using cell samples containing 0.1x volume of 
trypan blue.  Percent viability was calculated as the number of live cells excluding trypan blue 
divided by the total number of cells. 
LDH Assays 
 Cell culture samples were collected from duplicate wells per mouse for each timepoint.  
Samples were centrifuged at 200 x g for 5 minutes at room temperature.  The clarified 
supernatant was stored at -80°C until use.  The amount of LDH released into the culture media 
was measured by a colorimetric assay following the manufacturer’s protocol (Clontech).  
Results were standardized to the total LDH released from cells treated with 1% Triton-X (100% 
lysis control) in order to control for differences in cell plating densities.  Absorbance values were 
corrected by values at 0h to control for differences in initial viability.  The percentage of total 
LDH released was calculated using the formula: ((Absorbance at time X – Absorbance at 
0h)/(Absorbance of 100% lysis control – Absorbance at 0h)) x 100%. 
Flow cytometry 
 Fluorescently activated cell sorting (FACS) was used to detect Gr-1 receptor expression, 
phosphatidylserine translocation, and nuclear membrane permeability using the fluorescently 
labeled agents APC-conjugated anti-Gr-1 (Ly-6G and Ly-6C; 553129, BD Pharmingen), FITC-
conjugated Annexin V (An V; BD Pharmigen), and propidium iodide (PI; Cell Technology).   
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 Triplicate wells were pipette-mixed and 400 µL was collected and stained for either Gr-1 
and An V or for PI.  For samples stained with Gr-1 and An V, 4 mL of PBS was added as an 
initial wash step, and then cells were washed with Annexin V binding buffer.  Cells were 
resuspended in 110 µL of binding buffer containing 5 µL of An V and 5 µL of mouse BD Fc 
Block (anti-CD16/CD32; 553142, BD Pharmigen), which was used to prevent background 
staining.  Samples were incubated for 10 minutes and then 2 µL of Gr-1 or isotype antibody was 
added.  Samples were incubated 10 minutes and then 400 µL of binding buffer was added.  
FACS staining was done at room temperature.  Gr-1 positive/negative gate parameters were set 
using a sample stained with APC-conjugated IgG2b, κ isotype control (553991, BD Pharmigen).  
For samples stained with PI, cells were collected and stained directly in culture media to avoid 
unnecessary disturbances to the cells or removal of dead cells.  PI was used at 0.01x volumes.  
Samples were scanned using a Beckman Coulter CyAn ADP Analyzer, and data were analyzed 
using Summit V5.2 software.  
Animal Care and Use 
 All experiments were conducted in accordance with the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals as well as the Institutional Animal Care and Use 
Committee guidelines of UNC Chapel Hill.  
Statistical analyses  
 A two-tailed unpaired t-test was used to determine statistical probability of differences 
between WT and Mefv-/- neutrophils, with a significance limit of p ≤ 0.05. 
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Results 
Development of neutrophils is not impaired by the loss of Pyrin 
 As discussed in Chapter 2 and visualized in Figures 2.1 and 2.2, Mefv is expressed in 
myeloid-lineage cells, and specifically, in neutrophils, at a higher level than any other cell type.  
It is expressed in bone marrow neutrophils, a relatively immature and inactive neutrophil 
subpopulation.  Despite the already high expression level, Mefv expression was increased 23-
fold at the transcript level in mature peritoneal neutrophils compared to bone marrow 
neutrophils.   Since expression of Mefv was increased concurrently with cell maturation, we 
asked if Pyrin contributes to neutrophil differentiation.  Since neutrophils develop from myeloid 
precursor cells in the bone marrow, we characterized the abundance and maturity of neutrophils 
within the bone marrow of wild-type and Mefv-/- mice.  By visual analysis of cells stained with 
Hema-3, greater than 95% of cells fit the morphological criteria of neutrophils.  The total 
number, viability, and relative abundance of neutrophils in the bone marrow was unaffected by 
the loss of Pyrin (Figure 5.1A and data not shown).  Neutrophils are also commonly identified by 
Gr-1 surface receptor expression.  The Gr-1 receptor is involved in neutrophil adhesion, and it 
expression is restricted to mature neutrophils.  Using FACS analysis, Gr-1 expression was 
found to be similar (p = 0.82) between WT and Mefv-/- samples (Figure 5.2).  These analyses 
suggest that Mefv-deficiency does not cause a defect in neutrophil development. 
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Figure 5.1.  Mefv-deficiency does not affect neutrophil differentiation.  The 
polymorphonuclear fraction was isolated from total bone marrow of wild-type (WT 129) and 
Mefv-/- (KO) mice using a density (Histopaque) gradient.  A, Micrographs of cells from WT (left) 
and KO (right) mice.  Cells were cytospun and stained with Hema-3.  Neutrophils have an 
almost translucent cytoplasm and a darkly stained, multi-lobular, U-shaped nucleus.  B, The 
percentage of cells expressing Gr-1 was detected by FACS analysis.  Each dot represents one 
mouse.  p = 0.82. 
 
Neutrophil recruitment in Mefv null mice is normal 
 Since an large number of neutrophils are detected at inflamed tissues in FMF patients (12), 
and excessive neutrophil recruitment can cause uncontrolled  inflammation, we postulated that 
121 
 
exacerbated neutrophil recruitment to peripheral tissues contributes to FMF disease pathology.  
Thus, we predicted that recruitment of neutrophils would be augmented in Mefv-/- animals 
compared to controls.  To test this hypothesis, Zymosan-A, a component of yeast, was used to 
induce peritonitis and elicit neutrophils to the peritoneal cavity.  Neutrophils were rapidly 
recruited to the peritoneal cavity, and by 4 h post-treatment, the peritoneal cavity contained 6-
fold more cells compared to that of untreated mice, and 95% of cells were classified as 
neutrophils based upon morphological analysis, which is striking increase from untreated mice 
in which less than 5% of peritoneal cells were neutrophils.  The total number of peritoneal cells 
and the percentage of cells expressing Gr-1 was similar between Mefv+/+ and Mefv-/- animals 
(Figure 5.3A and B).  These studies indicate that Pyrin deficiency does not augment, nor inhibit, 
neutrophil recruitment. 
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Fig
ure 5.2.  Mefv-deficiency does not affect neutrophil recruitment.  Mefv+/+ (WT 129) and 
Mefv-/- mice were treated by i.p. injection with 1 mL of 1 mg/mL Zymosan-A.  At 4 h after 
treatment, peritoneal cells were collected.  A, The total number of peritoneal cells was 
determined using a hemocytometer.  Results are representative of several independent 
experiments.  B, The percentage of peritoneal lavage cells expressing Gr-1, as determined by 
FACS analysis.  Each dot represents one mouse, n = 5 mice per genotype. 
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Neutrophil survival 
 Since inflammatory episodes in FMF patients are characterized by neutrophilia, yet we 
were unable to detect a difference in neutrophil recruitment, we reasoned that Pyrin might affect 
neutrophil survival.  To examine this, the constitutive cell death of recruited peritoneal 
neutrophils was monitored ex vivo.  The percentage of cells retaining integrity of the cell 
membrane was determined by trypan blue exclusion and this number decreased at each 
timepoint tested:  0, 4, 6, 12, and 17 h.  Additionally, the level of lactate dehydrogenase (LDH), 
an enzyme that is released as cells die, in the supernatant of cultured neutrophils was 
monitored over a 24 h timecourse.  Both methods of testing showed that at least 90% of 
neutrophils died by 24 h in culture, and the rate of cell death was especially rapid between 6 
and 16 h.  However, the extent and the rate of neutrophil cell death was unchanged between 
Mefv+/+ and Mefv-/- neutrophils (Figure 5.3A and B).  FACS analyses was also used to determine 
if there were small changes in the survival of Mefv+/+ and Mefv-/- neutrophils that could not be 
detected by trypan blue or LDH assays.  At 0, 4, and 8 h, the percentage of wild-type and Mefv-/- 
neutrophils that were stained with Gr-1 and Annexin-V or Propidium Iodide was similar (Figure 
5.3C and D).  Consisent Gr-1 expression at all timepoints indicated that results were not skewed 
by a loss of receptor expression (Figure 5.3E).  The rapid decrease in total cell counts made 
FACS analysis inconsistent at later timepoints, but LDH release remained a precise assessment 
of cell survival even at the later timepoints.  These analyses indicate that a loss of Pyrin does 
not affect constitutive neutrophil cell death.   
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Figure 5.3.  The loss of Pyrin does not affect neutrophil survival.  Recruited peritoneal cells 
were collected from wild-type and Mefv-/- mice at 4 hours after treatment with Zymosan-A.  
Peritoneal lavage cells were placed in culture at a density of 106 cells/mL at 0 h.  At least 90% of 
cells were classified as neutrophils by morphological assessment of cells stained with Hema-3 
and visualized under a microscope.  A, The percentage of cells excluding trypan blue was 
assessed at the indicated times using a hemocytometer.  B, Neutrophil cell death is represented 
as the percent of total lactate dehydrogenase (LDH) released into the media at each timepoint 
compared to 100% lysis control samples.  n = 4 wild-type and 5 Mefv-/- mice for A and B.  
Results of 3 replicate wells/mouse were averaged in B.  C and D, The percentage of apoptotic 
(Annexin-V+) neutrophils (Gr-1+), in C, or dead (Propidium Iodide+) cells, in D, at 0, 4, and 8 h.  
The percentage of Gr-1+ cells was similar at each timepoint.  n = 5 mice per genotype. 
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Discussion 
 The high expression of Mefv in neutrophils, alongside previous functional research using 
neutrophils from FMF patients, suggests that the Pyrin protein has an important function in 
neutrophils.  However, we did not detect a change in neutrophil development, recruitment, or 
survival due to the loss of Pyrin expression.   
 Recruitment of neutrophils to the peritoneal cavity was similar between WT and Mefv-/- 
animals, despite elevated Mefv expression concurrent with recruitment (see Chapter 2).  We 
used an established experimental system to elicit neutrophils; zymosan-A-induced peritonitis 
has been used in previous studies to detect genes important in neutrophil recruitment in mice, 
including LTB4, TNF-α, and IL-8 (13, 14).  Furthermore, colchicine impacts neutrophil 
chemotaxis (5), so it is logical to assume that FMF patients have altered neutrophil chemotaxis 
caused by mutations in Pyrin.  However, our study is the first to compare WT neutrophils with 
neutrophils lacking Pyrin.  The data presented here leaves open the possibility that Pyrin is 
involved in neutrophil migration in response to other stimuli.  It is also important to keep in mind 
that most studies describing altered chemotaxis of neutrophils following colchicine treatment 
examine neutrophils in ex vivo assays.  Previous studies have shown neutrophil phenotypes in 
vitro that cannot be detected in vivo (15).  The difference between the in vitro and in vivo 
environment cannot be overlooked, especially since neutrophils dynamically respond to external 
cues from other cell types.  Thus, it is also possible that a mechanism(s) prevents altered Pyrin 
function from having an effect in vivo. 
 We also saw no differences in the rate of spontaneous, or constitutive, apoptosis of 
neutrophils.  In contrast, neutrophils from FMF patients display altered survival ex vivo.  The 
spontaneous apoptosis of neutrophils from FMF patients was increased compared to healthy 
controls (17).  Additionally, while exposure to LPS extends the lifespan of wild-type neutrophils, 
LPS treatment reduces the lifespan of neutrophils from FMF patients (9). 
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 Pyrin protein binding partners ASC, Caspase-1, and Siva are expressed in neutrophils.  
Expression of ASC, a Pyrin protein binding partner, is absent or weak in non-activated human 
neutrophils, but is expressed by neutrophils at sites of peripheral tissue inflammation.  Its 
expression is upregulated by LPS and by IL-1α, IL-1β, IFN-α, IFN-γ, and TNFα pro-inflammatory 
cytokines.  These results suggest that ASC is a positive regulator of inflammation in neutrophils 
at the early stages of an immune response.  However, caspase-dependent, Fas-mediated death 
signaling also increases human ASC expression concurrent with neutrophil apoptosis, 
suggesting that in later stages of the immune response, ASC promotes apoptosis of neutrophils 
and resolution of inflammation (18).  Caspase-1 shows a similar pattern.  Its expression is 
increased by LPS (Chapter 2 and (19)), but Caspase-1 deficient neutrophils show a delay in 
spontaneous neutrophil apoptosis in vitro, suggesting that Caspase-1 promotes apoptosis in 
neutrophils (15).  Siva, which also interacts with Pyrin, is a proapoptotic protein (20).  Whether 
or not Siva modulates apoptosis in neutrophils is unknown.  Gene network mathematic 
predictions have failed to link Siva-mediated apoptosis to the pathogenesis of FMF (21). 
 It remains possible that the experimental systems used in these studies lack the resolution 
required to detect a phenotype in neutrophils from Mefv null animals.  For example, the methods 
used to assess neutrophil development from myeloid precursor cells are not sensitive to 
potential variations within the Gr-1+ neutrophil subset.  In humans, many neutrophil subsets are 
described, but these states are not well-defined for mouse neutrophils.  Furthermore, neutrophil 
survival was examined in vitro because this method allows greater sensitivity; however, in vivo, 
non-activated neutrophils can migrate to the bone marrow, spleen, or liver where they 
apoptosis, and activated neutrophils can be phagocytosed by macrophages.  Thus, it is possible 
that a difference in neutrophil survival is the result of coordinated processes which are only 
detectable via in vivo models.  We cannot rule out the possibility that further studies may reveal 
a role of Pyrin in neutrophil physiology.  However, our studies demonstrate that Pyrin-deficient 
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neutrophils respond normally under at least some external conditions.  Therefore, the neutrophil 
deposition seen in FMF and the ability of colchicine to prevent FMF attacks may be mediated by 
altered production of extrinsic cytokines or chemokines that indirectly affect neutrophil function. 
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CHAPTER 6 
In vivo models of peritonitis 
 
 Inappropriate activation or resolution of an immune response can lead to inflammatory 
disorders such as Familial Mediterranean Fever (FMF).  FMF is an autoinflammatory disorder 
caused by mutations in the gene Mefv which encodes the protein Pyrin.  Previous studies 
presented in Chapter 4 indicate that Pyrin negatively regulates IL-1β production, but the 
contribution of Pyrin to innate immune responses in vivo remains unclear.  To study the role of 
Pyrin in the initiation and resolution of innate immune responses in vivo, inflammation was 
induced in Mefv null mice via multiple peritonitis models.  Using physiological parameters, 
cellular profiling, and molecular protein assays, we were able to detect active innate immune 
responses in wild-type and Mefv-/- animals.  However, Mefv null mice did not display impaired or 
exacerbated inflammation compared to wild-type mice.  Compensatory mechanisms may 
prevent Pyrin-deficiency from altering immune responses in vivo, in response to at least some 
innate immune stimuli. 
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Introduction 
 The acute inflammatory attacks that are characteristic of Familial Mediterranean Fever 
(FMF) are mediated by the innate immune system.  An innate immune response is a very 
dynamic process that results from the interplay of resident immune cells and epithelial cells that 
perceive immune stimuli, recruited immune cells that migrate to the site of inflammation, 
endothelial cells that are involved in immune cell extravasation, and physiological processes 
including fever.   
 The kinetics of cellular efflux, cell activation, and cell death are intricately regulated.  Cell 
recruitment is orchestrated by multiple cytokines and chemokines, including IL-1β, TNFα, IL-8, 
macrophage inflammatory protein-2 (MIP-2), and monocyte chemoattractant protein-1 (MCP-1) 
(1), the majority of which are released by macrophages.  Since we previously showed that Pyrin 
regulates IL-1β levels (see Chapter 4), it is important to note that IL-1β enhances the 
recruitment of neutrophils to localized sites of inflammation (2).  During pathogen clearance and 
resolution of the immune response, the kinetics of immune cell death are controlled by a 
balance of pro-apoptotic and anti-apoptotic, or survival, signals intrinsic and extrinsic to the cell 
and is affected by the presence of a pathogen or immune stimulant (3, 4).  Cell death can be 
either an autonomous process or involve the interplay of multiple phagocytic immune cells.  
Phagocytosis of neutrophils by macrophages is an important mechanism for limiting tissue 
inflammation (5).  Given the interplay of numerous processes and cell types involved in immune 
cell recruitment and cell death, it is important to examine these processes in vivo. 
 Fever accompanies the inflammatory episodes of FMF (6).  Fever is a regulated 
physiological response that facilitates survival of the host during infection (7).  In mice, the body 
temperature markedly declines before a subsequent, subtle fever response (8).  The initial 
hypothermic response is often used to study pathogen-induced changes in temperature 
regulation.  The magnitude and duration of hypothermia correlates with the endotoxin load in 
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LPS-induced peritonitis models (9).  Since our previous work in Chapter 4 indicates that Pyrin 
negatively regulates IL-1β production, it is important to note that IL-1β mediates body 
temperature in both humans and mice (7, 10).  In mice, IL-1β levels increase in a dose-
dependent manner following LPS treatment in vivo (9), and IL-1β-deficient mice treated 
systemically with LPS have a shortened hypothermic phase compared to wild-type mice (10-
12).  Thus, by modulating IL-1β production, or through another uncharacterized function, Pyrin 
may modulate thermic responses. 
 Previous studies suggest that Pyrin is involved in cell recruitment and survival during 
inflammation (8).  In FMF patients, extreme neutrophil deposition is apparent in inflamed 
tissues, and the ex vivo survival of neutrophils harvested from FMF patients is altered (3, 13).  
Also, previously described interactions between Pyrin and cytoskeletal elements (14-16) may 
influence cell shape, which is necessary for extravasation; cell motility, which is necessary for 
cell migration; and cell death, which is influenced by cytoskeletal integrity (17).   
 To assess the contribution of Pyrin in the activity, initiation, and resolution of the innate 
immune responses in vivo, we induced peritonitis in Mefv-/- and Mefv+/+ (WT) mice.  We drew 
upon knowledge of the most common symptoms for FMF—peritonitis, immune cell deposition in 
peripheral tissues, and fever—to guide testing of Pyrin-deficient mice.  We exposed mice to 
thioglycolate, LPS, and Psuedomonas aeruginosa, and compared the physiologic, cellular, and 
molecular responses of Mefv-/- and WT animals.  We found that Mefv-/- and WT mice had similar 
innate immune responses in these experimental systems. 
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Materials and Methods 
Thioglycolate-induced peritonitis 
 Mice were treated with 2 or 3 mLs of 3% Brewer’s thioglycolate medium by i.p. injection.  
The peritoneal cavity was lavaged with 4 mLs of PBS to collect peritoneal cells.  Total peritoneal 
cells were counted using a hemocytometer.  Lavage samples were cytospun and stained with 
Hema-3.  Cell identity was based upon classification of morphology using microscopic visual 
analysis.  FACS analysis was used to detect 7AAD, Gr-1+, and Mac-1+ staining as previously 
described in Chapter 5.  Peritoneal lavage fluid was used to determine IL-1β concentration by 
ELISA (BD Biosciences).  Lavage samples were processed to isolate myeloperoxidase (MPO) 
enzyme and its catalytic activity was evaluated by colorimetric assay. 
In vivo LPS treatment 
 Mice were treated with 2.5 mg/kg or 0.25 mg/kg of LPS (serotypes 127:B8 and 055:B5, 
respectively) by i.p. injection.  Body temperature was measured with a rectal thermometer 
probe.  Mice were sacrificed at 20 h (2.5 mg/kg of LPS) or 24 h (0.25 mg/kg of LPS).  The 
peritoneal cavity was lavaged with 4 mLs of PBS.  Weight loss was calculated using body 
weights measured at 0 h and the time of harvest.  Peritoneal lavage fluid was used to determine 
IL-1β and TNFα concentrations by ELISA (BD Biosciences).  Peritoneal cell concentrations and 
MPO were measured as described above. 
Pseudomonas aeruginosa infection 
 Cultures of WT PAK strain bacteria were started from glycerol stocks and grown overnight 
in Luria broth media.  A 1:100 dilution was made in brain-heart infusion media and cultures were 
grown to OD 0.3.  A 1:27 dilution in PBS was used for injections.  The CFU/mouse was 
calculated by plaque assay using a dilution of the injected culture and determined to be 5.4 x 
106.  Mice were harvested at 19 h post-infection.  The peritoneal cavity was lavaged with 4 mLs 
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of PBS.  Blood was collected by cardiac puncture.  Samples were lysed to release intercellular 
bacteria.  Dilutions were spread on Luria broth plates and the number of bacterial plaques was 
counted following an overnight incubation of the plates at 37°C.  Cellularity and IL-1β 
concentrations of peritoneal lavage fluid, body weight, and body temperature were measured as 
described above. 
Animal Care and Use 
 All experiments were conducted in accordance with the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals as well as the Institutional Animal Care and Use 
Committee guidelines of UNC Chapel Hill.  
Statistical analyses  
 A two-tailed unpaired t-test was used to determine statistical probability of differences 
between wild-type and Mefv-/- cohorts, with a significance limit of p ≤ 0.05. 
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Results 
A loss of Pyrin does not affect cell recruitment or survival in vivo 
 Since autoinflammatory disorders such as FMF result from overactivation or a lack of 
resolution of the innate immune response, we reasoned that Mefv might play a role in either 
mobilization of cells to an inflamed tissue and/or retention of cells at the inflamed tissue.  To 
evaluate the kinetics of cell recruitment, cell retention, and cell death in Mefv null mice, 
peritonitis was induced with the sterile immunostimulant, thioglycolate, which has been used in 
several previous studies to distinguish differences in neutrophil and/or macrophage recruitment 
in knock-out mice (18).  Cellularity in fluid lavaged from the peritoneal cavity was evaluated at 
multiple times post-treatment.  Both neutrophils and macrophages were recruited to the 
peritoneal cavity in this experimental system (Figure 6.1A), which is consistent with previously 
published results for WT mice (1).  Neutrophil recruitment was rapid:  neutrophils were detected 
in the lavage fluid at 2 h after the induction of peritonitis.  The absolute number of neutrophils 
continued to increase through 5.5 h but was decreased at 24 h and more markedly decreased 
by 4 d (Figure 6.1B).  Macrophages displayed slower kinetics, as there was not a significant 
increase in the total number of macrophages at 2 h or 4 h, but an increase was noted at 24 h 
and was more significant at 3 d and 4 d (Figure 6.1A, C, and data not shown). 
 We analyzed 4 h and 4 d timepoints more extensively and assessed total cellularity, the 
percentage of dead cells, and cellular composition in the peritoneal lavage fluid.  Following 
treatment with 3 mLs of 3% thioglycolate, mice displayed a 6-fold increase in the total number of 
peritoneal lavage cells at both 4 h and 4 d post-treatment.  Total cellularity was similar in Mefv+/+ 
and Mefv-/- mice at both timepoints (Figure 6.1D).  At 4 h, 10% of cells were dead, and 50% of 
cells at 4 d were considered dead by 7AAD staining.  Since thioglycolate is a sterile 
immunostimulant, these values reflect endogenous mechanisms of regulating inflammation by 
controlled cell death.  The percentage of dead cells was similar for Mefv+/+ and Mefv-/- mice at 
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both timepoints (Figure 6.1E).  Similar values of both total cell number and percentage of dead 
cells suggest that cell recruitment and cell death kinetics are not affected by the loss of Pyrin.  
Consistent with this, there was no difference in the cell composition of Mefv+/+ and Mefv-/- 
animals at 4 h or 4 d (Figure 6.1F and G).  Similar studies using Zymosan A, a component of 
Saccharomyces cerevisiae yeast, to induce peritonitis also showed that at 4 h post-treatment, 
the total number of cells and the percentage of Gr-1+ neutrophils in the peritoneal cavity were 
similar between WT and Mefv-/- animals (see Chapter 5 and Figure 5.2).   
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Figure 6.1. Loss of Mefv does not affect peritoneal cell recruitment or survival.  Mefv+/+ 
and Mefv-/- mice were treated with 3 mLs of 3% Brewer’s thioglycolate medium by i.p. injection.  
At the indicated times, the peritoneal cavity was lavaged with 4 mLs of PBS to collect peritoneal 
cells.  A, The total number of peritoneal lavage cells at the indicated times after the induction of 
peritonitis.  B, The percentage of granulocytes was determined by visual analysis of cytospin 
samples stained with Hema-3.  Samples correspond to A.  n = 3 mice per genotype for A and B.  
C, Peritoneal cell concentration at 3 d after the induction of peritonitis, as determined by 
hemocytometer.  n = 15 mice per genotype.  D, The total number of peritoneal lavage cells at 4 
h and 4 d after the induction of peritonitis.  E, The percentage of peritoneal cells from D that 
were stained with 7AAD, a marker of dead cells.  F, The relative abundance of neutrophils 
(Mac-1+/Gr-1+) and macrophages (Mac-1+/Gr-1-) in the peritoneal lavage fluid at 4h, as 
determined by FACS analysis.  Samples correspond to the 4 h timepoint in D.  G, The 
percentage of granulocytes, macrophages, and lymphocytes was determined by visual analysis 
137 
 
of cytospin samples stained with Hema-3.  Samples correspond to the 4 d timepoint in D.  n = 3 
– 5 mice per genotype for D – G.   
 We also considered the possibility that a subtle difference in immune cell recruitment and/or 
clearance might be resolved by inducing a weaker immune response.  Using a 1/3 lower dose of 
thioglycolate to induce peritonitis, we examined the 4 d timepoint.  However, we found no 
difference between Mefv+/+ and Mefv-/- cohorts in the total number of cells, the percentage of 
dead cells, or the relative number of neutrophils (Figures 6.2A – C).  These results suggest that 
a loss of Pyrin function does not affect cell recruitment, cell retention, or cell death in the 
peritoneal cavity following treatment with thioglycolate.   
Mefv +/+ Mefv -/-
2.0
2.5
3.0
3.5
4.0
ce
lls
/m
L 
(x
 1
06
)
Mefv +/+ Mefv -/-
0
1
2
3
4
5
%
 7
A
A
D
+ 
ce
lls
Mefv +/+ Mefv -/-
5
10
15
20
25
M
PO
 (u
g/
m
L)
A B C
 
Figure 6.2. Loss of Mefv does not affect the cell profile at 4 d after the induction of mild 
peritonitis.  Mefv+/+ and Mefv-/- mice were treated with 2 mLs of 3% Brewer’s thioglycolate 
medium by i.p. injection.  At 4 d after the induction of peritonitis, the peritoneal cavity was 
lavaged with 4 mLs of PBS to collect peritoneal cells.  A, Peritoneal cell concentration at 4 d, as 
determined by hemocytometer.  B, The percentage of cells stained with 7AAD as detected by 
FACS analysis.  C, The relative abundance of neutrophils as determined by myeloperoxidase 
(MPO) activity within peritoneal lavage samples.  n = 8 Mefv+/+ and 9 Mefv-/- mice. 
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A loss of Pyrin does not affect the response to LPS in vivo 
 Next, wild-type and Mefv-/- mice were evaluated following treatment with 2.5 or 0.25 mg 
LPS/kg body weight (serotypes 127:B8 and 055:B5, respectively).  Mice were lethargic following 
LPS treatment in a dose-dependent manner that was independent of Mefv genotype.  LPS 
induced a rapid drop in temperature, with core body temperature reaching a minimum at 2 hours 
after treatment.  Both the magnitude of the drop in temperature, as well as the kinetics of the 
temperature change and subsequent recovery of the animals was similar in the Mefv-/- and 
control cohorts.  No difference was observed in the cryogenic response of the Mefv-/- and wild-
type control animals to i.p. LPS at both doses of endotoxin examined (p > 0.8; Figure 6.3A and 
B).  In addition to hypothermia, LPS treatment results in a measurable drop in body weight.  
Weight loss was also similar between WT and Mefv-/- cohorts (Figure 6.3C).  At 20 (2.5 mg/kg 
LPS) or 24 (0.25 mg/kg LPS) hours after treatment peritoneal lavage samples were collected.  
The total number of immune cells present in the peritoneal cavity increased with the dose of 
LPS, however neither the number or composition of cells recruited to the peritoneal cavity 
distinguished the Mefv-/- mice from control animals (Figure 6.3C).  The concentration of IL-1β 
and TNF-α cytokines in the peritoneal lavage fluid was examined by ELISA.  In WT and Mefv-/- 
animals, levels of both cytokines were below the limit of detection (data not shown). 
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LPS Dose Genotype % Wt loss Peritoneal cells/mL MPO (ng/mL)
2.50 mg/kg WT 5.74 ± 0.50 8.18 ± 0.89 x 10 6 133.0 ± 6.07
Mefv-/- 5.20 ± 0.61 (p = 0.51) 7.95 ± 0.94 x 10 6 (p = 0.88) 138.3 ± 10.54 (p = 0.65)
0.25 mg/kg WT 5.54 ± 0.65 9.32 ± 0.87 x 10 5
Mefv-/- 5.02 ± 0.44 (p = 0.51) 9.11 ± 0.80 x 10 5 (p = 0.83)
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Figure 6.3.  Loss of Mefv does not affect the response to LPS.  WT and Mefv-/- mice were 
treated with 2.5 mg/kg (A, n = 8 WT and 5 Mefv-/- mice) or 0.25 mg/kg (B, n = 18 and 19) crude 
LPS by i.p. injection at time 0 h, as indicated by arrows.  Rectal temperature at the indicated 
times is shown in A and B.  The table shown in C lists other parameters of inflammation 
corresponding to the mice in A and B:  percent of body weight lost between 0 h and the time of 
harvest, concentration of immune cells present in the peritoneal lavage fluid, and relative 
abundance of neutrophils in lavage samples as determined by myeloperoxidase (MPO) activity 
within peritoneal lavage cell samples. 
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A loss of Pyrin does not affect the outcome of Pseudomonas aeruginosa infection 
 To examine whether or not Pyrin shapes the overall immune response to live pathogens, 
mice were infected with Pseudomonas aeruginosa.  P. aeruginosa is an opportunistic bacteria 
that can cause pneumonia, necrotising enterocolitis, urinary tract infection, skin infection, and 
septic shock in humans.  In mice, depending upon the initial bacterial burden, wild-type mice 
either die or completely clear the bacteria by 48 hours post-infection (19).  P. aeruginosa 
infection induces inflammasome-dependent IL-1β release (20), so it is reasonable to 
hypothesize that mutations in Pyrin may alter IL-1β production and/or the course of infection.  
The bacterial load was optimized in this study so that WT 129 mice would show signs of 
bacterial burden but no lethality at a relatively late time-point post infection, so that a role for 
Pyrin in either the early phase and/or the late phase of the response would be evident.  5.4 x 
106 CFU/mouse were injected into the peritoneal cavity of mice, and animals were assessed at 
19 h post-infection.  While all mice had some bacteria remaining in the peritoneal cavity at 19 h, 
mice were split into two populations.  One group showed signs of bacterial clearance.  Bacterial 
burdens in these mice ranged from 102 – 103 CFU/mL, which is less than the initial burden of 
1.35 x 106 CFU/mL.  The other group showed signs of bacterial proliferation, having burdens of 
107 – 109 CFU/mL, which is above the initial load.  Importantly, the same population split was 
seen in WT and Mefv-/- groups, indicating that the response of individual mice within each 
genotype differs more than the response of mice between the two genotypes at this timepoint 
(Figure 6.4A).  The bacterial load in the blood showed a similar trend.  Mice that were clearing 
the bacterial infection in the peritoneal cavity had no bacteria in the blood, while some mice with 
high bacterial loads in the peritoneal cavity were also septic.  Again, the population split was 
independent of the Mefv genotype.  50% of WT animals (2 of 4 tested) were septic, and 43% (3 
of 7) Mefv-/- mice were septic (Figure 6.4B).  The total number of peritoneal cells was increased 
in infected mice compared to PBS (vehicle) treated mice; however, the cell counts were similar 
between WT and Mefv-/- animals (Figure 6.4C).  The IL-1β concentration in the peritoneal lavage 
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fluid correlated with bacterial burden; mice with the highest bacterial burdens also had the 
highest production of IL-1β; however, cytokine levels were not affected by the loss of Pyrin 
(Figure 6.4D).  Corresponding to the cell and molecular indicators of inflammation, infection 
caused a 7% loss of body weight, and a decrease in body temperature, but again, results were 
independent of the Mefv genotype (Figure 6.4E and data not shown).  Together, these results 
suggest that a loss of Pyrin does not affect the outcome of P. aeruginosa bacterial infection; 
however, a more extensive timecourse analysis is necessary. 
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Figure 6.4.  Loss of Pyrin does not affect the outcome of Pseudomonas aeruginosa 
infection.  5.4 x 106 CFU/mouse or PBS vehicle were injected into the peritoneal cavity of WT 
and Mefv-/- mice (n = 7 and 7), and animals were assessed at 19 h post-infection.  The 
peritoneal cavity was lavaged with 4 mLs of PBS.  A and B, Number of live bacteria (colony 
forming units (CFU) per mL of peritoneal lavage fluid, A, or mL of blood, B.  The initial burden in 
the peritoneal cavity was determined by plating a sample of the injected solution.  C, Peritoneal 
cell concentration, as determined by hemocytometer.  Mice with greater bacterial loads in the 
peritoneum had slightly lower cell counts.   D, IL-1β concentration in peritoneal lavage fluid was 
determined by ELISA.  E, The percent of body weight lost during the course of infection (19 h).  
Each dot represents one mouse.  
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Discussion 
 This chapter describes studies to assess the in vivo innate immune response of Mefv null 
mice.  These studies provide a functional complement to the work described in previous 
chapters in which we characterized the activation and survival of individual immune cell types 
isolated from the mouse.  Following exposure to thioglycolate, LPS, and P. aeruginosa, WT and 
Mefv-/- mice showed similar physiological, cellular, and IL-1β responses.  Peritoneal exposure to 
thioglycolate and LPS demonstrated that Mefv-/- mice recruit and retain inflammatory cells at 
sites of inflammation normally (p = 0.83 and 0.88, respectively).  The hypothermic response 
induced by LPS was similar in Mefv-/- and WT mice.  No differences in cytokine production or 
bacterial load were detected between Mefv-/- and WT mice following P. aeruginosa infection.  
While our results failed to support our hypothesis that Pyrin-deficiency causes exacerbated 
innate immune responses, they leave open the possibility that Pyrin may be involved in some, 
but not all, immune responses.  It is also possible that compensatory mechanisms within the 
mouse prevent Pyrin-deficiency from altering the immune response in vivo. 
 Since we wanted to test the contribution of Pyrin to the general innate immune response, 
we used sterile peritonitis models, so that the interpretation of our results was not complicated 
by the pathogenicity of a microorganism.  Furthermore, we chose LPS because Mefv 
expression is induced by LPS (Chapter 3 and previously published reports (8)).  This affect on 
gene expression is not unique to murine Mefv.  In rats, intratracheal instillation of LPS increases 
Mefv expression in bronchial aviolar lavage cells (21), and treatment with LPS also increases 
expression of human MEFV (22).  Consistent with expression data, exacerbated hypothermia 
was observed after LPS treatment in mice carrying alleles encoding a truncated Pyrin protein.  
However, the possibility that Pyrin is involved in pathogen defense through a mechanism that is 
only apparent upon infection with live pathogens, such as bacterial clearance, was also 
addressed.  Pseudomonas aeruginosa activates NF-κB-dependent Il1β transcription and 
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inflammasome-dependent IL-1β release (20, 23-26).  Specifically, association of LPS with TLRs 
2 and 4 and of flagellin with TLR5 results in MyD88 and NF-κB dependent Il1β transcription.  
Induction of Il1β expression is dose-dependent according to the bacterial burden (24-26).  
Release of IL-1β from macrophages exposed to P. aeruginosa in vitro is dependent upon 
Caspase-1, Nlrc4, and Nlrp3, but not Pycard (20, 23).  Accordingly, Caspase-1 cleavage is 
absent in Nlrc4-/- macrophages, and in vivo, reduced IL-1β production in Nlrc4-/- mice was 
accompanied with increased bacterial burden (20).  Given these previous findings, P. 
aeruginosa infection was a good model system to evaluate the contribution of Pyrin to bacterial 
defense.   
 Previous work has demonstrated that genetic perturbation of Mefv in mice causes 
exacerbated inflammatory responses.  Chae, et al. created and characterized mice carrying a 
disrupted Mefv allele.  The promoter and 5’ end of the gene, which encodes the pyrin domain 
and a small portion of the linker region, were maintained, but the remaining 3’ end, which 
encodes the B-box, coiled-coiled, and B30.2 domains, was replaced with DNA encoding green 
fluorescent protein (GFP).  This allele, Mefvtrunc, encodes a truncated Pyrin protein that the 
authors describe as hypomorphic.  Homozygous mutant mice exhibited phenotypes resembling 
FMF.  An increased number of inflammatory cells was observed at 4 d after thioglycolate-
induced peritonitis, perhaps as a result of impaired macrophage cell death in these animals (8).  
Relative to wild-type mice, homozygous mutant mice displayed exacerbated LPS-induced 
hypothermia and increased lethality following LPS and D-gal treatment.  Peritoneal 
macrophages from these mice produced more IL-1β after immune stimulation in vitro.  It is 
unclear why Mefvtrunc/trunc mice with hypomorphic Pyrin function would have different immune 
responses compared to WT littermates, while Mefv-/- mice with no Pyrin function have 
responses similar to coisogenic WT mice.  While effort was taken to match experimental 
variables between these studies, factors such as housing conditions and genetic background 
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could not be controlled.  For example, the gut microbiome is influenced by external housing 
conditions, and it significantly alters the course of peritoneal inflammation (27).  The genetic 
background of mice affects endotoxin-induced lethality and IL-1β production in WT mice (28).  
Furthermore, IL-1 receptor antagonist (IL-1ra) deficiency has varying degrees of severity in 
BALB/cA, C57BL/6, and 129 mice (reviewed in (29)).  Interestingly, the cellularity of Mefv-/- and 
WT cohorts in this study was similar to that of Mefvtrunc/trunc mice in the previous study, but 
differed from the wild-type mice.  The dramatic difference between wild-type responses lends 
support to the idea that genetic and/or microbiome influences may contribute to the findings of 
these studies. 
 In chapter 3, we showed that the loss of Pyrin increases IL-1β levels, however, release of 
mature IL-1β requires a danger signal.  Thus, it is not surprising that IL-1β levels were not 
dramatically increased in vivo.  Mefvtrunc/trunc mouse macrophages, on the other hand, released 
significant IL-1β in response to LPS.  Therefore, it is not surprising that cell recruitment and 
thermic responses, which are regulated in part by IL-1β, were exacerbated in these mice.  It is 
important to note that the mechanism of cellular recruitment induced by thioglycolate differs 
from that induced by IL-1β.  In most cases, knock-out mice that display a difference in IL-1β-
induced cell recruitment also display a difference in thioglycolate-induced cell recruitment (18).  
However, an example to the contrary is Icam2-/- mice, which have reduced neutrophil 
recruitment in response to IL-1β treatment but not thioglycolate treatment (30).  It remains 
possible that changes in IL-1β production alter cellular recruitment in Pyrin-deficient mice. 
 It is possible that the experimental systems that we chose were not sensitive enough to 
resolve a functional contribution of Pyrin.  We submit several arguments against this possibility.  
1) We used well-established model systems that have been used in the past to detect functional 
changes in mouse models.  2) We reproduced experiments that were used previously to 
demonstrate inflammatory hyperresponsiveness in homozygous Mefv mutant mice.  3) We 
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further mitigated this risk by using multiple models of inflammation.  We chose diverse models 
to stimulate robust (thioglycolate, Zymosan-A, and P. aeruginosa) and mild inflammation (0.25 
mg/kg LPS), in order to entertain the possibility that Pyrin modulates only robust or only mild 
inflammation.  4) Large cohorts were used in these studies in order to resolve a more subtle 
phenotype.  However, the variability that is inherent to in vivo studies does severely limit the 
ability to conclude that there is no phenotype in Mefv null animals.  Nevertheless, our studies 
suggest that a complete loss of Pyrin function does not affect the sensitivity or magnitude of an 
innate immune response in vivo following treatment with at least some stimuli. 
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CHAPTER 7 
Conclusions and Perspectives 
 
Summary 
 This dissertation summarizes our work to elucidate the role of Pyrin in innate immune 
responses.  Using a reverse genetics approach with Pyrin-deficient mice, we were able to 
examine the outcome of a complete loss of Pyrin function in an endogenous system.  Building 
upon previous research addressing Pyrin function in systems with hypormorphic or 
hypermorphic Mefv expression, and guided by the pathology of FMF and Mefv expression, we 
chose to investigate the contribution of Pyrin in macrophage-dependent IL-1β production and in 
neutrophil processes.  We identified a role of Pyrin in IL-1β production, as a negative regulator 
of inflammasome-mediated IL-1β levels.  Pyrin null neutrophils, however, did not display altered 
phenotypes in an unstimulated state or in the context of innate immune responses, despite 
especially high expression of Mefv in wild-type neutrophils.  Our results are consistent with a 
model in which mice in a steady-state have adequate immune function despite the loss of Pyrin, 
but during inflammation, the loss of Pyrin causes functional changes, and specifically, a loss in 
appropriate regulation of IL-1β levels.  
 Previous research is consistent with a functional contribution of Pyrin to the innate immune 
response and a model in which abnormal function, due to FMF-associated mutations, causes 
uncontrolled inflammation.  Previous studies using in vitro human and mouse model systems 
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have shown that Pyrin contributes to macrophage-dependent IL-1β production (1-8); however, 
its specific contribution is unclear.  Studies using neutrophils isolated from FMF patients indicate 
that neutrophils have altered chemotaxis, phagocytosis, oxidative burst, and survival (9-15), 
although the association of mutations in Mefv with these neutrophil phenotypes has not been 
determined.  Thus, we addressed questions which remained as to how mutations in Mefv alter 
the innate immune response to cause FMF pathology.   
 We found that macrophages from wild-type and Mefv-/- mice release a similarly low amount 
of IL-1β after treatment with LPS; however, following the addition of a number of different agents 
that stimulate the inflammasomes, IL-1β levels in the supernatant of macrophages from Mefv-/- 
animals were elevated compared to those in the supernatant of macrophages from wild-type 
mice.  While the concentration of IL-1β and the magnitude of the difference between Mefv-/- and 
wild-type macrophages changed depending on the treatment, the effect of Pyrin-deficiency 
remained the same.  Exposure to NLRP1b, NLRP3, and NLRC4-dependent stimuli all led to 
increased levels of IL-1β in the supernatant of Mefv-/- macrophages compared to wild-type 
macrophages.  Neutrophils, on the other hand, did not display any deficits due to a loss of Pyrin.  
No differences in development, recruitment, or survival were found.  In vivo, the induction of 
peritonitis did not lead to detectable changes in the recruitment or survival of macrophages or 
neutrophils, or in the overall health of mice, as detected by parameters of body temperature, 
weight loss, and bacterial load.  While the data from these studies suggest that there are 
mechanisms to protect against an alteration to the in vivo inflammatory response to at least 
some stimuli, further testing of Pyrin null mice is critical for making these conclusions.  Certainly 
the importance of Mefv is clear, based upon its conservation in the genome and the association 
of mutations with an autoinflammatory phenotype. 
 This chapter discusses how our findings further previous research on Pyrin and FMF, 
primarily regarding the role of Pyrin in IL-1β production, and then hypothesizes where Pyrin fits 
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into the pathway for IL-1β production and release.  Given that Pyrin negatively regulates IL-1β 
production, other mechanisms of endogenous regulation of inflammasome-dependent IL-1β 
production are discussed, in order to create a context for Pyrin’s role in the complex regulation 
of IL-1β synthesis and release.  Many questions remain, regarding not only Pyrin’s regulation of 
IL-1β, but also mechanisms that regulate Pyrin’s function.  Finally, the genetics of FMF are 
revisited, given our findings that a loss of Pyrin function leads to an IL-1β phenotype that is 
characteristic of FMF. 
Previous mouse models 
 Work published previous to our study also demonstrated that a genetic perturbation 
targeted to Mefv led to exacerbated pro-inflammatory responses.  The targeted Mefv allele 
encodes a truncated Pyrin protein, in which the pyrin domain and a small portion of the linker 
region are fused to green fluorescent protein (GFP).  Homozygous mutant mice (Mefvtrunc/trunc) 
displayed exacerbated LPS-induced hypothermia, increased inflammatory cell recruitment in 
response to thioglycolate, and increased lethality following LPS and D-gal treatment.  
Furthermore, peritoneal macrophages from Mefvtrunc/trunc mice had excessive IL-1β production 
and decreased apoptosis in vitro (1).  These findings certainly support an important role for 
Pyrin in vivo and suggest that disrupting Mefv significantly alters innate immune responses to 
induce and/or maintain exacerbated inflammatory responses.  However, there are limitations 
which prevent a logical inference to the function of human Pyrin and the consequences of FMF-
associated mutations based upon studies using Mefvtrunc/trunc mice.  Due to the presence of a 
partial protein, and furthermore, a GFP-fusion protein, it is difficult to define the disrupted allele 
as causing a partial or complete loss of wild-type Pyrin function or as producing a gain of wild-
type function or even novel function.  It is interesting that in Pyrin null mice, elevated IL-1β levels 
were also detected, but exacerbated hypothermia, cellularity, and sepsis-induced lethality 
phenotypes, and the decreased macrophage cell death phenotype, were not reproduced.  It is 
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possible that these differences result from function(s) of the truncated, GFP-fusion, Pyrin protein 
that is present in Mefvtrunc/trunc mice. 
 A major caveat to using the mouse to model human Pyrin function is the absence of the 
B30.2 domain from the mouse protein.  Recently-published work addresses the function of the 
B30.2 domain by creating a hybrid Mefv gene in which the promoter, PYD, BB, and C-C 
domains of the mouse protein are intact, and the B30.2 domain of the human Pyrin protein is 
attached to the C-terminal end (16).  Despite significant effort, a knock-in of the WT B30.2 
domain could not be created, perhaps because it was incompatible with life.  However, within 
this system, the effects of three missense mutations in the B30.2 domain were examined.  All 
three mutations, collectively referred to here as mutB30.2, caused delayed growth, spontaneous 
inflammation, more circulating immune cells, and elevated IL-1β levels in homozygous mice.  
Heterozygous MefvmutB30.2/+ and MefvmutB30.2/- were unaffected.  The investigators concluded that 
mutations in the B30.2 region cause a gain-of-function and have a dosage effect.  Similar to the 
Mefvtrunc/trunc mice, it is difficult to define the chimeric Pyrin protein as causing a gain-of-function.  
To address this question, it was emphasized that Pyrin deficient mice, with a loss-of-function, 
had no disease phenotype in the assays used for testing.  Specifically, the relative number of 
circulating CD11b+ cells was similar to Mefv+/+ mice.  Mefv-/- mice did not display increased IL-1β 
processing in response to NLRP3, NLRC4, or AIM2 stimuli.  However, mice did secrete more IL-
1β following treatment with LPS alone.  In contrast, our results show that the loss of Pyrin 
causes significantly elevated IL-1β levels following treatment with NLRP3, NLRC4, and NLRP1b 
inflammasome stimuli, but not following treatment with LPS alone.  Taking these IL-1β 
phenotypes into consideration, the conclusions that Pyrin null mice have no phenotype and that 
B30.2 missense mutations cause a gain-of-function are less clear.  Another possible conclusion 
from studies using mutB30.2 mice is that the introduction of the wild-type B30.2 domain into the 
mouse protein causes a gain-of-function, either increased wild-type function or novel function, 
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and that missense mutations in the B30.2 domain cause a partial loss of the gained function.  
This later model in which missense mutations cause a loss-of-function is more consistent with 
autosomal recessive inheritance of FMF. 
 
Where in the pathway? 
 IL-1β was undetected in peritoneal lavage samples from Mefv-/- and WT mice at 20 and 24 
h following in vivo exposure to LPS, 4 h or 4 d following thioglycolate treatment, and untreated 
cells.  Therefore, the removal of Mefv from the mouse does not cause spontaneous IL-1β 
release.  Furthermore, in our studies, treatment with LPS alone did not alter IL-1β production 
from Mefv null macrophages in comparison to WT macrophages.  Thus, the regulation of IL-1β 
production by Pyrin is independent of IL-1β transcription.  Rather, inflammasome activation 
remains a requirement for the release of IL-1β from Pyrin-deficient macrophages.  This is 
consistent with the episodic nature of inflammation in FMF—an unknown endogenous stimulus 
activates an inflammatory response, but severe inflammation is not chronic. 
 Pyrin can negatively regulate IL-1β production that is mediated by multiple inflammasomes.  
Therefore, Pyrin most likely contributes to a part of this pathway which is common to multiple 
modes of pathogen uptake and signaling through multiple inflammasome complexes.  Since 
ASC and Caspase-1 are common between the inflammasomes, a likely possibility is that Pyrin 
interacts with ASC and/or Caspase-1, sequestering them away from inflammasome complexes.  
Previous studies detected protein interactions between Pyrin and both ASC and Caspase-1 (1, 
2, 6-8, 17).  In particular, one study demonstrated that Pyrin competed with NLRP3 for binding 
to ASC (3). 
 Mice deficient in inflammasome components ASC or Caspase-1 are more resistant to 
endotoxin-induced lethality than WT mice (18), while mice lacking IL-1β have unaltered 
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susceptibility compared to wild-type mice (19).  These data should be reproduced using all three 
knock-out mice in parallel, but they provide preliminary in vivo evidence that inflammasome-
dependent, IL-1β-independent signaling contributes to inflammation.  Indeed, the formation of 
inflammasome complexes is associated with not only IL-1β production, but also inflammation-
induced cell death (20).  As expected, we observed an increase in macrophage cell death 
following exposure to stimuli which activate inflammasome complexes.  However, 
inflammasome-associated cell death was not affected by the loss of Pyrin.  This places Pyrin’s 
role in inflammasome function as part of a divergent pathway that is limited to IL-1β production 
and not cell death.   
 Initial work suggested that inflammasome activation leads to both IL-1β production and cell 
death in a ASC-dependent, Caspase-1-dependent manner.  Thus, it was perplexing to us that 
Pyrin affected IL-1β production but not cell death.  We anticipated that if Pyrin affected 
inflammasome complex formation, or a theoretical common function upstream of inflammasome 
complex formation, we would observed changes in cell death as well as IL-1β production.  
However, more recent work has begun to tease apart two partially overlapping, but independent 
pathways for IL-1β production and cell death.  IL-1β production in response to Legionalla 
pneumophila requires NLRC4, ASC, and Caspase-1, but cell death is dependent on only 
NLRC4 and Caspase-1 and not ASC (21).  These findings elucidated the possibility that Pyrin 
could interact with ASC and affect IL-1β production without affecting cell death.  Further 
research has shown that divergent pathways control IL-1β production and cell death in response 
to Francisella novicida, Salmonella typhimurium, and Pseudomonas aeruginosa, as well as 
Legionella pneumophila.  Caspase-1 and ASC are both required for IL-1β production, but 
Caspase-1 is also absolutely required for cell death and ASC is not (22).  These results are 
consistent with a model in which Pyrin sequesters ASC to prevent the formation of 
inflammasomes complexes that mediate IL-1β production.  However, importantly, the “death 
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complex” is formed by CARD-CARD interactions between NLRC4, NLRP1b, or a CARD-Aim2 
chimera and Caspase-1.  Thus, there is still no model to explain how Pyrin can regulate NLRP3 
inflammasome complex formation without affecting cell death as well as IL-1β production.   
 Our results are consistent with a model in which Pyrin negatively regulates IL-1β release 
from the cell.  IL-1β, IL-18, IL-33, and high mobility group box protein 1 (HMGB1) are uniquely 
shuttled to the plasma membrane in endolysosomes, in contrast to most proteins which are 
sorted within the Golgi into vesicles released from the cell (23).  The interplay between 
inflammasome complex formation, endolysosomes, and cytokine release is undefined.  
Immunofluorescence microscopy studies place the inflammasome complexes and ASC specks 
within the cytosol, however, Caspase-1 may cleave pro-IL-1β within the endolysosomes.  
Although not directly proven, sequestering Caspase-1 activity within the endolysosomes would 
explain how the cell might protect itself against off-target cleavage of other proteins by 
Caspase-1 (24).  In support of this model, mature Caspase-1 release can be detected 
concurrent with IL-1β release (25).  The mechanism by which IL-1β and Caspase-1 enter the 
endolysosomes is a mystery (24).  Are active transporters required or do endolysosomes form 
around ASC specks?  Another unanswered question is what cytoskeletal elements and 
associated proteins are necessary for shuttling of the endolysosomes through the cell.  Since 
Pyrin has been shown to interact with cytoskeletal elements in addition to inflammasome 
complexes, it is reasonable to hypothesize that Pyrin may be a link between these elements that 
are necessary for IL-1β production.  This link, called an immune synapse, was previously 
described. 
 There are several approaches to test the model that Pyrin is involved in IL-1β release from 
the cell.  Cellular colocalization would be an ideal way to visualize an interaction between Pyrin, 
the cytoskeleton, and active Caspase-1, however, reagents necessary to facilitate image 
resolution to such detail are currently unavailable.  A more amenable method to test the 
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hypothesis that Pyrin interacts with inflammasome proteins ASC and/or Caspase-1 in cells is to 
quantify the formation of ASC specks and the activation of Caspase-1.  If Pyrin interacts with 
ASC to prevent inflammasome complex formation, then the percentage of ASC-speck positive 
cells should be increased in macrophages from Pyrin-deficient mice compared to macrophages 
from wt mice.  Similarly, Caspase-1 activity should be increased.  If Pyrin interacts with the 
catalytic subunits of pro-Caspase-1 or mature Caspase-1, then Caspase-1 activity will still be 
increased, however, ASC-speck formation should be similar between Pyrin-deficient and wt 
cells.  This pattern of results is seen in cells treated with Caspase-1 inhibitors (26).  It is 
important to recognize that Pyrin’s affect on IL-1β production is subtle and a phenotypic 
difference in these assays is also likely to be subtle.  Therefore, a detectable difference argues 
for a role of Pyrin in inflammasome complex formation and/or function, but results which are 
similar between WT and Mefv null cells is inconclusive.  It could indicate that Pyrin does not 
affect inflammasome function, but alternatively, it could indicate that the phenotype could not be 
resolved by these assays.   
 An easy, albeit inconclusive, way to suggest that Pyrin’s regulatory action is through 
endolysosome shuttling rather than inflammasome complex formation is to compare HMGB1 
release from Pyrin deficient and sufficient macrophages following treatment with LPS.  Since 
HMGB1 is released through endolysosomes, but does not require Caspase-1 cleavage, 
detection of HMGB1 levels provides a nice assay to separate Caspase-1 activation and 
endolysosome shuttling functions.  Elevated levels of HMGB1 release from Pyrin-deficient 
macrophages suggest that Pyrin’s effect is on a function common to HMGB1 and IL-1β release, 
i.e. endolysosome shuttling.  Similar levels of HMGB1, on the other hand, argue that the 
regulatory role of Pyrin is limited to IL-1β and not HMGB1, and thus suggests that Pyrin 
regulates inflammasome function. 
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 Together, these assays provide complementary methods to detect whether Pyrin affects 
inflammasome complex formation or IL-1β release.  A question that could remain following this 
work is how Pyrin affects IL-1β release following inflammasome stimulation, but has no effect on 
IL-1β release in response to LPS alone.  In mice, little IL-1β is released without additional 
danger stimuli to activate the inflammasome.  Given the subtle regulatory effect of Pyrin, it is 
possible that a difference in IL-1β levels following LPS treatment could not be detected.  It is 
also possible that a small amount of mature or immature IL-1β is released from macrophages 
through another mechanism, such as passive diffusion from dying cells (7).  Pro-IL-1β can be 
cleaved following its release from the cell (27).  Further experiments are necessary to address 
this possibility.  Initially, it would be interesting to test IL-1β release following other stimuli that 
activate production of pro-IL-1β but do not activate the inflammasome.  It would also be 
interesting to examine a mouse with Caspase-1 and Pyrin deficiencies.  This would be another 
way to discern whether or not the regulatory effect of Pyrin is dependent upon the 
inflammasome complex, although given the small amount of IL-1β release independent of the 
inflammasome, the detection limit of reagents may prevent resolution of a phenotype. 
  
Endogenous regulation of inflammasome-dependent IL-1β production 
 Considering the severe consequences which result from unregulated IL-1β signaling, it is 
not surprising that there are multiple stages at which IL-1β signaling is controlled.  As previously 
mentioned, IL-1β transcription and the stability of pro-IL-1β protein is influenced by multiple 
factors (28-30).  Additionally, regulation of inflammasome complexes influences IL-1β release.  
This section focuses on regulation of inflammasome signaling as a mechanism to fine-tune the 
timing and magnitude of IL-1β production. 
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Sequestration of inflammasome complex proteins 
 Two classes of negative regulators that prevent inflammasome protein interactions are 
CARD-only proteins (COPs) and PYD-only proteins (POPs).  As their names suggest, these 
proteins have CARD or PYD protein binding domains, but lack the functional NACHT and LRR 
domains that are necessary to promote Caspase-1 activation.  COPs and POPs bind to the 
CARD or PYD domains, respectively, of the NLRs, ASC, and/or Caspase-1 to prevent 
inflammasome complex interactions and Caspase-1 activation.  Human COP, INCA (inhibitory 
CARD) and ICEBERG have been shown to block IL-1β production using in vitro overexpression 
systems (31-33).  Similarly, human pyrin-only proteins POP1 and cPOP2 have been shown to 
regulate IL-1β production in vitro.  POP1 was originally shown to increase IL-1β production, but 
a recent protein binding study suggests that POP1 may decrease NLR-dependent IL-1β 
production, similar to cPOP2 (34-37).  The in vivo function of these genes has not been 
examined, because they are absent from the mouse genome.  Pyrin, on the other hand, is 
suspected to act as a POP that negatively regulates IL-1β production in both humans and mice.   
 Additionally, Caspase-12 deficient mice display increased IL-1β cytokine production, but the 
significance of Caspase-12 in humans is questioned because the region that mediates the 
regulatory effect in mice is missing from the human gene (38).  Bcl-2 and Bcl-XL, on the other 
hand, bind NLRP1 and reduce Caspase-1 activation in human cell lines, and Bcl-2 deficient 
mice showed increased IL-1β production in response to muramyl dipeptide (MDP) treatment in 
vivo (39).  p202, a HIN-family protein, inhibits AIM2-dependent inflammasome activity in 
response to dsDNA.  p202 can bind dsDNA and also AIM2, so it may function to sequester one 
or both of these to prevent Caspase-1 activation (40).  The serpin proteinase inhibitor 9 (PI-9) 
inhibits Caspase-1 and pro-IL-1β processing in human vascular smooth muscle cells (41).   
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Feedback loops 
 In addition to inflammasome complex disruption, a second mechanism of regulation occurs 
through feedback loops that converge upon NF-κB.  NF-Κb promotes transcription of IL-1β, 
NLRP2, NLRP3, ICEBERG, and MEFV.  Increasing IL-1β, NLRP2, and NLRP3 transcription 
should increase inflammasome-dependent IL-1β production and promote an inflammatory 
response, whereas ICEBERG and Pyrin inhibit IL-1β production.  Activation of the IKK/NF-κB 
pathway, in turn, is regulated by IL-1β, TNFα, NLRP2-4, Pyrin, and ASC in a complex manner.  
Reconstitution of the pathway in HEK293T cells indicates that IL-1β or TNFα treatment alone 
induces NF-κB activity, and overexpression of NLRP3 or Pyrin also increases NF-κB activity 
above baseline (42).  ASC alone dose-dependently reduces NF-κB activity (43) and abrogates 
the effects of IL-1β and TNFα (42).  Interestingly, although NLRP3 and Pyrin increase NF-κB 
activity in untreated cells, they reduce the effect that TNF-α treatment has in promoting NF-κB 
activity.  Moreover, while ASC alone reduces TNFα-dependent NF-κB activity, ASC increases 
NF-κB activity when NLRP3 or Pyrin is combined with TNFα.  In this study, ASC affects IKKα 
and IKKβ activity through its PYD (42).  To add further regulation, the expression of Mefv and 
IL-1 receptors 1 and 2 (IL-1r1 and IL-1r2) are also driven by NF-κB in a TNF-α dependent 
manner (44).   
 Other investigations have shown that, in untreated cells, Pycard (ASC) overexpression 
induces NF-κB activity (45).  The NLRs PYNOD (NLRP10) and NLRP2 reduce NF-κB activity 
which is promoted by ASC.  PYNOD binds to ASC (46) to inhibit ASC-mediated induction of NF-
κB activity.  NLRP2 inhibits NLRP3-mediated induction as well as ASC-mediated induction of 
NF-κB activity (45).  NLRP2 expression is promoted by NF-κB in a TNFα-dependent manner.  
Since TNFα is itself regulated by NF-κB activity, NLRP2 mediates a feedback regulatory loop 
(47).  Fas-associated factor 1 (FAF1) also binds to NLRP3 and inhibits NLRP3 and ASC-
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mediated activation of NF-κB.  Furthermore, immune stimulants can influence the expression of 
regulatory genes.  For example, LPS increases NF-κB-mediated transcription of pro-IL-1β, ASC, 
NLRP3, Pyrin, and FAF1 (48).  Thus, timing of NF-κB-driven gene expression and NF-κB 
regulation can shape the transcriptome and the immune response.  As previously mentioned, in 
one study Pyrin increased NF-κB translocation (49) and in another study Pyrin increased NF-κB 
activity (42), but other investigators have seen no change in NF-κB activity following the 
overexpression of Pyrin (3, 8). 
 In addition to regulatory loops that affect NF-κB activity, NF-Κb-mediated regulatory loops 
also affect inflammasome activity.  In addition to IL-1β, NLRP2, NLRP3, ICEBERG, and MEFV, 
as previously mentioned, Serpin plasminogen activator inhibitor 2 (PAI-2) and Bcl-XL are NF-κB 
regulated genes.  Both negatively regulate Caspase-1 dependent IL-1β secretion.  Therefore, 
NF-Κb-dependent genes negatively regulate IL-1β release, whose transcription is positively 
regulated by NF-κB.  Interestingly, PAI-2 is not expressed in THP-1 cells, which release IL-1β 
following stimulation with LPS only (50).  PYNOD, mentioned above as an inhibitor of ASC-
dependent NF-κB activity, also inhibits IL-1β release.  Using both human and mouse proteins, 
PYNOD was shown to co-immunoprecipitate with IL-1β and Caspase-1, indicating that its affect 
on IL-1β release occurs through inflammasome complex interaction and not just NF-κB-
regulated transcription of pro-IL-1β.  In Jurkat cells, PYNOD expression slightly increased 
following LPS stimulation, thus PYNOD expression can also be regulated by inflammatory 
signaling in at least some hematopoietic cells (46). 
 A recent study in mice demonstrated another mechanism of inflammasome regulation:  cell-
mediatied suppression by adaptive immune cells.  Activated effector and memory CD4+ T-cells 
suppress inflammasome activity during the primary adaptive immune phase and during 
secondary immune challenge.  T-cell ligands, including CD40, mediate this effect (40).  These 
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findings provide a nice conceptual advancement as to how the innate immune response can be 
resolved, at least in part, by action of the adaptive immune response. 
PRY-SPRY Domain 
 Another TRIM-family protein, TRIM30α, has been shown to regulate IL-1β production at 
both the transcriptional level and inflammasome-mediated processing level.  Knockdown of 
TRIM30α in the immortalized mouse macrophage cell line J774 led to increased IL-1β 
production in response to multiple NLRP3-inflammasome elicitors (51).  Overexpression of 
TRIM30α in transgenic mice cause reduced IL-1β production in vivo following treatment with 
MSU (51).  Another SPRY-containing protein, estrogen-responsive B-box protein, was also 
shown to regulate inflammasome activity, albeit in a positive manner (52). 
 In summary, regulation of inflammasome-dependent IL-1β production is a complex process, 
mediated by NF-κB activation and regulatory feedback loops that converge upon Caspase-1 
activity.  Further research efforts are necessary to discern how all of these regulatory 
mechanisms, now including Pyrin, synergize to provide appropriate regulation of IL-1β-
dependent immune responses. 
 
Regulation of Pyrin’s function 
Splice variants 
 One interesting area for future research involves the study of Mefv splice variants.  Several 
investigators have observed that Mefv has one primary transcript but several minor transcripts 
(53).  To date, studies have characterized splice variants in PBMCs, granulocytes, and sonovial 
fibroblasts (54).  So far, it appears that some splice variants may be unique to one or more cell 
types.  However, no study has used the same methodology to detect splice variants of different 
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cell types in parallel.  Thus, the apparent differences in the presence of splice variants between 
cell types could reflect the relative detection capabilities of the experimental systems used.  
Future studies should address whether or not splice variants vary in a qualitative or quantitative 
way between different cell types.  A related question is whether or not splicing changes within a 
cell type as the cell matures or becomes activated.  Indeed the abundance of minor splice 
variants increases in sonovial fibroblasts following activation with LPS (54).  Is splicing also 
regulated by external signals from neighboring cells through soluble mediators or cell-cell 
interaction?  Another important question is:  What are the functional consequences of 
differential splicing?  Do splice variants have increased, decreased, or novel function in 
caparison to the primary transcript?  By potentially changing the overall structure of Pyrin, these 
transcripts could favor different protein-protein, protein-cytoskeletal, or intramolecular 
interactions.  Or perhaps they change the protein stability of Pyrin.  A third avenue for future 
research regarding Mefv splicing is addressing the hypothesis that mutations in Mefv affect 
splicing.  So far, there is no evidence to directly support this hypothesis, and there are no 
mutations at splice donor or acceptor sites.  However, since the abundance of minor transcripts 
increases concurrently with immune activation, and FMF disease is caused by aberrant immune 
activation, it seems possible that mutations could increase the abundance of splice variants and 
cause immune activation. 
 To address the first question, cells could be sorted based upon type, maturity, and 
activation by flow cytometry and assessed for the relative abundance of splice variants by 
quantitative real-time PCR.  This experiment should be done using both human and mice 
tissues, since there is substantial evidence for splice variants of the human Mefv gene, but a 
broader range of tissues is available from the mouse.  To assess the function of splice variants, 
two complementary experimental systems could be used.  First, Mefv genes capable of 
expressing only one splice variant could be overexpressed in a human cell line that lacks 
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endogenous expression of Pyrin.  This system allows for independent evaluation of the function 
of each splice variant.  IL-1β production, NF-κB activity, ASC-speck formation, Caspase-1 
activity, and cellular localization should be assessed.  Second, antibodies specific to a splice 
variant of Pyrin could be used to determine protein binding capabilities and cell localization of 
endogenous Pyrin in primary human cells.  This method is likely to produce results with better 
correlation to what occurs in vivo, but technical limitations could prevent a clear interpretation of 
results.  Lastly, to assess the hypothesis that mutations affect splicing, Mefv genes with FMF-
associated mutations could be overexpressed in a human cell line followed by quantification of 
the abundance of each splice variant by real-time PCR. 
Cleavage of Pyrin 
 The human Pyrin protein was shown to be cleaved by Caspase-1.  By, overexpressing 
human Pyrin and Caspase-1 proteins in murine PT67 cells, the Pyrin protein was observed at 
multiple molecular weights.  The production of the lower molecular weight form of Pyrin was 
blocked by the Caspase-1 inhibitor z-VAD-fmk (49).  It is important to note that Pycard is not 
expressed in PT67 cells.  The expression of Pycard (ASC), as is typical in an endogenous 
system, could alter the interaction of Pyrin and Caspase-1, since Pyrin binds to both of these 
proteins.  ASC may sequester Pyrin or Caspase-1 from interacting with the other or promote the 
formation of a trimeric protein complex.  It is also interesting to note that these cells were 
unstimulated.  In another study using THP-1 monocytes, two different weights of endogenous 
human Pyrin were detected by western blotting with an antibody that recognizes the N-terminal 
portion of Pyrin, similar to the aforementioned study.  The estimated size of the smaller protein 
correlates nicely.  Stimulation of cells with cold temperature (30°C) stimulated NLRP3 
inflammasome-mediated Caspase-1 activity, and decreased the abundance of full-length Pyrin.  
However, the Caspase-1 inhibitor did not prevent the disappearance of the predominant 85 kDa 
Pyrin band.  Thus, this study suggests that Caspase-1 does not mediate cleavage of Pyrin.  The 
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authors instead suggest that Pyrin is degraded when the NLRP3 inflammasome is activated by 
cold temperature (5).   
 In FMF patient samples, there is a higher percentage of a low molecular weight form of 
Pyrin, compared to healthy controls (49).  It is tempting to conclude that Caspase-1-mediated 
cleavage of Pyrin is increased as a result of FMF-associated  mutations within the Pyrin protein 
and that the cleavage of Pyrin alters its function to produce the FMF disease phenotype.  
However, interpretation of data from human patient samples is complicated by a couple 
experimental limitations.  First, the presence of a lower molecular weight band is not necessarily 
indicative of cleavage of Pyrin.  Instead, it could be the natural protein product of a shorter 
transcript of the MEFV gene.  Second, it is unclear if the samples from FMF patients and 
healthy controls have similar cell populations.  Differential splicing of MEFV in neutrophils and 
macrophages (or perhaps other cell types) could explain the difference in the relative 
abundance of isoforms of the Pyrin protein. 
 Caspase-1 is expressed in most cells which express Pyrin:  human macrophages (55), 
neutrophils (56, 57), dendritic cells (58), B and T lymphocyte cell lines (59, 60), and primary 
fibroblasts (61), and it can be detected by RT-PCR in synovial tissue of some, but not all 
patients with arthritis or healthy controls (62).  Caspase-1 activity is increased in the psoriatic 
lesions of the skin (63), and in B-cells, Caspase-1 can mediate apoptosis (59, 60), thus 
Caspase-1 is functional in non-myeloid cells.  The overlapping expression pattern of Caspase-1 
with Pyrin is consistent with the idea that Caspase-1-mediated cleavage of Pyrin mediates the 
function of Pyrin.   
 However, the site of Caspase-1 cleavage of Pyrin is not conserved among all species.  The 
cleavage site was mapped to amino acids 330 – 31 of the human protein, between aspartate 
and serine amino acids (49).  The amino acid sequence is conserved in the chimpanzee, 
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monkey, and dog Pyrin proteins.  In the mouse and rat protein, however, the corresponding 
amino acids are two serines.  Thus, it is unlikely that the mouse and rat Pyrin protein can be 
cleaved by Caspase-1, although cleavage may be conserved in the chimpanzee, monkey, and 
dog. 
 
The genetics of FMF 
 Inferences about the function of Pyrin have been made based upon dominant versus 
recessive inheritance:  dominance suggests that mutants have a gain-of-function; recessivity 
suggests mutants have a loss of WT Pyrin function.  Our data indicate that a loss of Pyrin 
function causes aberrant IL-1β production.  We did not identify a phenotype in intrinsic 
neutrophil function, but the loss of Pyrin function may affect neutrophils in a manner that was 
beyond our detection by the assays we chose for testing.  Together, our data support a model 
for FMF-associated mutations causing a loss-of-function, which in turn supports a recessive 
inheritance model.  We cannot, however, rule out the possibility that some point mutants create 
a gain-of-function phenotype. 
 It is surprising that there is a large population of FMF patients with only one or no identified 
mutation in MEFV, although analysis is typically confined to examination of mutational hotspots.  
Two phenomena could explain this:  1) the recently established Tel Hashomer criteria and 
molecular genetic testing for mutations in MEFV facilitate diagnosis of FMF in milder cases, 
including asymptomatic individuals, and milder cases may be associated with unidentified 
mutations in MEFV, and 2) in response to changing selection pressures, new allelic variants are 
emerging that are beyond detection of current testing panels.  Thus, caution should be used 
when concluding dominant or recessive inheritance patterns based upon an absence of 
molecularly-defined mutations. 
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 Intramolecular interactions within Pyrin were reported by multiple investigators (5, 7), and 
could be an indication that either Pyrin interacts with itself on a monomeric level, or that Pyrin 
forms multimers with itself.  Indeed, there is evidence to support a model in which Pyrin forms 
homotrimers (7).  It is interesting to assimilate this idea with our knowledge of FMF inheritance.  
Our research indicates that the loss of function of one allele is not compensated through 
increased expression of the other allele of Mefv.  Thus, if we assume that both wt and mutant 
alleles are expressed equally in heterozygous individuals, then it is reasonable to assume that 
each trimer of Pyrin could have 0, 33, 67 or 100% of the function of a trimer from homozygous 
WT individuals.  These percentages represent the extreme where one allele has full function 
and the other allele has a complete loss-of-function.  In actuality, since mutations are point 
mutations, and primarily missense mutations, they may cause only a partial loss-of-function.  
Additionally, most individuals with two mutant alleles are compound heterozygotes.  Therefore, 
the range of functionality of Pyrin trimers varies greatly.  On a phenotypic level, this broad 
functionality could explain the broad range in severity or apparent penetrance of FMF disorder.  
This does not rule out the possibility that there are genetic modifiers of the FMF phenotype. 
 The presence of the same MEFV genotype in patients with different FMF severity, even 
asymptomatic in some cases, indicates that there is really interesting biology that we don’t yet 
understand.  Unidentified modifiers of FMF pathology probably exist.  Modifiers of disease 
penetrance and/or severity of symptoms can be either genetic or environmental.  For example, 
in a large cohort of 2,067 patients, there was a female:male ratio of 1.38 (64).  This bias may be 
due to the contribution of sex-specific genetic modifiers, but this conclusion warrants further 
investigation.  An environmental influence of FMF pathology is clear.  The country of residence 
affects the prevalence of MEFV mutations, the emergence of new mutations, and disease 
severity, specifically the risk of developing amyloidosis (65, 66).  Populations within the 
countries of France, Turkey, Armenia, Spain, Lebanon, and Italy carry the largest number of 
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sequence variants (66-69), suggesting that environmental stressors within the Mediterranean 
region are selecting for Mefv allelic variants.   
 Mefv may protect against a pathogen that is most prevalent in the Mediterranean region.  
Functional protein analysis supports this hypothesis.  The PRY-SPRY region within the B30.2 
domain of Pyrin forms a 3D-structure with hypervariable loops, similar to the variable regions 
within immunoglobulin proteins.  The PRY-SPRY domain is common to Tripartite motif (TRIM) 
family proteins.  Among these are TRIM5α and TRIM21 (Ro52).  A single amino acid 
substitution within TRIM5α has led to susceptibility for HIV infection in humans while 
chimpanzees that retain the evolutionary wild-type sequence remain resistant to HIV.  Mutations 
within TRIM21 lead to systemic lupus erethymatosus susceptibility.  Mutations in TRIM5α and 
TRIM21, along with the most severe disease-causing mutation (M694V) within Pyrin/TRIM20, 
map to a hyper-variable loop region of the PRY-SPRY domain.  Thus, both the structural 
similarity between Pyrin and other TRIM-family proteins, and the association of PRY-SPRY 
mutations with disease, support a model in which the amino acids within the variable loop 
regions undergo frequent substitutions throughout evolution.  These allelic variants may be 
maintained as a way of adapting new or better immune defenses to resist a pathogen(s).  
Consistent with this hypothesis, Pyrin expression is increased in response to treatment with 
LPS, retroviral infection, and treatment with some pro-inflammatory cytokines (7, 70).  To 
provide a conceptual framework for this hypothesis, the phenotypes caused by mutations in 
Mefv may follow a model for mutations in the beta globin chain of hemoglobin, wherein 
heterozygosity provides protection against malaria, but homozygosity causes the sickle-cell trait. 
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